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Abstract 
The objective of this research was to develop new polymeric nanomaterials for biomedical 
applications. It was envisioned that through careful design and synthesis, as well as the study 
of structure-property relationships, the development of materials with new properties and 
functions could be achieved. As a starting point, several poly(ester amide)s (PEAs) 
composed of α-amino acids, diols, and diacids, with varying chemical structures, molecular 
weights, and polydispersity indices were prepared and their thermal, rheological and 
mechanical properties were studied. The resulting data will aid in the design and selection of 
PEAs with optimal properties for targeted applications. Subsequently, a novel PEA-paclitaxel 
(PTX)-poly(ethylene oxide) conjugate was prepared and assembled into micelles to achieve 
controlled release of PTX via the hydrolysis of ester linkages. This system was compared 
with an analogous micellar system into which PTX was physically encapsulated and it was 
shown that the release of PTX from the covalent system was slower and more sustained. To 
provide an alternative release mechanism, a functionalized PEA with a photodegradable 
backbone covalently conjugated to both PTX and PEO was designed and prepared. Upon UV 
irradiation, micelles, formed from this graft copolymer through self-assembly, disintegrate. 
This feature accelerates the release of PTX compared with non-irradiated micelles, likely due 
to the increased exposure and hydrolysis of the ester linkages conjugating the drug to the 
support, upon micelle disruption. Finally, cross-linked polymer nanoparticles (nanogels) 
functionalized with Gd(III) chelates were designed, synthesized and characterized as 
enhanced contrast agents for magnetic resonance imaging (MRI). These nanogels exhibited a 
T1 relaxivity nearly 6-fold higher than the clinical contrast agent Magnevist. This result is 
rationalized by the decrease in tumbling and rotational rates as a result of rigidity introduced 
by the cross-linking. A preliminary in vivo evaluation of this new agent was performed and 
the agent exhibited good contrast and enhanced circulation in the vasculature relative to 
Magnevist.  
Keywords  
poly(ester amide)s, micelles, covalent conjugation, paclitaxel, UV irradiation, MRI contrast 
agent, nanogels 
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Chapter 1  
1 General introduction on polymers for biomedical 
applications 
The development of new biodegradable polymers is a rapidly emerging field that holds great 
promise for revolutionizing drug delivery systems, tissue engineering applications and 
biomedical sensors. The first reported biomedical application of polymers was in Nylon 
sutures in the early 1940s.
1
 At that time, biomedical polymers were limited to the 
commercially available materials such as poly(methyl methacrylate) (PMMA), poly(ethylene 
terephthalate) (PET) and poly(vinyl chloride) (PVC), as only limited synthetic tools were 
available for synthesizing new materials (Figure 1.1).
1,2
 These polymers have since been 
commercialized for medical applications including use as artificial bone, artificial heart 
valves, hip implants, artificial lenses and vascular grafts. Research continues to optimize the 
stability and performance of these materials in vivo.  
Recently, the pharmaceutical and biotechnology industries have developed a wide array 
of drug candidates based on proteins and nucleic acids, which cannot be delivered by 
conventional methods because of issues such as low solubility, first-pass metabolism and 
site-specificity. The successful clinical application of these new drugs is providing the 
driving force for the development of new biomaterials for controlled drug delivery and gene 
therapy applications. Likewise, an increased need in the emerging field of tissue engineering, 
where polymers are used to assist regeneration of three-dimensional tissue, is also providing 
an impetus for the development of new biocompatible and implantable polymers. Over the 
last few years, the synergistic advances in molecular and developmental biology along with 
the invention of new synthetic methods and polymer designs have resulted in a large 
expansion of biomedical polymer architectures and applications. 
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Figure 1.1. Chemical structures of PMMA, PET and PVC. 
1.1 Biomaterials 
A biomaterial is a substance that has been engineered to affect the course of a therapeutic or 
diagnostic procedure in human or animal medicine, either alone or as part of a complex 
system, by controlling various material interactions with biological components.
3
 Although 
biomaterials are primarily used for medical applications, they are also used for growing cells 
in cultures,
4
 synthesizing biosensors,
5
 executing bio-separations,
6
 and forming the scaffolds 
for diagnostic gene arrays.
7
 Recently, nano-scale materials have been investigated for 
biomedical applications including drug carriers,
8
 tumour imaging tools,
9
 cell-targeted 
therapy,
10
 cell sensors/microchips,
11
 and cell tissue scaffolds.
12
 Nano-sized biomaterials are 
attractive for many biomedical applications because they are comparable to many biological 
structures such as enzymes, antibodies and DNA plasmids with respect to their size and 
shape.
13
 Nanomaterials exhibit unique physical, mechanical, electronic and magnetic 
properties due to their submicron size and consequently, their large surface-to-volume ratio. 
Furthermore, their large functional surface allows these materials to be modified to tailor the 
chemical and/or physical properties of the material for a specific biomedical application.
14
 
Specifically, nanomaterials such as polymer conjugates,
15
 polymeric nanoparticles,
16
 
liposomes,
17
 micelles,
18
 nanogels,
19
 and dendrimers
20
 have been successfully used in the 
development of pharmaceutical delivery systems.  
Each of the possible applications has unique structural and functional requirements that 
are best met by a specific polymeric architecture and material. Consequently, the field has 
two over-arching goals at this early date, the development of a wider selection of polymeric 
materials and structures and the development of a functional model better able to predict the 
desired formulation for a given application through a better comprehension of the direct 
relationship between structure and properties in synthetic biopolymers. 
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1.2 Polymer structure-property relationships 
1.2.1 Thermal properties  
In the study of biodegradable polymers and their applications, knowledge of the thermal 
properties such as glass transition temperature (Tg), melting temperature (Tm) and thermal 
degradation are essential in the selection of materials for various applications. 
Thermogravimetric analysis (TGA) is used primarily to determine the thermal stabilities of 
materials as well as their compositional properties.
21
 While all polymers have a Tg, a 
transition that occurs in the amorphous regions of polymers, only polymers with a regular 
chain structure can crystallize and exhibit a Tm.
21
 It has been shown that both the Tg and the 
degree of crystallinity have significant effects on both the mechanical properties and the 
degradation rates of biodegradable polymers.
22
 For example, poly(L-lactide) (PLLA) is a 
semi-crystalline polymer  with a Tg of 60–65 °C and a Tm of approximately 175°C (Figure 
1.2). PLLA has a slow-degradation rate, good tensile strength, low extension and a high 
modulus (approximately 4.8 GPa) and hence, has been considered an ideal biomaterial for 
load bearing applications, such as orthopaedic fixation devices.
23
 In contrast, Poly(D/L-
lactide) (PDLLA) is an amorphous polymer has a glass transition temperature of 55–60 °C 
(Figure 1.3).
24
 Due to its amorphous nature the polymer exhibits much lower strength (1.9 
GPa) compared to PLLA.  Being a low strength polymer with a faster degradation rate 
compared to PLLA, it is a preferred candidate for developing drug delivery vehicles and as 
low strength scaffolding material for tissue regeneration.
24
 Polydioxanone (PDS) which is a 
semi-crystalline polymer, exhibits a very low glass transition temperature ranging from 10 to 
0 °C (Figure 1.3). Due to the high crystallinity and hydrophobicity of the polymer, it can be 
considered a slow to moderately degrading polymer. PDS has also been investigated for 
several orthopaedic applications including use as fixation screws for small bones and 
osteochondral fragments.
25
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Figure 1.2. Chemical structure of PDLLA, PLLA and PDS.  
1.2.2 Mechanical properties 
The mechanical properties of polymers are affected by the combined effects of crystallinity, 
molecular weight (MW), Tg, branching, crosslinking and sometimes the thermal history of 
the particular samples.
26
 Mechanical tests provide useful information on the material’s 
ultimate tensile strength (UTS), Young’s Modulus (modulus of elasticity), yield strength and 
elongation at break. These properties are important in materials selections for end use 
applications. For example, polyglycolide (PGA) showed excellent mechanical properties due 
to its high crystallinity with a Young’s  modulus of approximately 12.5 GPa and has been 
investigated for use in bone internal fixation devices (Biofixs) (Figure 1.3).
27
 On the other 
hand, the mechanical performance of polyanhydrides were found to be less than optimal for 
load bearing applications, such as for orthopaedic implants.
28
 For example, the Young’s 
modulus for poly[1,6-bis(carboxyphenoxy) hexane] (PCPH) is only 1.3 MPa,
29
 which is well 
below the modulus for human cancellous bone (40-60 MPa) (Figure 1.3).
30
 Recently, the 
mechanical properties of poly-(1,8-octanediol-co-citric acid) with ultimate tensile strengths 
of approximately 6 MPa, Young’s moduli ranging from 0.9 to 16 MPa and maxium 
elognations of around 265% of initial length
31
 similar to that of arteries and veins (up to 
260%)
32
 and elastin (up to 150%)
33
 suggest that it is a promising biodegradable polymer for 
vascular tissue engineering. Therefore, to summarize, although the mechanical responses of 
polymers are complex, it is possible to gain an understanding of the broad principles that 
determine these parameters. Polymers can potentially be rationally designed and synthesized 
for a particular application. 
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Figure 1.3. Chemical structure of PGA and PCPH. 
1.2.3 Rheological properties 
Rheological properties are useful in evaluating biomaterials for their suitability in processing 
operations and can be used to estimate and predict the molecular orientations that are formed 
in these materials while shear stress is applied or removed during a process. For example, 
proper ﬂow properties allow hydrogels to be excellent candidates for injectable therapeutic 
delivery vehicles. Schneider et al. reported a peptide-based hydrogel which undergoes 
considerable shear thinning, resulting in a low viscosity gel upon the application of a proper 
shear stress.
34
 However, once the external stress is removed, the material rapidly self-heals 
into a solid again. This feature allows small molecules that were encapsulated during gel 
formation to be delivered via syringe with precision to target sites.  
In another study, Langer and co-workers investigated the rheological properties of a 
polymer blend of hyaluronic acid (HA) and hydroxypropylmethyl cellulose (HPMC), 
including yield stress, rheological synergism and shear thinning to optimize their properties 
as injectable drug delivery vehicles (Figure 1.4).
35
 Rheology is also a powerful tool for 
understanding the gelation mechanisms for forming a specific network, paving the way for 
further development of hydrogels for tissue repair and drug delivery.
36
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Figure 1.4. Chemical structure of HA and HPMC (R=CH3 or CH2CH(CH3)OH or H). 
1.3 Drug delivery  
While many advances have been made in the development of therapeutics to treat human 
diseases over the past several decades, many drugs and drug candidates still face the 
traditional conflict between efficacy and bioavailability. Some common challenges 
encountered with highly active current and potential drugs include low aqueous solubility, 
short plasma circulation half-life, susceptibility to rapid degradation in plasma, and high 
toxicity.
37,38
 As blood circulates, small molecule drugs pass through the liver where 
Cytochrome P450 and other enzymes metabolize them, rendering drugs inactive or increase 
their toxicity.
39
 With half-lives on the order of minutes, small molecule drugs are rapidly 
excreted from the body. In kidneys, circulating macromolecules with hydrodynamic radii 
smaller than the glomerular pores (4 nm to 14 nm) will permeate the membrane and be 
excreted, thus requiring large doses and/or lengthy infusions.
40
 The organs responsible for 
drug clearance are easily damaged by many potential drug candidates. For example, cisplatin 
causes severe nephrotoxicity (kidney toxicity).
41
 In addition to clearance by the kidneys, free 
drugs may be removed via the reticuloendothelial system (RES).
41
 In a process called 
opsonization, a circulating protein, opsonin, binds to foreign particles, increasing the ability 
of phagocytic cells to recognize the foreign substance. Particles that are over 200 nm in 
diameter, highly charged or hydrophobic are highly susceptible to opsonin binding and 
removal via the RES. Once bound by opsonin, the liver and spleen can more effectively 
remove these circulating particles or phagocytic cells can break them down to be removed by 
the lymphatic system.
42
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Delivery platforms such as polymers, micelles, liposomes, and nanoparticles (NP) are 
being explored as effective methods to modulate drug activity (Figure 1.5).
43-46
 Some 
potential advantages of therapeutic macromolecular supports include: (1) improving drug 
water solubility; (2) carrying drugs to the site of action, thereby limiting metabolism and 
toxicity and enhancing the therapeutic efficacy; (3) improving the pharmaceutical and 
pharmacological properties of drugs, potentially without the need to alter drug molecules; (4) 
enhancing circulation times to half-lives ranging from hours to days and (5) carrying a high 
capacity loading of drug within a single macromolecular entity or assembly. 
 
Figure 1.5. Different platforms for drug carriers: a) micelles b) liposomes c) nanoparticles.  
Because the pharmacokinetics of a drug are significantly influenced by the carrier, 
important factors such as drug release rates and blood circulation times can be altered simply 
by changes to the delivery system rather than of the active pharmaceutical agent itself, 
obviating the need to balance efficacy and bioavailability. Furthermore, there is the potential 
for significantly higher specific accumulation in tumors as opposed to the small molecule 
drug alone, due to the passive targeting phenomenon known as the "enhanced permeation 
and retention" (EPR) effect.
47
 The EPR effect was described in great detail and validated by 
Maeda et al.
42,48,49
 Their investigations showed that most solid tumors have poorly formed 
vasculature, with loose junctions between the endothelial cells near the tumor, and little to no 
lymphatic system (Figure 1.6).
42,48
 Therefore they exhibit enhanced vascular permeability, 
which will ensure a sufficient supply of nutrients and oxygen to tumor tissues for rapid 
growth. Macromolecules larger than 40 kg/mol in the blood stream can escape from tumor 
vessels and accumulate in tumor tissues due to the lack of lymphatic drainage.
44,49
 In 
contrast, in healthy tissue tight junctions between the cells lining the blood capillaries prevent 
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macromolecules, but not small molecules, from entering normal tissue. The use of small-
molecule anticancer drugs leads to systemic toxicity, as a result of poor tumor targeting. 
 
Figure 1.6. Increased uptake of macromolecular carriers in tumor tissue as compared to healthy 
tissue due to the EPR effect. Adapted from reference 44. (Nature Nanotechnology 2007, 2 (12), 
751-760, Reproduced with permission from Nature Publishing Group).  
Targeting refers to differential spatial localization and describes directing drugs 
specifically to desired cells and tissues. This differential spatial localization of nano-carriers 
encompasses two different approaches referred to as ‘‘passive’’ or ‘‘active’’ targeting.50 
Passive targeting involves the prolonged circulation of the carrier bearing no affinity ligands 
and its preferential accumulation in the active site directly due to the inherent 
biophysicochemical properties of the nanocarrier such as size, shape, charge and flexibility 
via factors such as the EPR effect.
16,50
 In contrast, active targeting requires surface 
modification of the nanocarrier to incorporate affinity ligands with specificity to disease 
tissues and cells.
16,50
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1.3.1 Polymer–drug conjugates  
The attachment of drugs or other biological species directly to a polymer backbone has been 
the subject of extensive investigation over last few decades.
51-53
 Polymers with functional 
handles provide the opportunity to covalently graft the drug to polymer chains, allowing 
them to deliver high doses of drugs. The advantages of polymer–drug conjugates compared 
to free drugs have been well documented.
54,55
 For example, in clinical trials, the 
biocompatibility of N-(2-hydroxypropyl)methacrylamide (HPMA) as a drug carrier has been 
demonstrated, as has a decrease of  non-specific side effects when compared to low 
molecular weight drugs alone.
56,57
 The polymers used as drug conjugates can be divided into 
two groups: natural and synthetic polymers. 
Polymers such as albumin, chitosan, and heparin occur naturally and have been a material 
of choice for the delivery of oligonucleotides, DNA, and protein, as well as drugs.
58
 A 
current example of a clinically used natural polymer-drug conjugate (noncovalent) is PTX 
albumin bound nanoparticles (brand name: Abraxane) for the treatment of patients with 
breast cancer resistant to conventional therapy.
59
 
Today, the most commonly used synthetic polymers for the development of drug 
conjugates include HPMA and its copolymers, poly(D,L-lactide-co-glycolide) (PLG), 
poly(lactic acid) (PLA), poly(L-glutamic acid) (PLGA), poly(caprolactone) (PCL), and 
poly(amino acids) (Figure 1.7).
60
 In particular, PLGA was the first biodegradable polymer to 
be used for the synthesis of drug conjugates. For example, in Xyotax, PTX was conjugated to 
PLGA through an ester bond (Figure 1.8).
62,63
 Xyotax was shown to preferentially target 
ovarian tumours and is now in clinical trials.
61,62
 Another example is IT 101, which is a 
conjugate of the anticancer drug camptothecin (CPT) and a linear β-cyclodextrin-based 
polyethylene oxide (PEO) to PLGA (Figure 1.8). Pharmacokinetic and preclinical studies 
have demonstrated that this conjugate exhibits a longer plasma half-life and better 
accumulation in the tumor tissue than CPT alone.
63
 PK1, comprised of doxorubicin (DOX) 
covalently bound to HPMA copolymer by a peptidyl linker is another example of a polymer–
anticancer drug conjugate. It entered clinical trials more than a decade ago and the clinical 
phase II trial for women with advanced breast cancer is still ongoing (Figure 1.8).
64
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Figure 1.7. Chemical structure of some common synthetic polymer for drug conjugation. 
 
Figure 1.8. Chemical structure of Xyotax , IT-101 and PK1. 
Although polymer-drug candidates show excellent promise, their transition from bench to 
clinic has been slow. This is at least partly due to the complex biological behavior of the 
formulation in that small modifications, to either the conjugation efficiency or the polymer 
molecular weight and architecture, can have non-linear effects on the pharmacokinetic 
parameters. Thus, the resulting materials can be considered a novel material requiring 
additional regulatory attention.  
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1.3.2 Micellar drug delivery systems 
 Micelles are one of the most heavily investigated types of nano-carriers and some examples 
are currently in clinical trials as advanced as phase II.
65
 Micelles are formed through self 
assemblies of amphiphilic block copolymers with large solubility differences between the 
hydrophilic and hydrophobic segments in aqueous medium, allowing them to form  micelles 
in the nanoscopic size range with fairly narrow size distributions. 
Micelles have been developed as drug delivery carriers for hydrophobic drugs.
66-69
 
Potential advantages of micelles over other nanoparticle delivery systems include: (1) 
enhancing the solubility of hydrophobic drugs through encapsulation in the micelle’s 
hydrophobic core region or, alternatively, through grafting the drugs to the hydrophobic side 
chain of the polymer; (2) increasing the in vivo drug circulation times and tumor targeting via 
EPR effect due to the small size of the particles; (3) controlling the rate of drug release from 
the carrier through tuning the chemical structure of the core-forming block; (4) improving the 
targeting efficiency of micelles by preparing micelles responsive to an external stimulus such 
as temperature or pH through modification of  the chemical structure of the micelle-forming 
block copolymer. Numerous studies have been published on the preparation of polymeric 
micelles and on their properties. Many good recent reviews exist, dealing with various 
aspects of polymeric micelle preparation, physicochemical and biological properties, and 
possible applications as pharmaceutical carriers.
67-70
 Micelles have been used successfully for 
delivering drugs such as PTX and DOX. These drugs can be loaded into polymeric micelles 
in two ways: physical encapsulation or chemical covalent attachment. Each method has its 
own advantages and disadvantages, which are discussed below in more detail. 
1.3.2.1 Micelles containing non-covalently encapsulated drugs 
The existence of hydrophobic interactions or hydrogen bonds between the micelle-forming 
block copolymer and the drug provides the basis for the encapsulation of drugs in polymeric 
micelles. In this system, the encapsulation efficiency of the micelle system is strongly 
dependent on the payload/core interaction.
67
 For example, in the encapsulation of PTX in 
polymeric micelles that consist of PEO- poly(2-(4-vinylbenzyloxy)-N,N-diethylnicotinamide) 
(PDENA), the polymer with longer PDENA block resulted in an increased loading of PTX.
71
 
Partial replacement of the benzyloxy group in PEO–poly(β-benzyl- L-aspartate) (PEO-b-
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PBLA) with acetyl ester has also been used by Yokoyama et al. to incorporate (6-[4-deoxy-
4-(2E,4E)-tetradecadienoylglycyl]amino-l-glycero-β-l-mannoheptopyranosyl]amino-9H-
purine (KRN-5500, a water-insoluble anticancer drug) in polymeric micelles.
72-74
 Another 
example is SP1049C which is a pluronic polymeric micelle NP composed of a DOX and 
non-ionic, triblock copolymers formed from a hydrophobic polypropylene (PPO) block 
flanked by two PEO blocks (Figure 1.9). It is currently undergoing phase II studies in 
patients with metastatic cancer of the esophagus and esophageal junction that have been 
refractive to standard chemotherapy treatments.
65
  
The use of micelles to deliver hydrophobic drugs has become a prominent strategy in the 
field of drug delivery. Micelles can be designed to be biocompatible and biodegradable. 
Furthermore, the physicochemical properties of micelles can be tuned, resulting in materials 
with various adjustable properties. More importantly, in this delivery system, where the drug 
is physically encapsulated, it can be delivered without any chemical modification to its 
structure. Thus for, polymeric micelles are much more efficient and safer other methods 
currently in use. However, this strategy is usually associated with premature drug release 
prior to EPR-mediated tumor accumulation. In order to minimize this limitation, one 
approach would be to chemically conjugate the drug to the hydrophobic block of a micelle-
forming material through a covalent bond. 
 
Figure 1.9. Chemical structure of SP1094C formulation. 
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1.3.2.2 Micelles containing covalently conjugated drugs  
The covalent immobilization of drug molecules within a micellar carrier can be achieved 
through the formation of hydrolyzable chemical bonds between the functional group(s) on 
the polymer and the drug. In this case, drugs can be chemically conjugated to either an 
activated free terminus or to the side chain of a hydrophobic block in the micelle. For 
example, 7-ethyl-10-hydroxy-campothecin (SN-38), a hydrophobic anticancer drug, was 
attached covalently to the pendant carboxyl groups of PEG-b-polyglutamate copolymer via 
an ester linkage. This formulation enhances the water-solubility of SN-38 and allows the 
delivery of higher doses of SN-38 than those possible with SN-38 alone (Figure 1.10).
75
 In 
another example, DOX was conjugated to a PEO-b-poly(aspartic acid)(Asp) block 
copolymer to increase the entrapment of DOX inside the hydrophobic core of PEO-b-P(Asp)-
DOX micelles.
76
 PTX was attached covalently to the pendant carboxyl groups of PLGA of 
{PLAA-co-[(PGA-alt-PLGA)]}-b-PEG-b-{PLAA-co-[(PGA-alt-PLGA)]} via an ester 
linkage. The resulting micelles did not exhibit initial burst release but release was pH 
dependent and the PTX maintained its cytotoxic profile against RBG-6 cells (Figure 1.10).
77
  
Drug conjugated micellar carriers hold a promising future due to their superior 
performance relative to other drug carriers. The conjugation of drugs to the hydrophobic 
cores of micelles not only sustains their release but also protects them against degradation, 
decreases their side effects and increases their overall therapeutic efficiency. The peripheries 
of micelles also can be used to conjugate targeting agents, and then the micelles can be 
accumulated selectively in certain tissues in the body. However, batch to batch 
reproducibility and also small changes in the micelle's drug conjugation efficiency may 
significantly change the pharmacokinetic parameters and tissue biodistribution. The resulting 
formulation would also be considered a new chemical entity, complicating regulatory 
approval. 
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Figure 1.10. Schematic structure of a) SN-38- PEG-b-PLGA b) {PTX- PLAA-co-[(PGA-alt-
PLGA)]}-b-PEG-b-{PTX-PLAA-co-[(PGA-alt-PLGA)]}. 
1.4 Paclitaxel delivery 
PTX, was first isolated from the bark of Taxus brevifolia, first discovered by Wall and Wani. 
It is one of the most effective chemotherapeutic drugs and is used to treat a broad range of 
cancers such as lung, ovarian, and breast cancer, amongst others.
78
 PTX is a hydrophobic 
drug and has very poor aqueous solubility (~0.4 μg/mL). To enhance its solubility, it is 
commercially formulated in Cremophor EL (CrEL), which is polyoxyethylated castor oil, 
and dehydrated ethanol (50/50, v/v) under the trademark “Taxol”. However, CrEL is known 
to cause serious side effects, such as hypersensitivity reactions, and considering the amount 
of CrEL (26 mL of CrEL) that is needed for an average patient for a single intravenous 
administration dose, it is a major limitation for clinical use of PTX.
79
  
As discussed above, nano-carrier delivery systems are promising vectors for clinical use. 
Among the first generation of NP for PTX delivery, Abraxane, a PTX protein-bound NP 
formulation with the particle size of around 130 nm, was approved by the FDA in 2005 for 
the treatment of metastatic breast cancer.
80
 Although, this formulation reduced toxicity by 
removing the need for the use of the toxic excipient-CrEL, and a dose can be administered 
within 30 min without pretreatment, Abraxane does not impact the circulation half-life as it 
rapidly dissociates into its constituent albumin and PTX molecules.
81
 Furthermore, PTX is a 
substrate of protein named P-glycoprotein (P-gp), which can export PTX from the cell and 
likely induces drug resistance.
82
 Therefore, alternative PTX formulations are still in demand. 
15 
 
1.4.1 Polymeric micelles for PTX delivery  
Much research has been conducted towards the development of a micellar PTX delivery 
systems. Two approaches that have been frequently used are the incorporation of PTX  in 
micelles or the conjugation of PTX to the hydrophilic block of micelle-forming block 
copolymers. For example, the NK105 micellar formulation was constructed using PEO as the 
hydrophilic segment and modified polyaspartate as the hydrophobic segment. To increase the 
hydrophobicity and thus increase the interactions between PTX and the polymer backbone, 
half of carboxylic groups of the polyaspartate block were modified and converted to 4-
phenyl-1-butanolate.
83,84
 A drug loading up to 23% (w/w) and a particle size of 
approximately 85 nm was achieved. NK105 showed similar cytotoxicity in human tumor cell 
lines include lung, gastric, oesophagus, colon, breast and ovarian compared to PTX.
85
 
Currently, a phase II study in patients with advanced stomach cancer is underway 
(Figure.1.11).
85
 
 
Figure 1.11. Structure of NK105 formulation. 
Paxceed® is another polymeric micellar formulation where PTX is encapsulated in 
PDLA-b-methoxypolyethylene oxide (mPEO) diblock copolymers. The micellar formulation 
significantly improved the maximum tolerated dose (MTD) of the drug upon intraperitoneal 
injection in an MV-522 lung tumor bearing mouse model.
86
 Currently, Paxceed® is in phase 
II clinical trials.
87
 Genexol-PM is the most successful PTX micellar formulation to date, 
which is composed of PDLA-b-PEO diblock copolymers. Genexol-PM was approved in 
Korea in 2007.
80
 It is currently in phase II clinical development in the USA.
88,89
  
Other PTX-loaded PLA-based micelles have also been reported. For example, PEO-PLA-
PEO exhibited slower drug release compared to PLA-PEO-PLA micelles. Both of the 
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micelles showed a 4-fold decrease in monocyte cell uptake compared to a simple PLA 
nanoparticles.
90-92
 In another study, a four-armed (star-branched) copolymer of PLA and 
PEO was synthesized. The micelles from star-shaped copolymers exhibited more complete 
release of drug than diblock copolymers. Furthermore, the lower hydrodynamic radius of 
star-shaped polymers may result in better clearance of the carrier polymer from the body 
(Figure 1.12).
91
 
 
Figure 1.12. Chemical structure of a) PLA-PEO-PLA and PEO-PLA-PEO b) a four-armed 
(star-branched) co-polymer of PLA-PEO. 
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Compared to micellar PTX physical encapsulation, there are only a few examples of PTX 
covalently immobilized at the micelle core. For example, PTX modified with a levulic, 3-
(acetyl)acrylic acid) and 4-(2-oxopropyl)benzoic acid spacer was conjugated to random 
copolymers of HPMA with 6-methacrylamidohexanohydrazide via hydrazone linkages 
provided a pH sensitive micellar system. These micelles showed better antitumor efficacy in 
the 4T1 model of mammary carcinoma than free PTX (Figure 1.13).
93
  
Recently, Kim et al. developed a PTX conjugate polymeric micelle, consisting of PEO 
and arginine-grafted (cystaminebisacrylamide-diamine) ABP for the co-delivery of DNA and 
PTX. APP micelles showed increased cell uptake efficiency and higher anticancer potency 
than PTX alone (Figure 1.13).
94
 Recently, Zhong et al. reported a PTX conjugate using PEO-
b-poly(acrylic acid) (PEO-PAA) block copolymers as the support. The drug was attached via 
an acid-labile acetal linkage to the PAA block using ethylene glycol vinyl ether as a linker. 
The resulting micelles of these copolymers exhibited potent antitumor activity to KB, HeLa, 
and PTX-resistant A549 cell lines (Figure 1.13).
95
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Figure 1.13. Chemical structure of a) PTX-APP b) PTX-HPMA c) PTX-PEG-ABP.  
1.5 Stimuli-responsive polymers 
Despite considerable advances having been made in the development of controlled drug 
delivery technologies over the last few decades, most still have the shortcoming that drugs 
release at a predetermined rate that can’t be tuned to the particular patient needs or changing 
physiological environment. This shortcoming may be overcome by developing stimuli-
responsive materials, also termed "smart", “intelligent" or “environmentally sensitive" 
systems, in which materials undergo sharp responses to environmental changes such as 
pH,
96,97
 temperature,
98,99
 light,
100,101
 redox
102,103
 or other chemical changes, potentially 
leading to enhanced drug efficacy and improved therapeutic index. 
Possible advantages of the use of stimuli-responsive polymers in drug delivery include: 
(1) the ability to control the timing, duration and dosage of the drug in response to a given 
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stimulus; (2) the ability to release the drug at a specific location by exploiting the difference 
in environmental properties at the site of disease and (3) the ability to minimize the drug 
release when the trigger is in an off state. The response of these materials has to be 
predictable, reproducible, and proportional to the intensity of the signal for applications in 
drug delivery.  
A few illustrative examples of stimuli-responsive micellar systems are offered for clarity. 
In one model, a mixed polymeric micellar system composed of poly(L-histidine)-b-PEO 
(PH-PEO) and PLLA-b-PEO displayed ultra-sensitive pH dependence which could be tuned 
by varying the mixing ratio of the two polymers. A two-stage destabilization process was 
observed when the pH was changed from 7.4 to 6.0. First, significant destabilization of the 
micelle core occurred when the pH dropped from 7.0 to 6.8, which induced an increase in 
micelle size. As the pH was further lowered to 6.0, further disruption of the micelle core 
caused ionized PH-PEO unimers to dissociate from the micelles.
104
 A second example is a 
temperature-sensitive micelle based on poly(N-(2-hydroxypropyl)methacrylamide lactate) 
and PEO (pHPMAmDL-b-PEO). PTX was loaded into these micelles at up to 2 mg/mL by 
simply mixing a PTX solution in ethanol with an aqueous polymer solution in the presence of 
heat.
98
 Another example is a micelle consisting of an HA-deoxycholic acid (HA-ss-DOCA) 
conjugate that has been used to deliver PTX. This micelle contains characteristic disulﬁde 
linkages on the side chains which are prone to rapid cleavage through thiol-disulﬁde 
exchange reactions with intracellular reducing molecules, especially glutathione, resulting in 
rapid drug release under reducing conditions.
105
  
Among all possible triggers, light is a particularly attractive stimulus for drug delivery 
because its intensity and wavelength can easily be modulated through the use of filters.
101
 
Furthermore, photo-processes start or stop when the light is switched on or off, allowing for 
complete control of the release process, unlike relying on physiological pH, temperature or 
enzymatic strategies. Thus, both complete spatial and temporal control of the drug release 
can be achieved.
106
  
The most common design of photo-responsive amphiphilic polymers involves the 
incorporation of a photocleavable unit in the main-chain of one of the blocks.
100
 These are 
designed so that once formed, the micelles may be disrupted by photo-irradiation. As the 
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amphiphilic copolymer degrades, the micelle becomes increasingly compromised, resulting 
in the release of the encapsulated molecules. For instance, Zhao et al. developed a micelle-
forming ABA triblock copolymer containing a PEO-based hydrophilic block  and a 
hydrophobic polyurethane block containing o-nitrobenzyl groups (PEO-b-PUNB-b-PEO). 
Upon, UV irradiation, the fast degradation of the photocleavable units inserted into micellar 
core was implied by the rapidly observed disintegration of the micelles. In this case, burst 
release of the loaded hydrophobic guest molecules was also achieved (Figure 1.14a).
107
  
 
Figure 1.14. Structure of a) PEO-b-PUNB-b-PEO b) PEO-b-poly(disulfide-alt-nitrobenzyl)-
b-PEO. 
Alternatively, the same group designed a triblock copolymer of PEO-b-poly(disulfide-alt-
nitrobenz)-b-PEO incorporating both a redox-cleavable disulfide group and a photocleavable 
o-nitrobenzyl group. This dual feature allowed either burst release of an encapsulated agent 
through UV light irradiation, slow release by the action of a reducing agent, or release with 
concomitant fast and slow profiles using the two stimuli concomitantly (Figure 1.14b).
108
  
Polymeric micelles based on block copolymers that form stimuli-sensitive structures have 
drawn interest for delivery applications, particularly for hydrophobic compounds. However, 
they suffer from a number of drawbacks. For example, in the case of photo-responsive 
polymers, UV and visible-wavelengths cannot be used for deep-tissue triggering. 
Furthermore, the biodegradability, biocompatibility and the toxicity of the products resulting 
from the degradation reactions have not yet been extensively studied.  
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1.6 MRI contrast agents  
1.6.1 Basic principles of MRI 
Over the last few decades, MRI has become a primary imaging modality. The popularity of 
this non-invasive technique is likely due to the fact that it does not require ionizing radiation 
as in X-ray computed tomography (CT), or radioactive material as in positron emission 
tomography (PET).
109,110
 MRI also exhibits excellent spatial resolution and provides soft 
tissue contrast for the conveyance of anatomical information.
111
 An MRI image is often 
based on the relaxation time of water proton spins in a sample in the presence of an external 
magnetic field, following a radiofrequency (RF) pulse. The resulting image is also based on 
the spatial distribution of the density of water protons.  
There are two types of relaxation that the protons in water molecules can undergo 
following perturbation with a radiofrequency pulse: longitudinal and transverse. The first 
type of relaxation, called longitudinal relaxation, is defined by the nuclei returning to their 
parallel alignment with the magnetic field (Bo) direction after being aligned perpendicularly 
to it. The amount of time that is required for 63% of the magnetization in the Bo direction to 
be recovered is termed T1. Transverse relaxation, the second type, occurs when the nuclei 
that had been in coherence in a single vector perpendicular to Bo become randomly 
distributed around Bo (i.e. the perpendicular vector would be zero). The time required for 
63% of the magnetization to undergo this relaxation is termed T2.
112
 These relaxation times 
can be probed by the use of selective pulse sequences in MRI. 
Although MRI was initially hoped to provide a contrast between different tissues based 
on the differences in water densities and proton relaxation times in these tissues, this inherent 
contrast is sometimes insufficient to distinguish between healthy and diseased tissues. To 
address this limitation, MRI contrast agents have been developed.
113
  
1.6.2 Gadolinium contrast agents 
Gd(III) chelates have been in use for decades as contrast agents in clinical diagnostic 
radiology. The presence of paramagnetic Gd(III) ions affects the relaxation properties of 
neighboring protons and influences the intensity of the image. T1 relaxivity is described by 
equation (1.1). 
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(1/T1)obs= (1/T1)d + r1[ Gd(III)] (1.1) 
where T1obs is the observed relaxation time, T1d is the relaxation time of the sample prior to 
addition of contrast agent, [Gd(III)] is the concentration of gadolinium contrast agent and r1 
is the relaxivity. Relaxivity is typically expressed in units of mM
-1
s
-1
. In fact, the lanthanide 
ion, Gd(III), is usually preferred as an MRI contrast agent. It is not only because it has high 
spin number (seven unpaired f -electrons) which allow for a very large magnetic moment of 
7.9 Bohr magneton (BM) but also for its symmetric electronic state (8S
7/2
 ground state), 
which makes the electronic relaxation time much longer than compare to other lanthanide 
(III) ions, 10
-8
-10
-9 
s.
114
 The water bound Gd(III) ion is toxic and therefore to avoid toxicity 
of the free ion, Gd(III) is typically attached to a chelating agent. For example, the octadentate 
ligand diethylene triamine pentaacetic acid (DTPA) and Gd(III) form a strong complex that 
remains intact for the length of time it is in vivo.
111
 The interaction of water with the Gd(III) 
ion is mediated by two coordination mechanisms - water molecules that are directly 
coordinated with the metal center and those that are diffusing near the complex, known as 
inner and outer sphere water respectively. It is primarily the inner sphere coordination to the 
Gd(III) ion that can be altered to enhance its relaxivity. 
The chemical structure of Figure 1.15 illustrates some of the major parameters that 
govern the relaxation properties of complexes as they relate to inner sphere water 
interactions. The rotational correlation time, τR, is the rate of which the chelating agent 
tumbles in space. The mean residence lifetime, τm, is the time that the coordinated water 
molecule interacts with the Gd(III) ion. The number of water molecules bound to the metal 
center is defined by q, the hydration number. Relaxivity can be enhanced by altering each of 
these parameters. Altering the rotational correlation time can dramatically affect the 
relaxivity.
109
 As the molecular tumbling is slowed, relaxivity is typically increased. 
Therefore, one approach to increase relaxivity is to increase the molecular weight of the 
complex. This can be achieved by using a receptor unit or protein as the chelating agent. It 
has been shown that when Gd(III) complexes are bound to proteins such as serum albumin, 
their relaxivity increases due to the higher molecular weight of the entire complex, which 
causes the tumbling rate to decrease.
113
 For example, solution studies of human serum 
albumin showed that albumin-Gd-DTPA possesses a longitudinal relaxivity r1 of 14.8 mM
-1
 
s
-1
, a value three times that of the monomeric chelate when measured under the same 
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conditions, a result of the larger molecular weight of the contrast agent and hence its higher 
rotational correlation time τR.
113
 In spite of its initial success, covalently labeled albumin 
suffers from several undesirable traits. Elimination of the agent is slow and incomplete, and it 
has been shown to remain in circulation for more than a week, eventually accumulating in 
liver and bone.
113
 Furthermore, a general limitation of protein-based agents is the 
requirement for large quantities of protein, as well as their potential immunogenicity. 
 
Figure 1.15. Illustration of the major parameters governing the relaxivity of Gd(III) chelates.   
To address the limitations of protein-based MRI contrast agents, significant effort has 
been put forth into the conjugation of Gd(III) complexes to high molecular weight molecules 
such as polymers,
115-117
 dendrimers 
118
and other macromolecular structures 
119
 in hopes of 
slowing their tumbling rates. For example, a well studied macromolecular Gd-DTPA contrast 
agent, involved the attachment of Gd-DTPA to poly-L-lysine, resulting in a T1 relaxivity 
three times higher than that of Gd-DTPA.
120
 Kobayashi and coworkers have developed a new 
class of macromolecular Gd-DTPA contrast agents which are bound to poly(propylene 
imine)(PPI) dendrimers (Figure 1.16). The fifth generation dendrimer exhibited a relaxivity 
of 29 mM
-1
s
-1
.
121
  
24 
 
 
Figure 1.16. PPI dendrimer conjugated to Gd-DTPA complex. 
Recently, Shiraishi et al. developed a polymeric micellar contrast agent. A block 
copolymer, PEO-b-poly(L-lysine) was used for conjugation of the chelate 1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to all amine groups of the lysine 
residues. An MRI analysis showed that the signal intensity of the tumor was enhanced 2-fold 
by the use of this contrast agent (Figure 1.17).
122
 
 
Figure 1.17. Chemical structure of PEO-P(Lys-DOTA-Gd). 
However, one aspect that is critical in the design of macromolecular Gd(III) chelates is 
the rigidity of the macromolecule. Flexible macromolecules lead to relatively low 
relaxivities,
123
 similar to those of small molecules as the conjugated chelates can still tumble 
 
= Gd(III) 
complex 
of 
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in solution in a manner similar to small molecules. In contrast, the use of more rigid 
macromolecules such as proteins
124
 and dendrimers
125
 have led to higher relaxivities. 
1.7 PEAs 
While aliphatic poly(α-esters) such as PLA,126-128 PLGA129,130 and PCL131-133 and their 
copolymers have been extensively investigated and used as biodegradable polymers for a 
wide range of biomedical application, they still lack of some desirable properties. For 
example, PGA or PLA can undergo a bulk degradation process by the non-specific scission 
of the ester backbone into glycolic and lactic acids.
24,134
 Although these byproducts are 
present in natural human metabolic pathways, a large accumulation of these acidic species 
has been demonstrated to result in some cell toxicity and tissue inflammation in certain 
applications.
135
 This, combined with their low mechanical performance due to weak 
intermolecular forces and lack of inherent functional groups required for biological 
recognition or covalent conjugation of drugs has limited to some extent their utility in some 
biomedical application.
134
 Compared to aliphatic polyesters, aliphatic polyamides possess 
higher thermal and mechanical stability due to strong intermolecular interactions caused by 
hydrogen bonding.
136,137
 Although, susceptibility of the amide linkages of synthetic 
polyamides to enzymatic hydrolysis can be achieved by improving their chain flexibility and 
hydrophobicity, they are generally quite resistant to enzymatic hydrolysis. Synthetic poly(α-
amino acids) and other polyamides containing α-amino acids have been considered, but their 
preparation on large scale is still challenging due to the use of expensive and unstable N-
carboxyanhydride monomers.
138
 In addition, poly(amino acid)s have been found to be 
immunogenic under some circumstances.
139
  
To address these limitations, it is reasonable to combine the favorable properties of these 
two classes of polymers to produce new polymeric materials possessing not only good 
biodegradability but also good materials and processing properties. Therefore, a variety of 
PEAs containing different monomers have been developed with different preparation 
methods. For example, polydepsipeptides composed of α-hydroxy acids and α-amino acids were 
prepared by the ring-opening polymerization of morpholine-2,5-dione derivatives (Figure 
1.18a).140 Polycondensations methods have also been utilized to react diamide-diol and ester-
diamine monomers with dicarboxylic acid derivatives (Figure 1.18b). New families of PEAs 
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including water soluble,
140
 unsaturated,
141
 and epoxy
142
 and polycationic
140
 PEAs have also 
been developed for different biomedical applications (Figure 1.19).  
 
Figure 1.18. Examples of PEAs prepared by a) ROP and b) polycondensation 
polymerization.  
 
Figure 1.19. Examples of PEAs with different structures and properties: a) water-soluble; b) 
unsaturated; c) epoxy; d) polycationic. 
PEAs derived from α-amino acids, diols, and dicarboxylic acids (Figure 1.20) are of 
particular interest for the current work, as they have been demonstrated to undergo hydrolytic 
and enzymatic degradation at physiological pH, thus providing the possibility for degradation 
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in a wide range of biological environments.
140,143
 Furthermore, the monomer components of 
the polymer can be selected from nontoxic metabolic intermediates including the natural 
amino acids as well as dicarboxylic acids such as succinic and fumaric acid, thereby allowing 
for the degradation products to also be non-toxic. In addition, by rational design of the 
backbone, the polymer’s chemical functionality and properties including solubility, 
crystallinity, biocompatibility, and degradation rate can be readily tuned.
140
 
 
Figure 1.20. General structure of the PEA. 
Puiggali et al. have prepared a variety of PEAs based on amino acids including glycine, 
alanine, or β-alanine with saturated aliphatic diols and diacids of different chain lengths.144-
146
 It was found that PEAs containing stiff units such as oxalic acid and terephthalic acid had 
higher glass transition temperatures (Tgs), which are anticipated to result in enhanced 
mechanical properties.
147
 Chu and coworkers have also prepared a number of PEAs based on 
hydrophobic amino acids including valine, leucine, isoleucine, norleucine, L-phenylalanine, 
and methionine with aliphatic diols and diacids. The thermal properties and crystallinities of 
the polymers were found to vary depending on the constituents. For example, PEAs 
containing L-phenylalanine were the most crystalline and had the highest Tgs.
148
 The same 
group has also recently reported a variety of L-phenylalanine-based poly(ether ester amide) 
(PEEA) composed of saturated or unsaturated dicarboxylic acids with different 
oligo(ethylene glycol)s.149 It was found that incorporation of flexible ether bonds in the 
backbones decreased the Tg compared to the similar PEAs based on saturated hydrocarbon 
diols. These PEEAs also showed a much higher tendency toward α-chymotrypsin catalyzed 
biodegradation than the corresponding PEAs derived from conventional aliphatic diols.
149
  
1.7.1 Functional PEAs 
Recently, the incorporation of functional groups along the backbone of PEAs using α-amino 
acids has opened prospects for many exciting new applications. For example, functional 
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handles are essential for the covalent attachment of drug molecules and targeting groups for 
drug delivery or growth factors and adhesion molecules, which are emerging as important 
components of medical implants and tissue engineering scaffolds. In addition, such side 
chains may provide dramatic effects on the polymer solubility, charge, biocompatibility, and 
biodegradation. 
Jokhadze et al. have reported the preparation of PEAs with pendant carboxylic acids by 
using both the α and ε-amines of L-lysine in the polymer backbone. These free carboxylic 
acids were further functionalized with 4-amino-2,2,6,6-tetramethylpiperidine-1-oxy (TAM), 
a biomedically useful cell growth inhibitor.
150
 Montserrat et al. have incorporated an ester of 
L-lysine as a diamine in the PEAs, but the ethyl ester protecting group of the pendant lysine 
carboxylic acid was not, and likely cannot be removed from the resulting polymer.
151
 Our 
group in collaboration with the Mequanint group has focused on the incorporation of -
amino acids with side chain functional handles and has recently reported the first synthetic 
approach for preparing PEAs with functionalizable pendant amine groups. In this strategy, 
the protected, functional amino acids such as carboxybenzyl-lysine-(t-butoxycarbonyl)-OH 
or carboxybenzyl-aspartic acid-(t-butyl ester)-OH were esterified using N,N′-
dicyclohexylcarbodiimide (DCC) couplings with butanediol to provide diamine 
monomers.
152-155
 Varying percentages of these monomers along with other monomers of 
varying structures were used in solution or interfacial based polymerization methods to 
demonstrate the synthetic versatility of the method and to arrive at polymers with varying 
physical properties. It was demonstrated that the pendant side chain amine/acid protecting 
group could be removed without degradation of the polymer backbone to provide pendant 
amine/acid groups on the polymer that could be coupled to model compounds including an 
amino acid and an oligo(ethylene glycol) derivative.152 
1.7.2 Biomedical applications of PEAs 
As discussed, PEAs have the potential to exhibit unique properties compared to other 
biodegrable polymers. For example, amino acid-based PEAs can easily be biodegraded by 
enzymes, such as lipases or α-chymotrypsin. This feature enhances their surface degradation, 
limiting the possibility of a large accumulation of acidic species in the local tissue which has 
been demonstrated to be problematic for aliphatic(α-esters). However, their biodegradability 
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in pure phosphate buffered saline is slow. This would provide the advantage of shelf-life over 
PGA, PLA, and their copolymers which are considered hydrolytically degradable. In contrast 
to aliphatic poly(α-esters), which possess limited functional groups, limiting their application 
for covalent conjugation of biomolecules including proteins and growth factors, monomers 
with pendant functional groups, including those based on amino acids such as lysine and 
aspartic acid can be incorporated to PEAs to provide functional handle for further 
conjugation of biomolecules. As such it is not surprising that these materials have shown 
promising potential applications in a wide range of biomedical research. 
Guo et al. developed biodegradable PTX-loaded microspheres of amino acid based 
PEAs. The particles were capable of encapsulating PTX with high efficiency (close to 
100%), suggesting that these PEA microspheres have the potential for the administration of 
highly hydrophobic anticancer drugs.
156
 The same group also prepared biodegradable hybrid 
hydrogels based on the amino acid derivative, DL-2-allylglycine (AG) poly(ester amide) 
(PEA-AG) and commercial PEO diacrylate (PEO-DA) or Pluronic diacrylate (Pluronic-DA) 
by UV photocrosslinking which can  used as sustained drug release systems.
157
  
Pan et al. investigated an oral insulin formulation based on microspheres consisting of a 
blend of PEAs. In this delivery system, L-lysine-/L-leucine-based PEAs with pendant acid 
groups were used as pH-responsive materials for the protection of insulin from the acidic 
environment of the stomach. Arginine-based PEAs (Arg-PEA) were also used to improve the 
intestinal absorption of the drug. The microspheres exhibited high drug loading and also 
improved the oral bioavailability of insulin.
158
 Liu and coworkers reported the use of 
arginine-based PEAs as a non-viral gene delivery vehicles with a high binding capacity 
toward plasmid DNA.
159
 
Langer et al. developed elastomeric PEAs based on a multifunctional amine group, 1,3-
diamino-2-hydroxypropane a polyol (glycerol or D,L-threitol) and sebacic acid. These 
polymers exhibited desirable physical and mechanical properties, which combined with in 
vitro and in vivo biocompatibility make them potentially suitable for the fabrication of semi-
permanent resorbable medical devices for use in long-term implantation applications. The 
conjugation of 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl, 4-Amino-2,2,6,6-
tetramethylpiperidinyloxy (4-amino-TEMPO), an anti-inflammation drug, to a carboxylic-
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acid-functionalized PEA has been investigated for a cardiovascular stent coating. This 
coating improved the natural healing response by attenuating the pro-inﬂammatory reaction 
to the implant and promoting growth of appropriate cells for repair of the tissue 
architecture.
160
 In another study, Reinhart-King and coworkers prepared PEA-based polymers 
that have carboxylic acid functional groups (i.e. negatively charged), and amino-functional 
groups (i.e., positively charged) and a nonfunctionalized PEA (uncharged) to investigate the 
effect of PEA charge on cellular response. Their study suggested that endothelial cell 
attachment, spreading, and growth were favored on positive and neutral PEA substrates when 
seeded at high density.
161
 
Knight et al. synthesized series of biodegradable PEAs from the α-amino acids L-alanine, 
L-phenylalanine, and L-lysine in an attempt to investigate human coronary artery smooth 
muscle cell (HCASMCs) interactions. HCASMCs cultured directly on bare PEA films 
attached and spread well up to 7 days of culture. Immunostaining of cells illustrated strong 
vinculin expression on all surfaces. These results suggested that PEAs can potentially be used 
in vascular tissue engineering applications.
154
 Recently, Zilinskas et al. reported the synthesis 
of a series of amphiphilic PEA-PEO graft copolymers through the conjugation of hydrophilic 
PEO to the pendant -amino groups of L-lysine residues in PEAs. The PEO-PEA graft 
copolymers were shown to self assemble into micelles that could encapsulate model 
hydrophobic drug, nile red in aqueous solution. It was found that the sizes of the micelles 
could be tuned by varying the PEO content of the polymers and the method of micelle 
preparation. These materials were also demonstrated to be nontoxic to HeLa cells.  
1.8 Research objectives 
The main objective of this thesis was to design, synthesize and characterize novel polymers 
for biomedical applications including drug delivery and MRI. Proof of concept studies were 
also performed to demonstrate the potential applicability of the new materials in their 
designed applications.  
In chapter 2, the design and synthesis of a diverse range of PEAs based on diols, 
dicarboxylic acids and -amino acids is described, along with a detailed characterization of 
their thermal, mechanical and rheological properties. This work forms a fundamental basis 
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for understanding the structure-property relationships of these materials in order to determine 
their suitability for different applications.  
In chapter 3, the preparation of a novel amphiphilic PEA-PEO graft copolymer with PTX 
conjugated via ester linkage is described and its assembly into micelles is studied. The aim of 
this work is to address the burst release problem commonly observed for polymer micelle- 
and nanoparticle-based drug delivery systems. The kinetics of the PTX release and the in 
vitro toxicity from both this covalent system and an analogous construct where the drug was 
simply physically encapsulated are also described. 
In chapter 4, the principles of chapter 3 are extended, to develop a photo-responsive 
micellar carrier based on an amphiphilic photodegradable PEA. The goal is to provide 
spatially and temporally controlled drug release in response to light as a stimulus. As in 
chapter 3, an ester linkage is used to conjugate the PTX, with the hypothesis that 
photochemically induced degradation of the polymer backbone will result in accelerated ester 
cleavage through increased exposure of the ester to water upon micelle disruption. The 
release kinetics as well as the in vitro toxicities of both photoirradiated and non-
photoirradiated are also discussed.  
Chapter 5 describes the design, synthesis, and study of new cross-linked polymer 
nanoparticles (nanogel) bearing conjugated Gd-DTPA complexes. The cross-linking 
approach is designed to increase the rotational correlation time of the complexes, thereby 
affording high relaxivity. The relaxivity as well as the preliminary in vivo evaluation of the 
agents is discussed. Although these nanogel agents are prepared from nonbiodegradable 
acrylamide-based backbones, PEAs have the potential to be used in a next-generation 
biodegradable version of these agents. 
Chapter 6 describes the main conclusions and contributions of this thesis as well as some 
prospects for future work. 
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Chapter 2  
2 Structure-property relationships for a series of PEAs 
containing amino acids  
2.1 Introduction 
In recent years there has been significant interest in the development of polymers that 
degrade in the environment or under physiological conditions. Biodegradable polymers are 
finding increasingly widespread application in a range of biomedical devices such as sutures, 
wound dressings, tissue engineering scaffolds, and drug delivery vehicles, as well as for 
various food and beverage packaging. Thus far, much effort has been focused on the 
development of polyesters such as PLA,
1,2
 PGA,
3,4 
and PCL.
5-7
 However, their application 
has been limited to some extent due to their poor hydrolytic and thermal stabilities as well as 
their relatively poor mechanical properties, which result from weak intermolecular 
interactions.
8
 Poly(amino acid)s have also been investigated,
9-12
 but their relatively expensive 
and sensitive synthetic approach
13
 and slow degradation
14,15
 have also limited their 
application. Conversely, the monomers for preparing PEAs are relatively inexpensive and the 
synthetic methods do not require inert atmosphere chemistry. PEAs, containing both ester 
and amide linkages in their backbones have been proposed as biodegradable polymers that 
may address the limitations of polyesters and poly(amino acid)s.
16,17
 The presence of ester 
moieties introduces the possibility for both enzymatic and non-enzymatic hydrolytic 
degradation mechanisms similar to those observed for polyesters while amide linkages 
provide opportunities for enzymatic degradation.
16,18-24
 In addition, the interchain hydrogen 
bonding interactions imparted by the amide bonds can potentially improve their properties 
and processability.
25-27
  
While a wide range of PEA backbones have been developed,
16,19,28,29
 the PEAs of interest 
in the present work are those composed of diols, dicarboxylic acids and -amino acids 
(Figure 2.1). This backbone composition is attractive as the monomers can be selected from a 
wide range of readily available, non-toxic metabolic intermediates including a diverse array 
of natural -amino acids, as well as natural dicarboxylic acids such as succinic and fumaric 
acid. A wide variety of PEAs having these structures have been synthesized and 
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studied.
16,30,31
 Their thermal properties
21,30
 and degradation rates
18,19,23,24
 have been found to 
depend on their specific chemical structures. Recently they have been explored for various 
applications including nanoparticles
31
 and micelles for drug delivery,
 31,32 
vascular stent 
coatings,
33,34
 and tissue engineering scaffolds.
35,36
 
 
Figure 2.1. General structure of the PEAs.  
Despite the promise of PEAs to provide improved processability and mechanical 
properties comparable to polyesters, there have been very few studies reported that explore 
the effects of PEA structure on their rheological and/or mechanical properties.
19,37,38
 An 
understanding of these properties will be critical to expand the application of PEAs both 
within and beyond the biomedical field. To address this, we describe here the synthesis of a 
series of PEAs with diverse chemical structures and a study of their thermal, rheological, and 
mechanical properties as a function of their structures and molecular weights (MWs). It is 
demonstrated that all properties of the PEAs depend significantly on their chemical 
structures, with some properties exhibiting a dependence on MW characteristics.  
2.2 Experimental section 
Polymer nomenclature. The polymers are labeled by the first letter of amino acid (A = L-
alanine; P = L-phenylalanine), the first letter of the diol (O = octanediol; B = butanediol; T = 
tri(ethylene glycol); C = cyclohexane dimethanol), the first two letters of the dicarboxylic 
acid moiety (Se = sebacic acid; Te = terephthalic acid), the method of preparation (Sol = 
solution; Int = interfacial) and finally in the case of the interfacial polymerization whether the 
polymer was fractionated (P) or unfractionated (U). For example, AOSe-Int-U represents 
Alanine-Octanediol-Sebacic acid, prepared by interfacial polymerization and  unfractionated. 
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General procedures and materials. AOSe, POSe, and PBSe (Figure 2.1) were prepared by 
Sol and Int methods as previously reported.
35
 The polymers prepared by Int method were 
either fractionated by just washing the precipitated polymer with water (U) or by water wash 
followed by Soxhlet extraction with ethyl acetate for 48 h (P). The polymers prepared by Sol 
method were fractionated by soxhlet extraction with ethyl acetate for 48 h. PBTe was 
prepared by a Sol method as previously reported
30
 then was fractionated by dialysis against 
DMF with Spectra/Por regenerated cellulose membrane with an 25 kg/mol molecular weight 
cutoff (MWCO) for 24 hours with changing of the dialysate every 8 hours, followed by 
dialysis against water and lyophilization. Solvents were purchased from Caledon 
Laboratories (Georgetown, ON). All other chemicals were purchased from Sigma Aldrich 
(Milwaukee, WI). Unless otherwise noted, all chemicals were used as received. Anhydrous 
tetrahydrofuran (THF) was obtained from a solvent purification system. N,N-
Dimethylacetamide (DMA) and triethylamine (NEt3) and CH2Cl2 were distilled from CaH2 
under argon. 
1
H (400 MHz) Nuclear Magnetic Resonance (NMR) spectra were obtained on a 
Varian Inova 400 spectrometer (Varian Canada Inc., Mississauga, ON). Chemical shifts are 
reported in parts per million (ppm) and are calibrated against the residual solvent signals of 
dimethyl sulfoxide (DMSO,  2.50 ppm). Infrared (IR) spectra were obtained using a Bruker 
Tensor 27 (Bruker Corporation, Milton, ON) as KBr disks. Absorption frequencies of the 
functional groups are reported in wavenumbers (cm
-1
). Size exclusion chromatography (SEC) 
data were obtained using a Waters 2695 Separations Module equipped with a Waters 2414 
Refractive Index Detector (Waters Limited, Mississauga, ON) and two PLgel 5 μm mixed-D 
(300 mm × 7.5 mm) columns connected in series (Varian Canada Inc., Mississauga, ON). 
Samples (5 mg/mL) were dissolved in DMF with 10 mM LiBr and 1 % (v/v) NEt3 and were 
injected (100 μL) at a flow rate of 1 mL/min at 85 °C. Molecular weights are reported in 
kilograms/mole (kg/mol) relative to polystyrene standards. 
Synthesis of PBTe by Int polymerization. Terephthaloyl chloride (2.1) (2.7 g, 14 mmol, 1.0 
equiv.) was dissolved in anhydrous dichloromethane (60 mL), and then added dropwise over 
30 min to an aqueous solution (60 mL) of the di-p-toluenesulfonic acid salt of L-
phenylalanine-butanediol diester (2.2)
30
 (9.9 g, 13.7 mmol, 1.0 equiv.) and sodium carbonate 
(2.9 g, 27 mmol, 2.0 equiv.) and the reaction mixture was stirred at room temperature for 17 
hours. Upon completion of the reaction, the solvent was removed in vacuo. The resulting 
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solid polymer was then washed with water and dried in vacuo to provide PBTe-Int-U (Yield: 
5.9 g, 83%); SEC: Mn = 11 kg/mol, Mw = 51 kg/mol, PDI = 4.7. DSC: Tg = 28, 95 C) and 
then further fractionated via soxhlet  extraction with ethyl acetate for 48 hours and dried in 
vacuo yielding polymer 2.4 (4.7 g, Yield: 65%). NMR spectral data agreed with those 
previously reported.
30
 SEC: Mn = 22 kg/mol, Mw = 63 kg/mol, PDI = 2.9. DSC: Tg = 102 C. 
Synthesis of PTSe by Int polymerization. This polymer was prepared as described above 
for PBTe except that sebacoyl chloride (2.4) (2.2 mL, 11 mmol, 1.0 equiv.) and di-p-
toluenesulfonic acid salt monomer (2.3)
39
 ( 9.0 g, 11 mmol, 1.0 equiv.) were used as the 
starting monomers. Upon completion of the reaction, the solvent was removed in vacuo. The 
resulting solid polymer was then washed with excess water to remove salts. (5.7 g, Yield = 
82 %). NMR spectral data agreed with those previously reported.
39
 SEC: Mn =41 kg/mol , 
Mw = 73 kg/mol, PDI = 1.8. DSC: Tg = 28 C.  
Synthesis of PCSe by Int polymerization. This polymer was prepared as described above 
for PBTe except that sebacoyl chloride (2.4) (2.2 mL, 11 mmol, 1.0 equiv.) and di-p-
toluenesulfonic acid salt monomer (2.5)
40
 ( 8.6 g, 11, 1.0 equiv.) were used as the starting 
monomers. The polymer was fractionated as described for PTSe (4.7 g, Yield = 68%). 
1
H 
NMR (400 MHz, DMSO-d6): δppm 8.22 (d, J=7.6, 2H),  7.17-7.28 (m, 10H ), 4.44-4.50 (dd, 
J= 5.3 and 12.5, 2H), 3.81-3.92 (m, 4H), 2.86-3.03 (m, 4H), 2.04 (t, J= 3.8, 4H), 1.59-1.65 
(m, 4H), 1.37-1.40 (m, 8H), 0.85-1.24 (m, 10H). IR: 3292, 3063, 3030, 2927, 2855, 2854, 
1739, 1650, 1539, 1498, 1456, 1194. SEC: Mn =17 kg/mol, Mw = 27 kg/mol, PDI = 1.6. 
DSC: Tg = 48 °C. 
Thermal analysis. Tgs of the polymers were measured by differential scanning calorimetry 
(DSC) using a Q1000 from TA Instruments. The procedure was a heat-cool-heat method. In 
the initial cycle, which eliminated the thermal history of the polymers, the sample was 
equilibrated at -50 °C then heated at 10 °C/min up to 250 °C. The cooling cycle was also 
performed at 10 °C/min to a final temperature of -50 °C. Finally, a second heating cycle, 
which provided the reported Tgs and Tms, was carried out to complete the thermal analysis. 
TG   was performed using a Q5000 from TA Instruments. The sample was heated to 600 °C 
under argon, at a rate of 10 °C /min, then heated to 800 °C under air for a complete 
decomposition. 
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X-ray diffraction. X-ray analysis was carried out using a Rigaku Miniflex X-ray Powder 
diffractometer fitted with a Cu anode. Scans were made from 4 – 35 degrees 2-Theta with a 
fixed Theta/2 Theta geometry and a variable divergence slit. 
Rheology. Viscoelastic properties were investigated using an ARES 2000 rheometer 
equipped with electrically heated parallel plates. Frequency sweep measurements were 
performed at 175 °C over a frequency range of 1–100 rad/s. The plate diameter was 25 mm 
and the gap between the plates was 1000 µm. Temperature-dependent studies were 
performed using a cooling ramp from 175 °C to 35 °C with a cooling rate of 2 °C /min.  
Mechanical properties. Four dog bone shaped polymer strips were cut (25 × 5 × 0.2 mm) 
from a polymer film using a punch press (see appendix). Samples dimensions were measured 
for each sample using a caliper. Tensile properties were measured on an Instron 3367 
equipped with a 50 N load cell at ambient temperature. The cross head speed was set to 5 
mm/min according to ASTM D412. The samples were then elongated to failure.  
2.3 Results and discussion 
2.3.1 Polymer design 
As shown in Figure 2.1, six different PEAs having diverse structures were selected for this 
study. AOSe and POSe were selected to compare the effects of having L-alanine versus L-
phenylalanine as the amino acid component, while maintaining eight-carbon aliphatic chains 
in the diol and dicarboxylic acid components. In particular, L-alanine and L-phenylalanine 
were selected as PEAs based on these amino acids have been shown to exhibit high 
degradation temperatures, facilitating melt processing.
18
 PBSe was selected to examine the 
effect of decreasing the length of the aliphatic chain in the diol moiety. PBTe was chosen to 
incorporate a rigid terephthalic acid spacer in the dicarboxylic acid component. PTSe 
contains a tri(ethylene glycol) chain, which has been previously demonstrated to impart 
semicrystallinity to PEAs with Tms in the region of 60 °C,
39
 which could be of interest for 
various applications. Lastly, the cyclohexane dimethanol component of PCSe was chosen to 
investigate the effect of introducing conformational constraints into the diol moiety, while 
maintaining an eight-carbon diol unit as in AOSe.  
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In addition to varying the constituent monomers, it was also of interest to investigate the 
effects of MW and MW distribution on the properties of the polymers. We have previously 
found that the method of synthesis and purification of PEAs has a significant effect on their 
MW characteristics. Int polymerization often leads to higher MWs than Sol 
polycondensations, likely because it is less impacted by the presence of impurities.
35
 While 
the materials prepared by Int polymerization initially have high polydispersity indices (PDIs), 
the PDIs can be significantly reduced by purification processes such as dialysis and soxhlet 
extraction, which remove lower MW polymers.
35
 Therefore, for selected polymers (AOSe, 
POSe, PBSe, and PBTe) different batches of materials prepared by Sol and Int methods with 
and without fractionation were prepared and studied. 
2.3.2 Polymer synthesis 
AOSe, POSe, and PBSe were prepared by Sol and Int polymerizations as previously 
reported.
35
 The samples designated as U were fractionated by just washing the precipitated 
polymer with water to remove salts, while those designated P were fractionated by water 
washing followed by soxhlet extraction or dialysis. The MW characteristics of these 
polymers, including the number average molecular weight (Mn), weight average molecular 
weight (Mw) and PDI are shown in Table 2.1. As expected, the polymers prepared by the Int 
method generally had higher MWs than those prepared by the Sol method. The MW was 
further increased and the PDIs were narrowed through purification.  
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Table 2.1. Molecular weight characteristics of the PEAs.  
PEA Mn (kg/mol) Mw (kg/mol) PDI 
AOSe-Int-P 40 48 1.2 
AOSe-Int-U 16 38 2.4 
AOSe-Sol 23 34 1.5 
POSe-Int-P 78 93 1.2 
POSe-Int-U 35 59 1.7 
POSe-Sol 30 48 1.6 
PBSe-Int-P 60 102 1.7 
PBSe-Int-U 48 91 1.9 
PBSe-Sol 41 82 2.0 
PBTe-Int-P 22 63 2.9 
PBTe-Int-U 11 51 4.7 
PBTe-Sol 23 36 1.6 
PTSe-Int-U 41 73 1.8 
PCSe-Int-U 17 27 1.6 
The synthesis of PBTe by the Sol method was performed as previously reported,
30
 and 
the Int polymerization was performed as shown in Scheme 2.1, using terephthaloyl chloride 
(2.1), and the di-p-toluenesulfonic acid salt of L-phenylalanine and butanediol (2.3)
30
. The 
product was fractionated as described above for the P and U batches. In this case, the Int-U 
prepared polymer had a significantly lower Mn than that prepared in Sol and the PDI was 
very high (4.7). This can likely be attributed to the poor solubility of PBTe in CH2Cl2, 
whereas its solubility in DMA, the solvent for the Sol polymerization is better. Still, PBTe 
eventually precipitates from DMA, likely limiting its molecular weight. 
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Scheme 2.1. Synthesis of polymers PBTe, PTSe and PCSe by Int polymerization. 
PTSe and PCSe were prepared by only Int polymerization and were fractionated only by 
washing with water. While the Sol synthesis of PTSe has been previously reported,
41
 for this 
study it was prepared Int from the di-p-toluenesulfonic acid salt of L-phenylalanine and 
tri(ethylene glycol) (2.4)
39
 and sebacoyl chloride (2.2) (scheme 2.1). PCSe has not previously 
been reported and it was prepared interfacially from the di-p-toluenesulfonic acid salt of L-
phenylalanine and cis/trans-cyclohexanedimethanol (2.5)
40
 and 2.2 (Scheme 2.1).  
2.3.3 Structure-thermal properties relations 
Although the thermal properties of -amino acid-based PEAs have been well studied, it was 
important to study in detail the thermal properties of the specific PEAs described in this 
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study in order to correlate these properties with the rheological and mechanical properties. 
First, TGA was performed in order to determine the decomposition temperatures of the 
polymers. As shown in Figure 2.2, all of the polymers were stable up to greater than 300 °C, 
with decomposition temperatures (Td) in the range of 325-365 °C (Table 2.2), which should 
easily allow for their processing in the melt. Above this temperature, they underwent 
decomposition via multiple stages as previously reported for PEAs.
42
 It should be noted that 
PBTe had a higher residual mass than the other polymers, which was expected due to its 
thermally stable aromatic hydrocarbon component. 
 
Figure 2.2. Weight loss as a function of temperature for PEAs (Int-U) as measured by TGA.  
Table 2.2. Thermal characterization data for PEAs. 
PEA Td (°C) Tg (°C) Tm (°C) 
AOSe-Int-P 355 12 190 
AOSe-Int-U 345 4 171 
AOSe-Sol 344 19 98, 168 
POSe-Int-P 364 28 103 
POSe-Int-U 355 22 89,163 
POSe-Sol 351 22 101 
PBSe-Int-P 345 40  
PBSe-Int-U 335 40  
PBSe-Sol 350 40  
PBTe-Int-P 338 102  
PBTe-Int-U 335 28, 95  
PBTe-Sol 328 96  
PTSe-Int-U 359 28 107 
PCSe-Int-U 325 48  
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Only minor effects of MW and MW distribution on the degradation temperatures of the 
polymers were observed, with a small lowering of the Td, explainable by differences in MW, 
a parameter known to affect the decomposition temperature.
43,44
 However, the Tds were still 
all in the range of 325-365 °C (see appendix). 
 Tgs and melting temperatures (Tms) for the polymers were measured by DSC. As shown 
in Table 2.2 and Figure 2.3, AOSe was semicrystalline with Tgs ranging from of 3 to 19 °C 
and Tms ranging from 169 to 190 °C depending on the method of preparation. POSe was also 
semicrystalline with Tgs ranging from 22 to 28 °C and Tms ranging from 103 to 163 °C. PTSe 
was semicrystalline with a Tg of 28 °C and Tm of 107 °C. In comparing POSe with PTSe, 
while the length of the spacer between the amino acids is the same in each case (8 atoms), the 
lower Tg of the PTSe may be attributed to the increased flexibility of the polyether units in 
comparison with the octyl chain. In some cases, multiple melting transitions were observed, 
which can likely be attributed to the melting of crystalline domains with different lamellar 
thicknesses. This has frequently been observed for polyamides.
45
 
 
Figure 2.3. Overlay DSC traces for PEAs (Int-U).  
PBSe, PBTe, and PCSe were amorphous with Tgs of 40, 28°C and 95-102 °C, and  
48 °C respectively. Comparing POSe and PBSe, the Tg appears to decrease as the number of 
methylenes in the diol moiety increases. This was expected as the longer chain makes the 
polymer more flexible. The pendent phenyl group on the amino acid moiety increased the Tg 
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as demonstrated by the comparison between the AOSe and POSe. This can be attributed to 
the phenyl group decreasing the flexibility of the polymer, as has been previously observed.
30
 
PBTe and PCSe exhibited the highest Tgs of 95-102 °C and 48 °C respectively. PBTe is 
rigidified by the inflexible aromatic acid backbone, which significantly increases the Tg. The 
cyclohexyl spacer in PCSe increases the rigidity of the polymer backbone to some extent, by 
comparison with POSe, also having a linear eight-carbon spacer. It also makes the polymer 
fully amorphous, unlike POSe.  
In comparing batches of the same polymer having different MWs and PDIs, a couple of 
trends emerged. In general the Tgs and Tms of the lower MW and more polydisperse samples 
were lowered, as expected, though not to a great extent. For example, the Tg of POSe-Int-P 
was 28 °C, while that of POSe-Int-U and POSe-Sol were 22 °C (Figure 2.4). In addition, 
extra transitions were sometimes observed for the lower MW, more polydisperse samples. 
For example, additional melting transitions were clearly observed for AOSe-Sol and POSe-
Int-U. For PBTe-Int-U an additional Tg at 28 °C was observed. This is likely a result of the 
very high PDI of 4.71 for this polymer sample. Additional very minor transitions were also 
observed for AOSe-Int-U. However, the amorphous polymers remained amorphous and the 
semicrystalline polymers remained semicrystalline regardless of the MW characteristics and 
the overall changes in thermal properties across the different batches were relatively modest.  
 
Figure 2.4. Overlay of DSC traces for POSe prepared by different methods.  
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2.3.4 X-ray diffraction 
Powder X-ray diffraction (XRD) was also performed to further assess the molecular 
orientations of the polymers. In general, the XRD patterns for amorphous polymers exhibit 
very broad peaks, consistent with the incoherent scatter from the amorphous solid, while 
crystalline polymers provide multiple sharp peaks consistent with diffraction from a 
crystalline lattice. As MW and PDI had only modest effects on thermal properties of the 
polymers, only unfractionated polymers prepared by Int-U were studied by XRD. As shown 
in Figure 2.5, the XRD results suggested that PBSe, PBTe and PCSe were amorphous, 
consistent with the presence of only a glass transition observed in DSC. POSe, PTSe, AOSe 
appear to have some degree of crystallinity with several peaks present, which is also in 
agreement with the DSC results, showing that these polymers have broad melting peaks. 
 
Figure 2.5. XRD of PEAs a) amorphous PEAs b) semicrystalline PEAs. 
2.3.5 Structure-rheological properties correlations 
The complex viscosities versus temperature and frequency were measured for all of the 
PEAs. The temperature ramp test is a sensitive test to provide information about phase 
transitions in polymer structures. As such, it is complementary to DSC and XRD. As shown 
in Figure 2.6, the complex viscosity for AOSe-Int-U and POSe-Int-U dramatically increased 
as the temperature was lowered from 175 °C to approximately 170 and 140 °C respectively. 
DSC showed that these polymers have broad melting transitions in these regions and the 
rapid increases in viscosities were likely a result of crystallization. PBTe-Int-U exhibited a 
rapid increase in viscosity at approximately 100 °C, likely a result of its glass transition in 
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this region. For PBSe-Int-U and PCSe-Int-U, gradual changes in viscosities were observed 
over a large temperature rangeas expected based on their thermal properties. In the case of 
PTSe-Int-U, the crystallization that was evident in the DSC and XRD results was not 
detected in the complex viscosity versus temperature measurements. This can likely be 
attributed to the flexible backbone of PTSe, which may require more time to organize into 
crystalline domains.  
 
Figure 2.6. Complex viscosity versus temperature for different PEAs.  
The viscoelastic effects on the complex viscosity versus temperature were also evaluated 
for AOSe, POSe, PBSe, and PBTe (Figure 2.7 and see appendix). It was found that in 
general, there were only modest effects resulting from the MW differences. These differences 
reflected the differences observed in the Tms and Tgs of these polymers. 
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Figure 2.7. Complex viscosity versus temperature for AOSe, showing the effect of MW and 
MW distribution.  
The complex viscosity versus frequency was also measured for the PEAs. These 
measurements were performed at 175 °C, which allowed all of the polymers to be in the melt 
state. As shown in Figure 2.8, all of the PEAs exhibited frequency-independent behavior, 
suggesting that they exhibit Newtonian behavior for this range of frequencies. The 
magnitudes of the complex viscosities were expected to be dependent on both the PEA 
chemical structure as well as Mw. It was found that across the diverse PEA structures, there 
was no strong correlation between Mw and complex viscosity. For example, PBTe and PCSe 
exhibited higher viscosities than would be expected based on a comparison of their Mws to 
those of other polymers, suggesting that the chemical structure had the dominant effect. In 
the case of these polymers, the presence of the highly rigid aromatic unit in the PBTe 
backbone and the cyclohexyl unit in the PCSe backbone may constrain the motion of these 
molecules, increasing their viscosities. On the other hand, despite its relatively high Mw, 
PTSe had the lowest complex viscosity of all the polymers. This is likely due to the flexible 
polyether units enhancing the chain motion of this polymer.  
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Figure 2.8. Complex viscosity versus frequency for all PEAs (175 °C). 
For AOSe, POSe, PBSe, and PBTe (Figure 2.9 and see appendix), the complex viscosities 
versus frequency were compared for the Int-P, Int-U, and Sol batches in order to investigate 
the effects of MW and polydispersity. As expected, the complex viscosities decreased with 
decreasing Mw and increasing PDI. Therefore, this study confirmed that the rheological 
properties are highly dependent on both the chemical structures and MWs of the PEAs and 
these values can be readily tuned through the choice of selected monomers as well as through 
the polymerization method. Furthermore, unlike polyesters, which are sensitive to hydrolytic 
degradation and require careful control of the processing conditions,
46
 it should be possible to 
use common processing technique such as extrusion, injection and compression molding to 
fabricate PEA materials.  
 
Figure 2.9. Complex viscosity versus frequency for POSe, showing the effect of MW and 
MW distribution.  
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2.3.6 Tensile testing 
Knowledge of the mechanical properties of PEAs is critical to determine their utility in 
various applications. For example, in vascular tissue engineering, a soft, tough, and 
elastomeric biodegradable polymer which can provide mechanical stability under 
physiologically relevant forces would be ideal to mimic the natural form of the extracellular 
matrix.
47
 In this study, the mechanical properties of the PEAs were first evaluated by tensile 
testing. Representative stress-strain curves for AOSe-Int-U, POSe-Int-U, PBTe-Int-U, and 
PTSe -Int-U are shown in Figure 2.10 and the measured mechanical properties are 
summarized in Table 2.3. PBTe-Int-U and PCTe-Int-U were too brittle and it was not 
possible to prepare samples for analysis. As shown in Figure 2. 10a, AOSe-Int-U and PBSe-
Int-U were also brittle with tensile strengths of 4.0 ± 1 and 20 ± 2 MPa, breaking strains of 
1.3 ± 0.4 and 2.3 ± 0.3 and Young’s moduli of 372 ± 103 and 1123 ± 220 MPa respectively. 
In case of PBSe-Int-U the brittleness was expected as this polymer has a Tg of 40 °C which is 
substantially higher than the test temperature of 23 °C. AOSe-Int-U is a semicrytalline 
material, and the crystalline domains likely impart brittleness to the material. However, this 
result needs to be further investigated. 
 
Figure 2.10. Tensile stress versus tensile strain a) PBSe-Int-U and AOSe-Int-U b) POSe-Int-
U and PTSe-Int-U.  
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Table 2.3. Tensile properties of PEAs. 
PEA 
 
Tensile strength
 a
 
(MPa) 
Breaking strain 
a
 
(%) 
Young’s modulus a 
(MPa) 
AOSe-Int-P 4 (±1) 1.3 (±0.4) 372 (±103) 
AOSe-Int-U 4.5 (±1) 2 (±0.5) 420 (±55) 
AOSe-Sol 5.5 (±2) 1.7 (±1) 350 (±60) 
POSe-Int-P 2.5 (±0.5) 556 (±74) 5.8 (±1.6) 
POSe-Int-U 2.0 (±1) 550 (±50) 4.6 (±2) 
POSe-Sol 1.5 (±1) 500 (± 100) 2.9 (±1) 
PBSe-Int-P 20 (±2) 2.3 (±0.3) 1123 (±220) 
PBSe-Int-U 15 (±3) 3.0 (±0.5) 850 (±80) 
PBSe-Sol 25 (±5) 3.5 (±1) 900 (±100) 
PTSe-Int-U 0.7 (±0.1) 220 (±20) 20 (±13) 
a
Errors on the measurements represent the standard deviations of four measurements per 
sample. 
POSe-Int-U and PTSe-Int-U both had lower tensile strengths and Young's moduli 
compared to PBSe-Int-U and AOSe-Int-U, but exhibit different behaviours from one another 
during extension as illustrated in Figure 2.10b. The tensile properties of POSe-Int-U were 
consistent with those of an elastomeric material and were comparable to poly(1,8-octaidiol-
citric acid)
48
 and poly(glycerol-sebacate)
47
 which have been shown to exhibit promising 
mechanical properties for tissue engineering applications. It is interesting to note that POSe-
Int-U had a maximum elongation of 556 ± 74% at break which is similar to that of the 
arterial and venous cellular lining (up to 260%),
49
 and much larger than that of tendons (up to 
18%).
50
 On the other hand, PTSe had the lowest tensile strength of 0.7 ± 0.1 MPa. After the 
necking point, a decrease in stress was observed until the polymer broke at 220 ± 20.  This is 
likely due to the flexible ether linkages, which may help the chains to slip easily past each 
other to relax the stress.  
The effect of MW and MW distribution was also investigated for AOSe, POSe, and PBSe 
(see appendix and Table 2.3). For AOSe and POSe, the mechanical properties were not 
greatly affected by the MW within the limits of the errors on the measurements. This is in 
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contrast to the mechanical properties of polyesters, where high MWs are required in order to 
obtain the desired mechanical properties. However, for PBSe, which exhibited elastomeric 
properties, the expected trend was observed in that decreasing MW and increasing the PDI 
tended to reduce the tensile strength, breaking strain, and Young's modulus. 
2.4 Conclusions 
A series of PEAs having diverse chemical structures were prepared by Int and Sol 
polymerization methods to obtain batches of material with different MWs and PDIs. The 
effects of PEA chemical structure and MW on the thermal, rheological, and mechanical 
properties were studied with the aim of elucidating structure-property relationship. All of the 
PEAs were very thermally stable and as expected, the thermal properties were greatly 
affected by the chemical structure of the PEA backbone but less so by the MW 
characteristics. The rheological behavior was also significantly affected by the chemical 
structure and also by the molecular weight, with more flexible PEAs, and those having lower 
Mw and higher PDIs resulting in lower viscosities. The mechanical properties of the PEAs 
were diverse, ranging from highly brittle solids to elastomeric materials. MW characteristics 
affected the mechanical properties of some, but not all of the PEAs. Overall, these results 
confirm previous work demonstrating that diverse thermal properties can be obtained by 
varying the chemical structure of PEAs but in addition provide a new framework for 
understanding the effects of PEA structure on their rheological and mechanical properties as 
well as the effects of MW on the thermal, rheological, and mechanical properties. This 
should be useful in the design and development of PEAs with optimal properties for specific 
applications. 
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Chapter 3  
3  A comparison of covalent and noncovalent strategies for 
PTX delivery using PEA graft copolymer micelles 
3.1 Introduction 
Over the past few decades there has been significant interest in the development of new drug 
delivery systems to address the problematic properties of drug molecules.
1-6
 Some common 
challenges encountered with current and potential drugs include low aqueous solubility, short 
plasma circulation half-life, susceptibility to rapid degradation in plasma, and high toxicity.
7,8
 
For example, PTX is a highly effective chemotherapeutic drug.
9
 However, due to its very low 
water solubility, it is formulated in a mixture of the surfactant CrEL and ethanol (Taxol).
10,11
 
Unfortunately CrEL is known to cause serious side effects, including hypersensitivity 
reactions,
12
 and is also reported to result in unpredictable pharmacokinetic behaviour.
13
  
Because of the challenges associated with the administration of PTX, the development of 
improved delivery systems for PTX has been an active area of research.
14-16 
Albumin-bound 
PTX nanoparticles (Abraxane) were approved in 2005 for the treatment of metastatic breast 
cancer and in 2012 for the treatment of non-small cell lung cancer.
17
 Genexol was approved 
in Korea in 2007 for breast cancer treatment
18
 and is currently in phase II clinical 
development in the USA.
19
 A number of different nanoparticle formulations based on 
polymers such as PLGA,
20
 PLA,
21,22
 PCL,
23,24
 chitosan,
25,26
 and HA
27,28
 have also been 
developed. Micellar systems based on amphiphilic copolymers such as PEO-
phosphatidylethanolamine,
29
 PEO-polyaspartate,
30
 PEO-PCL,
31
 PEO-b-PGLA-b-poly(L-
phenylalanine)
32
 and PEO-b-(PLLA-b-PCL)
33
 have also been investigated. Many of these 
systems have very promising antitumor efficacy and lower toxicity than Taxol. However, a 
common limitation encountered in such systems
20-33
 in which the drug molecule is only 
encapsulated through hydrophobic interactions with the micelle or nanoparticle core is the 
rapid or "burst" release of drug, in which a large percentage of the drug is released rapidly 
over the first several hours. This can limit the lifetime of the drug delivery system and in 
some cases can result in high systemic toxicity.
14
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The burst release of drug molecules can be mitigated through covalent immobilization 
strategies. For example, Cheng and coworkers have reported the polymerization of lactide 
from the 2'-hydroxyl moiety of PTX, followed by the formation of well-defined spherical 
nanoparticles from these conjugates.
34,35
 Conjugates of dendrimers
36,37
 and polymers such as 
heparin,
38
 poly((N-(2-hydroxypropyl) methacrylamide),
39
 and PLGA
40,41
 have also been 
reported, though care must be taken to maintain the water solubilities/dispersibilities of these 
systems due to the hydrophobicity of PTX. The development of nanosized micelles with PTX 
covalently immobilized at the micelle core is an attractive strategy for controlling the release 
of PTX while at the same time allowing excellent water dispersibility and  size control of the 
assemblies at the nanoscale. However, thus far, there are only a few examples of this 
approach. For example PTX has been conjugated  to the pendant carboxylic acid groups of 
triblock copolymers based on PEO and random copolymers of L-lactide and (3s)-
benzoxylcarbonylethyl-morpholine-2,5-dione.
42
 PTX has also been covalently incorporated 
into poly(disulfide amine) based micelles, which contained arginine moieties for co-delivery 
of drugs and DNA, though the release of PTX was not studied.
43
 With the aim of pH-
dependent PTX release, PTX was very recently conjugated to PEO-PAA block copolymers 
via acetal linkages and the resulting amphiphilic copolymers were assembled to form 
micelles.
44
  
PEAs are a class of polymers comprising both ester and amide linkages in their 
backbones. The amide linkages impart the potential for enzymatic degradation, while the 
ester linkages can be degraded through both enzymatic and non-enzymatic hydrolysis.
45,46 
 
While a variety of PEA backbones have been reported,
45
 those composed of amino acids, 
dicarboxylic acids and diols are particularly attractive as the constituent monomers can be 
selected from a variety of readily available and non-toxic molecules. In recent work, this 
class of polymers has been investigated in a wide range of biomedical applications including 
drug-loaded microparticles,
47
 tissue engineering scaffolds,
48
 vascular stent coatings,
49,50 
and 
hydrogels.
51,52
 The incorporation of amino acids with pendant side chain functional groups 
has allowed PEAs to be functionalized to impart specific properties for biomedical 
applications. For example, pendant guanidine groups can impart transfection capabilities,
53
 
carboxylic acids or amines can modulate of cell adhesion and proliferation on polymer 
films,
48
 and protected amines or thiols can be used to trigger PEA backbone degradation 
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upon stimulus-induced protecting group cleavage.
54
 Utilizing the pendant -amino groups of 
L-lysine resides in PEAs, our group has recently reported the synthesis of a series of 
amphiphilic PEA-PEO graft copolymers and their assembly into micelles in aqueous 
solution.
55
  
Using a PEA containing L-aspartic acid, we describe here use of the pendant carboxylic acid 
moieties to conjugate PTX via ester linkages, for a slow, controlled release of drug, as well 
as PEO chains to impart amphiphilicity, allowing the resulting graft copolymers to assemble 
into nanometer-sized micellar drug depots. To demonstrate the effects of covalent drug 
immobilization, we compare this system with an analogous PEA micelle in which the PTX is 
physically encapsulated. The release rates and in vitro toxicities of these systems are 
compared to demonstrate the potential advantages of covalent drug immobilization in this 
system.Experimental section 
General procedure and methods. All reactions were run under an argon atmosphere unless 
otherwise indicated. Flasks were oven dried and cooled in a dessicator prior to use. Starting 
monomers
56-58
 and amine terminated poly(ethylene glycol)
59
 (PEO-NH2) with MWs of 5 
kg/mol were synthesized as previously reported. Unless noted otherwise, all chemicals were 
purchased from commercial suppliers and used as received. Anhydrous CH2Cl2 was obtained 
by distillation over CaH2. IR spectra were obtained using a Bruker Tensor 27 instrument 
either as films from CH2Cl2 on NaCl plates or as KBr pellets. 
1
H NMR spectra were obtained 
at 400 MHz on a Varian Mercury 400 Spectrometer. Chemical shifts are reported in ppm and 
are calibrated against residual solvent signals of CDCl3 (δ 7.27) and/or DMSO-d6 (δ 2.54). 
All coupling constants (J) are reported in Hz. SEC data were obtained using a Waters 2695 
separations module equipped with a Waters 2414 refractive index detector (Waters Limited, 
Mississauga, ON, Canda) and two PLgel 5 μm mixed-D (300 mm × 7.5 mm) columns 
connected in series (Varian, Canada). Samples (5 mg/mL) dissolved in the eluent, which 
comprised 10 mM LiBr and 1 vol% NEt3 in DMF at 85 °C, were injected (100 μL) at a flow 
rate of 1 mL/min. Calibrations were performed using polystyrene standards. PTX was 
quantified by isocratic reverse-phase HPLC using a Waters 2695 separations module 
(Waters, Milford, USA), a Waters 2998 Photodiiode Array Detector and a LiChroCART 
125-4 RP-18 column (5 m, MerckMillipore, Damstadt, Germany). The mobile phase 
consisted of water/acetonitrile (40:60 v/v).The flow rate was 1.0 mL/min and the detection 
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wavelength was 227 nm.  100 μL of the analyte solution were injected. A calibration curve 
was prepared for PTX dissolved in water/acetonitrile (40/60 v/v). Dynamic light scattering 
(DLS) was performed on a ZetaSizer Nano instrument from Malvern (Worcestershire, UK).. 
Dialysis was performed using Spectra/Por 6 regenerated cellulose membranes from Spectrum 
Laboratories with a MWCO of 3.5, 12-14, or 50 kg/mol (Rancho Dominguez, CA, USA). 
Synthesis of polymer 3.4. To monomer 3.2
56
 (4.1 g, 5.7 mmol, 0.80 equiv) and sodium 
carbonate (1.5 g, 14 mmol, 2.0 equiv) in distilled water (30 mL), monomer 3.3
58
 (0.62 g, 1.4 
mmol, 0.20 equiv) in CH2Cl2 (15 mL) was added. After mixing the two phases for 30 min, 
sebacoyl chloride (3.1)  (1.7 mL, 7.0 mmol, 1.0 equiv.) in CH2Cl2 (15 mL) was added 
dropwise over 30 min. After completion (ca. 24 h), the organic layer was separated, washed 
with water and brine, and evaporated in vacuo. The resulting crude polymer was then 
dialyzed against DMF with a 12-14 kg/mol MWCO membrane for 24 h, changing of the 
dialysate every 12 h to provide polymer 4 (2.3 g, 60%). 
1
H NMR (400 MHz, DMSO-d6): δ 
8.21 (d, J = 7.8, 2 H), 7.16-7.28 (m, 8 H), 4.53 - 4.60 (m, 0.4 H), 4.41-4.49 (m, 1.6 H), 3.96-
4.05 (m, 4H), 2.96-3.04 (m, 1.6 H), 2.88 (dd, J = 13.6 and 9.4, 1.6H), 2.68 (dd, J = 16.0 and 
5.8, 0.4H), 2.53-2.58 (m, 0.4 H), 2.01 - 2.11 (m, 4H), 1.53-1.59 (m, 1H), 1.37-1.45 (m, 10H), 
1.12-1.17 (m, 8H). (KBr pellet, cm
-1
): FTIR 3312, 3065, 3031, 2928, 2856, 1741, 1640, 
1542. SEC: Mn = 29 kg/mol, Mw = 41 kg/mol, PDI = 1.4  
Synthesis of polymer 3.5. To polymer 3.4 (1.0 g, 1.7 mmol, 1.0 equiv) in CH2Cl2 (1 mL), 
trifluoroacetic acid (1 mL) was added and the reaction mixture was stirred for 2 h. After 
completion, toluene (15 mL) was added and the solvent was removed in vacuo to provide the 
unprotected polymer in quantitative yield. The resulting polymer was then washed with cold 
ethyl acetate (5 mL) three times to provide polymer 3.5 (0.98 g, 98%). 
1
H NMR (400 MHz, 
DMSO-d6): δ 8.19 (d, J = 7.8, 2H), 7.17 - 7.28 (m, 8H), 4.54 - 4.57 (m, 0.4H), 4.43 - 4.49 (m, 
1.7H), 3.97 - 4.06 (m, 4H), 2.98 - 3.03 (m, 2H), 2.85 - 2.91 (m, 2H), 2.67 - 2.73 (m, 0.4H), 
2.56 - 2.62 (m, 0.4H), 2.02 - 2.08 (m, 4H), 1.59 (br s, 0.6H), 1.46 (br s, 4H), 1.38 - 1.40 (m, 
2.4H), 1.16 - 1.22 (m, 2H), 1.12 (br s, 8H). FTIR (KBr pellet, cm
-1
): 3310, 3062, 3030, 2931, 
2852, 1741, 1647, 1543. 
Synthesis of PEA–PTX conjugate 3.6. To polymer 3.5, (0.20 g, 0.14 mmol of the pendant 
carboxylic acid groups, 1.0 equiv) in CH2Cl2 (4 mL) at 0 °C, PTX (0.063 g, 0.07 mmol, 0.5 
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equiv), DCC (0.036 g, 0.17 mmol, 2.4 equiv) and 4-(dimethylamine)pryidine (DMAP) (0.014 
g, 0.11 mmol, 0.8 equiv) were added. After 12 h, the reaction was warmed to room 
temperature and stirred for another 8 h. The reaction was then filtered out to remove the 
dicyclohexylurea byproduct and the filtrate was concentrated under vacuum to give the crude 
product. The polymer was then purified by dialysis against DMF with 12-14 kg/mol MWCO 
membrane for 24 h, changing the dialysate every 12 h to provide 3.6 (0.21 g, 80%). 
1
H NMR 
(400 MHz, DMSO-d6): δ 9.18 (d, J = 7.0, 0.19H), 8.22 (d, J = 7.4, 2H), 7.97 (d, J = 7.4, 
0.47H), 7.85 (d, J = 7.4, 0.44H), 7.71 (d, J = 7.0, 0.2H), 7.65 (d, J = 7.0, 0.42H), 7.40 - 7.57 
(m, 1.62H), 7.21 - 7.27 (m, 4H), 7.10 - 7.19 (m, 6H), 6.30 (br s, 0.2H), 5.84 - 5.86 (m, 
0.21H), 5.542 - 5.65 (m, 0.2H), 5.32 - 5.42 (m, 0.46H), 4.91 - 4.89 (m, 0.38H), 4.51 - 4.69 
(m, 0.59H), 4.42 - 4.48 (m, 2H), 3.96 - 4.06 (m, 4H), 3.57 (d, J = 6.3, 0.2H), 2.97 - 3.02 (m, 
2H), 2.80 - 2.91 (m, 2H), 2.25 (d, J = 11.3, 0.28H), 2.21 (s, 0.34H), 2.08 - 2.13 (m, 1.08H), 
2.03 (t, J = 7.2, 4H), 1.74 - 1.779 (m, 0.51H), 1.50 (br s, 0.88H), 1.41 - 1.45 (m, 3H), 1.34 - 
1.39 (m, 2.38H), 1.06 - 1.15 (m, 8H), 1.03 (br s, 0.85H), 0.99 (br s, 0.66H). IR (thin film, cm
-
1
): 3295, 3063, 3029, 2929, 2855, 1740, 1653, 1540.  
Synthesis of PEA–PEO graft copolymer 3.7. To polymer 3.5, (0.20 g, 0.14 mmol of the 
pendant carboxylic acid groups, 1.0 equiv) in CH2Cl2 (4 mL) at 0 °C, PEO-NH2 with a 
molecular weight of 5 kg/mol (0.35 g, 0.07 mmol, 0.5 equiv), DCC (0.036 g, 0.17 mmol, 2.4 
equiv) and DMAP (0.014 g, 0.11 mmol, 0.80 equiv) were added. After 12 h, the reaction was 
warmed to room temperature and stirred for another 8 h. The reaction was then filtered to 
remove the dicyclohexylurea byproduct and the filtrate was concentrated under vacuum to 
give the crude product. The polymer was then purified by dialysis against DMF using a 50 
kg/mol MWCO membrane for 24 hours, changing of the dialysate every 8 h, to provide 
polymer 3.7 (0.46 g, 87%). 
1
H NMR (400 MHz, DMSO-d6): δ 8.22 (d, J = 7.6, 2.11H), 7.24 - 
7.25 (m, 4H), 7.16 - 7.22 (m, 6H), 4.53 (br s, 0.38H),  4.45 (q, J = 7.6, 2H), 4.00 (br s, 
0.73H), 3.96 (br s, 4H), 3.60 - 3.64 (m, 0.99H), 3.51 (s, 123H), 3.36 - 3.43 (m, 1.87H), 3.24 
(s, 0.87H), 2.99 (dd, J = 5.3 and 13.5, 2H), 2.85 - 2.91 (m, 2H), 2.07 (br s, 0.74H), 2.03 (t, J 
= 7.0, 4H), 1.58 (br s, 0.9H), 1.42 - 1.47 (m, 4H), 1.38 (br s, 3.52H), 1.18 (br s, 2.33H), 1.12 
(br s, 8H). IR (thin film, cm
-1
): 3429, 3030, 2871, 1958, 1739, 1653, 1540.  
Syntheses of PEA–PTX–PEO graft copolymer 3.8. To polymer 3.6 (0.18 g, 0.06 mmol of 
the pendant carboxylic acid groups, 1.0 equiv) in CH2Cl2 (4 mL) at 0 °C, PEO-NH2 with a 
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molecular weight of 5 kg/mol (0.25 g, 0.05 mmol, 0.8 equiv), DCC (18 mg, 0.09 mmol, 1.3 
equiv) and DMAP (7 mg, 0.05 mmol, 0.8 equiv) were added. After 12 h, the reaction was 
warmed to room temperature and stirred for another 8 h. The reaction was then filtered to 
remove the dicyclohexylurea byproduct and the filtrate was concentrated in vacuo to give the 
crude product. The polymer was then purified by dialysis against DMF using a 50 kg/mol 
MWCO membrane for 24 h, changing of the dialysate every 8 h to provide polymer 3.8 (0.35 
g, 79%). 
1
H NMR (400 MHz, DMSO-d6): δ 9.16 (d, J = 6.6, 0.13H), 8.22 (d, J = 7.8, 2.19H), 
7.97 (d, J = 7.8, 0.5H), 7.85 (d, J = 7.8, 0.4H), 7.71 (d, J = 7.0, 0.2H), 7.64 - 7.67 (m, 0.43H), 
7.44 - 7.53 (m, 1.68H), 7.23 - 7.27 (m, 4H), 7.16 - 7.21 (m, 6H), 6.30 (s, 0.18H), 5.84 (t, 
0.18H), 5.56 (t, J = 8.20 Hz, 0.17H), 5.35 - 5.43 (m, 0.45H), 4.90 (d, J = 4.69, 0.37H), 4.61 - 
4.63 (m, 0.39H), 4.43 - 4.48 (m, 2H), 3.96 (br s, 4H), 3.67 - 3.69 (m, 0.41H), 3.51 (s, 61H), 
3.32 (br s, 2,.9H), 3.00 (dd, J = 5.5 and 13.7, 2H), 2.88 (dd, J = 9.4 and 13.7, 2H), 2.21 - 2.27 
(m, 0.57H), 2.08 (br s, 0.97H), 1.99 - 2.05 (m, 4H), 1.73 - 1.77 (m, 0.56H), 1.50 (br s, 1H), 
1.41 - 1.45 (m, 4H), 1.38 (br s, 2.58H), 1.11 (br s, 8H), 1.03 (br s, 0.74H), 0.99 (br s, 0.62H). 
IR (thin film, cm
-1
): 3292, 3063, 2890, 1740, 1653, 1540. SEC: Mn = 35 kg/mol, Mw = 100 
kg/mol, PDI = 2.8 
 Micelle formation. (a) Micelles containing covalently conjugated PTX (cov-PEA-PTX-
micelles): The PEA-PEO-PTX graft copolymer 3.8 (2.0 mg) was dissolved in THF (0.2 mL). 
The solution was stirred rapidly while distilled water was rapidly added to provide a final 
volume of 2 mL. THF was then removed by dialysis against distilled water using 12–14 
kg/mol MWCO membrane. The micelle solution was then filtered with a microfilter (pore 
size: 0.45 μm, Tuffryn® syringe filter, PALL) to eliminate the aggregated particles and dust 
prior to size determination.. (b) Micelles containing physically encapsulated PTX (noncov-
PEA-PTX-micelles): PEA-PEO graft copolymer 3.7 (2.0 mg) was added to 0.15 mL of PTX 
in THF (1 mg/mL) and then diluted to 2 mL with water. The THF was then evaporated. Free 
PTX was removed by filtration through 0.45 μm filter.  
Transmission electron microscopy (TEM). The micelle suspension (prepared as described 
above, 20 μL of 0.1 mg/mL) was placed on a Formvar/Carbon grid and was left to stand for 5 
min. The excess solution was then blotted off using a piece of filter paper. The resulting 
sample was dried in air overnight before imaging. Imaging was performed using a Phillips 
CM10 microscope operating at 80 kV with a 40 μm aperture. 
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In vitro release of PTX from cov-PEA-PTX-micelles. The in vitro release of PTX was 
evaluated by a dialysis method. 2 mL of micelles (PTX concentration: 100μg/mL) were 
placed into a pre-swollen dialysis bag with a 3.5 kg/mol MWCO and immersed into 500 mL 
of 10 mM phosphate buffer at 37 °C. Dialysis was performed with gentle stirring and the 
amount of PTX released into media was measured by HPLC every 24 h for 14 days. At each 
time point, an aliquot of  15 mL of the dialysate  was withdrawn and the  dialysate was 
replaced with fresh media. Then, the aliquot was removed via lyophilization and the solid 
was redissolved in 1 mL of 60:40 water:acetonitrile. The solution was filtered with a 0.2 μm 
pore size (Tuffryn® syringe filter, PALL) filter into a vial for detection of the PTX 
concentration by HPLC as described above. The cumulative PTX release was calculated. The 
release experiments were conducted in triplicate, and the results presented are the mean  
standard deviation.  
In vitro release of PTX from noncov-PEA-PTX-micelles. The release procedure was 
performed as described above for PTX-loaded micelles except that dialysis was performed 
for 48 h and the amount of PTX released into the media was measured at 1, 2, 3, 5, 7, 8, 10, 
24, and 48 h. At each time point, an aliquot of the dialysate (15 mL) was withdrawn and 
replaced with an equal volume of fresh buffer. After 48 h, the amount of PTX remaining in 
the dialysis bag was also measured using the same method. The release experiments were 
conducted in triplicate, and the results presented as the mean  standard deviation. 
In vitro anti-tumoral activity. HeLa cells were cultured at 37 °C and 5% CO2 in Dulbecco’s 
Modified Eagle Medium (DMEM)(Invitrogen) supplemented with 10% (vol/vol) fetal bovine 
serum (Invitrogen) and antibiotics (penicillin and streptomycin, 100 units/mL each). The 
cells were seeded into a Nunclon® 96-well U bottom transparent polystrol plate at a density 
of 2500 cells per well in a final volume of 100 μL of DMEM. Cells were allowed to adhere 
for 24 h at 37 °C in a humidified incubator with 5% CO2. Next, the growth medium was 
aspirated and was replaced with either the positive control - sodium dodecyl sulfate (SDS) in 
the cell culture medium at concentrations of 0.2, 0.15, 0.10, or 0.05 mg/mL, just the medium 
or testing materials. The cells were incubated with cov-PEA-PTX-micelles and noncov-PEA-
PTX-micelles at PTX concentrations of 25, 12.5, 6.2, 2.5, 1.2, 0.62, 0.31 ng/mL. Micelles 
without drug were also prepared as described above and evaluated at concentrations from 
300, 30, 15, 7.5, 3.6, 1.5 and 0.37 ng/mL. For comparison, PTX solubilized in CrEL/ethanol 
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was prepared according to Lee et al.
60
 In short, 6 mg of PTX was dissolved in 0.5 mL of 
dehydrated ethanol and to this solution 0.5 mL CrEL was added. This mixture was then 
sonicated for 30 min. This sample diluted to provide the same PTX concentrations as above. 
A control formulation without PTX was prepared using 1/1 CrEL/ethanol. This solution was 
diluted similar to similar CrEL/ethanol concentrations used in the PTX formulations 
described above to evaluate the toxicity of the vehicle. Eight replicates per concentration 
were performed. After 72 h, the media were aspirated and replaced with 110 μL of fresh 
medium containing 0.5 mg/mL (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) (MTT) reagent. After 4 h of incubation (37 °C, 5% CO2), the MTT solution was 
carefully aspirated and the purple crystals were dissolved by addition of 50 μL of 
spectroscopic grade DMSO. After shaking (1 second, 2 mm amp, 654 rpm), the absorbance 
of the wells at 540 nm was read using an M1000-Pro plate reader (Tecan). The absorbance of 
wells not containing cells but treated by all of the above steps was subtracted as a 
background and the cell viability was calculated relative to wells containing cells that were 
exposed to just culture medium. No (0%) cell viability was detected for the cells exposed to 
the highest concentrations of the positive control sodium lauryl sulfate, confirming the 
sensitivity of the assay. 
3.2 Results and discussion 
3.2.1 Polymer design and synthesis 
A PEA backbone based on L-phenylalanine, L-aspartic acid, 1,4-butanediol, and sebacic acid 
was selected based on its ease of synthesis by an interfacial method and the presence of 
carboxylic acid functional handles for conjugation of the hydrophobic PTX and a hydrophilic 
polymer PEO. PEO was chosen as the hydrophilic block for grafting due to its high water 
solubility, known biocompatibility in drug delivery applications, and its stealthy properties in 
vivo.
61,62
 Monomers 3.2 and 3.3 (Scheme 3.1) were prepared as previously reported. An 
80/20 ratio of 3.2/3.3 was selected for random incorporation into the polymer backbone as 
this would allow for sufficient content of PEO and PTX to be conjugated, while still allowing 
reasonably high MW polymers to be obtained, as the MW tends to decrease with increased 
incorporation of monomers with functional handles.
63,64
 As shown in Scheme 3.1, an 
interfacial polymerization was performed between sebacoyl chloride (3.1) and monomers 3.2 
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and 3.3 to provide PEA 3.4. The resulting material had a Mw  of 41 kg/mol and a PDI of 1.4, 
as measured by SEC in DMF relative to polystyrene standards. Treatment of this polymer 
with 1/1 TFA/CH2Cl2 afforded the corresponding carboxylic acid functionalized PEA 3.5. 
PEAs having pendant carboxylic acid moieties could not be characterized by SEC due to 
interactions of these polar moieties with the column. 
 
Scheme 3.1. Polymer synthesis and functionalization.  
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The reaction of PEA 3.5 with 0.5 equivalents of PTX per carboxylic acid moiety in the 
presence of DCC and DMAP provided PEA-PTX conjugate 3.6, having 24 wt% PTX, 
corresponding to a coupling yield of 90 %. Alternatively, 0.8 equivalents of PEO-NH2 with a 
MW of 5 kg/mol under the same conditions afforded the corresponding the PEA-PEO graft 
copolymer 3.7 having 50 wt% PEO. An attempt to couple 0.5 equivalents of PTX and 0.5 
equivalents of PEO-NH2 simultaneously was unsuccessful, likely due to the coupling of PEO 
preventing the subsequent coupling of PTX via steric hindrance, as PEO has a large 
hydrodynamic volume. However, it was possible to couple PEO-NH2 to the PEA-PTX 
conjugate 3.6 to provide the target PEA-PTX-PEO graft copolymer drug conjugate 3.8. The 
resulting polymers were purified by dialysis in DMF followed by water. The PTX and PEO 
contents of polymer 3.8 were determined by 
1
H NMR spectroscopy to be 10 wt% and 50 
wt% respectively (see appendix). The resulting polymer had a Mw of 100 kg/mol and a PDI 
of 2.8. This PDI is relatively high, but is of less concern for a biodegradable polymer such as 
a PEA than for a nondegradable polymer. As the aim is to administer the polymer is as a self-
assembled micelle, it is the PDI of the micelles that will be more critical in achieving 
uniform and reproducible biological behaviour.  
3.2.2 Preparation and characterization of micelles.  
A nanoprecipitation method was used to prepare the micelles. To obtain the micelles with 
covalently conjugated drug (cov-PEA-PTX-micelle), PEA-PTX-PEO (3.8) was dissolved in 
THF, and then water was added with rapid stirring. Finally, THF was removed by dialysis. A 
Z-average micelle diameter and PDI of 43  1 and 0.09 respectively were measured by DLS 
(Figure 3.1a). This size is ideal for in vivo applications as they can circulate in the blood 
without rapid removal by the RES system.  
For comparison, PEA-PEO (3.7) was used to prepare micelles with physically 
encapsulated PTX (noncov-PEA-PTX-micelle). This was accomplished by dissolving both 
5.7 and PTX in THF, followed by water addition and THF evaporation. Filtration through a 
0.45 m filter was used to remove unencapsulated PTX, which is essentially insoluble in 
water. HPLC was used to measure the efficiency of drug encapsulation in these micelles and 
it was found to be 98% (see appendix). In this case, the micelles had a diameter of 80  2 nm 
and a PDI of 0.15 as determined by DLS (Figure 3.1a). The larger micelle size in this case 
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can perhaps be explained by the higher hydrophilicity of the micelle core resulting in less 
densely packed micelle cores.  
TEM was used to image the micelles. As shown in Figures 3.1b and 3.1c, the solid 
spherical structures of the micelles were confirmed. Cov-PEA-PTX-micelles had diameters 
on the order of 25 nm while the noncov-PEA-PTX-micelles had diameters on the order of 50 
nm. This size reduction with respect to the DLS measurements is likely a result of the 
difference between the hydrated micelles measured in solution versus the micelles in the dry 
state measured by TEM. 
 
Figure 3.1. a) Representative DLS traces of micelles, b) TEM image of cov-PEA-PEO-
micelles, c) TEM image of noncov-PEA-PTX-micelles. 
3.2.3 In vitro release of PTX from micelles.  
The in vitro release proﬁles of PTX from cov-PEA-PTX-micelles and noncov-PEA-PTX-
micelles were evaluated using a dialysis method in pH 7.4 phosphate buffer solution at 37 
°C. The cumulative release percentages are shown in Figure 3.2. As expected, for cov-PEA-
PTX-micelles, no initial burst release was observed and the release profile was almost linear 
over a period of 14 days, with approximately 40% cumulative drug release over this period 
(Figure 3.2a). The slow release of drug can be attributed to the requirement for ester 
hydrolysis to occur within the hydrophobic environment of the micelle core, followed by 
diffusion out of the micelles core. In contrast, the release of PTX from noncov-PEA-PTX-
micelles was much more rapid, with 35% of the PTX released over the first 11 h and more 
than 70% over 25 h (Figure 3.2b). In this case the release is controlled by diffusion as a result 
of the partitioning between the micelle core and the large volume of aqueous buffer.  
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Figure 3.2. In vitro release of PTX from a) cov-PEA-PTX-micelles and b) noncov-PEA-
PTX-micelles at 37 °C in pH 7.4 phosphate buffer. Data represent the mean and standard 
deviation of three independent experiments.  
3.2.4 In vitro anti-tumoral activity.  
The in vitro cytotoxic activities of the different micelle compositions were evaluated using 
MTT assays
65
 in the HeLa cell line. For comparison, the cytotoxicities of empty micelles, 
PTX formulated with its vehicle (50/50 CrEL/ethanol) and the vehicle alone were also 
investigated. As shown in Figure 3.3a, PTX formulated with its vehicle was toxic at 
concentrations of 6.2 ng/mL and higher. However, the CrEL/ethanol vehicle alone was toxic 
at these concentrations, suggesting that it contributes to some extent to the toxicity of this 
formulation. As shown in Figure 3.3b, the polymer micelle formulations of PTX were toxic 
at similar concentrations to the CrEL/ethanol formutions, with cov-PEA-PTX-micelles 
exhibiting toxicity at 6.2 ng/mL and higher and noncov-PEA-PTX-micelles at 2.5 ng/mL and 
higher. In general, the cov-PEA-PTX-micelles were less toxic than the noncovalent system, 
consistent with the slower release of drug from this system. However, both systems were 
highly toxic, suggesting that they may exhibit high anti-cancer activity. In addition, no 
toxicity was observed for micelles of copolymer 3.7 formulated without drug at the same 
concentrations, suggesting that the vehicle is less toxic that CrEL/ethanol and may be better 
tolerated (see appendix). 
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Figure 3.3. In vitro cytotoxicity of PTX formulations as measured by the MTT assay 
following a 72 h incubation with HeLa cells: a) PTX formulated in CrEL/ethanol and the 
CrEL/ethanol vehicle alone; b) cov-PEA-PTX-micelles, noncov-PEA-PTX-micelles. 
3.3 Conclusions 
In conclusion, we have developed micelles based on PEA-PEO graft copolymers with 
covalently conjugated PTX for sustained drug release and have compared their micellization, 
PTX release profile, and in vitro toxicity to that of a similar system with noncovalently 
encapsulated drug. It was found that the cov-PEA-PTX-micelles exhibit smaller diameters 
than the noncov-PEA-PTX micelles and exhibit much slower release of PTX, as expected 
due to the requirement for hydrolytic ester cleavage at the hydrophobic micelle core. Both 
the cov-PEA-PTX-micelles and noncov-PEA-PTX-micelles exhibit high toxicity towards 
HeLa cancer cells, comparable to that of PTX formulated in CrEL/ethanol, while the PEA 
vehicle is less toxic than CrEL/ethanol. Overall, these results suggest that PEA-based 
micelles are highly promising delivery vehicles for PTX, and that the rate of drug release can 
be readily tuned through covalent or noncovalent drug incorporation, or perhaps a 
combination of both. Future work will involve their development for in vivo evaluation as 
well as the development of actively targeted analogues of these micelles. 
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Chapter 4   
4 Controlled release of PTX from biodegradable PEAs using 
UV light as a trigger 
4.1 Introduction 
In recent years, a wide variety of drug delivery systems have been developed to address the 
problematic properties of drug molecules, such as low aqueous solubility, short plasma 
circulation time, rapid in vivo degradation and systemic toxicity. The incorporation of 
therapeutics into polymeric systems such as nanoparticles, micelles, liposomes, or 
polymersomes has been shown to result in enhanced drug solubility/dispersibility, increased 
plasma half-life, reduced toxicity, and even enhanced therapeutic efficacy through targeting 
to the therapeutic site via EPR effect or through the conjugation of active targeting ligands.
1-4
 
In an optimized case, a drug delivery system would retain its payload during systemic 
circulation and release it selectively at the therapeutic target.
5
 With the aim of achieving this, 
stimuli-responsive polymeric materials have been developed for controlled-release drug 
delivery systems.
6-10
  
Among the various polymeric systems that have been investigated for drug delivery, 
micelles are particularly attractive and have been widely investigated.
11-13
 They are typically 
formed via the self-assembly of amphiphilic copolymers to form sub-100 nm structures 
comprising hydrophobic core regions that can serve as reservoirs for hydrophobic drugs, and 
hydrophilic shells that stabilize the micellar structure. Their small size and hydrophilic 
surface avoid recognition and uptake by the macrophages of RES after intravenous 
administration, a crucial requirement for achieving prolonged residence time in the blood 
compartment.
5
 This feature allows accumulation in tumor and other pathological tissues due 
to the EPR effect.
14
  
Polymeric micelles that are responsive to environmental changes in pH,
6,15,16
 
temperature,
17,18
 redox potential
19 
or external stimuli such as ultrasound
20-22
 or light 
23-25
 have 
been developed. Among the available stimuli, light is a particularly attractive trigger for use 
in controlling the behavior of biomaterials.
25
 It can be applied externally and does not require 
specific chemical reagents or environmental conditions. In addition, many parameters such as 
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light intensity and wavelength can be easily controlled and exposure areas with a resolution 
as small as 1 µm can be achieved.
26
 Photo-responsive polymeric micelles have been designed 
through the use of photochemical reactions to induce solubility changes in the hydrophobic 
block that lead to disintegration of the micelles and the release of physically encapsulated 
cargo in response to visible
27
 or IR
23
 light. Alternatively, photocleavable o-nitrobenzyl 
moieties were incorporated into the main chain of hydrophobic block to achieve micelle 
disruption upon irradiation.
27,28
  
We have recently developed a micellar carrier for the anticancer drug PTX based on 
amphiphilic PEA-PEO graft copolymers.
29
 PTX is one of the most effective anti-cancer 
drugs used in clinical practice and exhibits strong cytotoxic activity against a variety of 
cancers, especially breast and ovarian cancer.
30
 However, because of its low water-
solubility
31
 (0.25 μg/mL) PTX is currently formulated as a 50:50 mixture of CrEL and 
ethanol, called Taxol, which has been found to result in hypersensitivity reactions.
30
 
Consequently, patients receiving this drug require premedication.
32
 Many drug delivery 
systems have been developed for PTX with the aim of improving its properties.
33-36
  
PEAs, polymers containing both ester and amide linkages in their backbones are, 
promising materials for a wide range of biomedical applications
37-44
 as they can undergo 
degradation under a variety of enzymatic and non-enzymatic conditions and their monomers 
can be selected from a wide range of non-toxic metabolic intermediates. In our previous 
work, L-aspartic acid moieties were incorporated into the polymer backbones and the 
resulting pendant carboxylic acid groups were used to covalently conjugate PEO, resulting in 
an amphiphilic graft copolymer capable of forming micelles, as well as the 2'-hydroxyl group 
of PTX via an ester linkage.
36,45
 In comparison to most PTX drug delivery systems, which 
contain PTX only physically incorporated, it was shown that the covalent immobilization of 
PTX resulted in a slow and controlled release of the drug without the undesirable burst 
release effect which is frequently observed when drug molecules are physically encapsulated 
into micelles and nanoparticles.
17,46-48
 Nevertheless, as ester hydrolysis was quite slow in the 
hydrophobic cores of the micelles, it would still be desirable to selectively trigger a more 
rapid, "burst" release of PTX in the case of tumors treatment.  
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We report here the development of the first backbone photodegradable PEA and its 
application in the development of a photosensitive micellar carrier with covalently 
conjugated PTX. As shown in Figure 4.1, it was proposed that upon light-induced 
degradation of o-nitrobenzyl moieties in the hydrophobic PEA backbone, the micellar 
assemblies would be disrupted, resulting in increased exposure of the ester linkages between 
PTX and the PEA backbone to water, and thus accelerated hydrolytic release of PTX. To test 
this hypothesis, the synthesis of the photodegradable polymers, their self-assembly into 
micelles, and their photodegradation are described. Studies were performed to evaluate the 
effect of photoirradiation on PTX release and the effect of photoinduced release on the in 
vitro toxicity of the micelles.  
 
Figure 4.1. Micellar disruption and proposed acceleration in ester hydrolysis upon UV 
irradiation.  
4.1 Experimental section 
General procedures and materials. Compound 4.2,
49
 monomer 4.6
50
 and PEO-NH2
39
 with 
a molecular weight of 5 kg/mol were synthesized as previously reported. Solvents were 
purchased from Caledon Labs (Georgetown, ON). PTX (>99%, P-9600) was purchased from 
LC Laboratories. All other chemicals were purchased from Sigma Aldrich (Milwaukee, WI). 
Unless noted otherwise, all chemicals were used as received. Anhydrous CH2Cl2 was 
obtained by distillation over CaH2. Water was purified using an ultra pure water system 
(Barnstead EASYpure® II). Column chromatography was performed using silica gel 60 with 
a particle size range of 40-63 µm (SiliCycle Inc, Quebec City, QC). Dialysis was performed 
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using Spectra/Por 6 regenerated cellulose membranes from Spectrum Laboratories with a 
MWCO of 12-14 or 50 kg/mol (Rancho Dominguez, CA, USA). 
1
H (400 MHz) and 
13
C (100 
MHz) NMR spectra were obtained on a Varian Inova 400 spectrometer (Varian Canada Inc., 
Mississauga, ON). Chemical shifts are reported in ppm and are calibrated against residual 
solvent signals of DMSO ( 2.50, 40.25 ppm). All coupling constants (J) are reported in Hz. 
FTIR spectra were obtained using a Bruker Tensor 27 (Bruker Corporation, Milton, ON) 
using KBr pellets or thin films from dichloromethane on NaCl plates.  High-resolution mass 
spectrometry (HRMS) was performed using a Finnigan MAT 8400 electron impact mass 
spectrometer. SEC data were obtained using a Waters 2695 separations module equipped 
with a Waters 2414 refractive index detector (Waters Limited, Mississauga, ON) and two 
PLgel 5 m mixed-D (300 mm × 7.5 mm) columns connected in series (Varian Canada Inc., 
Mississauga, ON). Samples (5 mg/mL) dissolved in the eluent, which comprised of 10 mM 
LiBr and 1 % (v/v) NEt3 in DMF at 85°C were injected (100 L) at a flow rate of 1 mL/min 
and calibrated against polystyrene standards. DLS was performed on a ZetaSizer Nano 
instrument from Malvern (Worcestershire,UK). Ultraviolet-visible (UV-vis) spectroscopy 
was performed on a Varian Cary 300 Bio UV–visible spectrophotometer. Photochemical 
irradiation was performed using a medium pressure mercury lamp (Hanovia S9 PC 451050 
/805221), with 200-400 nm UV light and a receiving power of about 25 mW.cm
-2
, which was 
contained in a quartz water jacket, approximately 10 cm from the solution. The concentration 
of PTX was determined by isocratic reverse-phase HPLC using a Waters 2695 separations 
module ( Waters , Milford, USA) equipped with a LiChroCART 125-4 RP-18 column (5L 
MerckMillipore,Damstadt,Germany), and a photodiiode array detector (Waters 2998).  The 
mobile phase consisted of water/acetonitrile (60/40 v/v). The flow rate was 1.0 mL/min and 
the detection wavelength was 227 nm. 100 L of the analyte solution was injected. A 
calibration curve was prepared for PTX dissolved in water/acetonitrile (60/40 v/v). 
Synthesis of monomer 4.3. A suspension of L-phenylalanine (4.1) (5.9 g, 35 mmol, 2.2 
equiv.) and p-toluenesulfonic acidH2O (6.7 g, 39 mmol, 2.4 equiv.) in toluene (100 mL) was 
refluxed at 140 °C with stirring in a flask equipped with a Dean-Stark trap for 2 h to remove 
the residual water. To this solution, 2-nitro-1,3-benzenedimethanol (4.2)
49
 (3.0 g, 16 mmol, 
1.0 equiv.) was added and the reaction mixture was heated at reflux for 48 h. The reaction 
mixture was then cooled and filtered to isolate the crude product, which was recrystallized 
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from water (100 mL) to provide monomer 4.3 (6.6 g, 50%). 
1
H NMR (400 MHz, DMSO-d6): 
δ 8.43 (br s, 6H), 7.66-7.62 (m, 3H), 7.47 (d, J = 8.2, 4H), 7.19 - 7.30 (m, 10H ), 7.10 (d, J = 
7.8, 4H), 5.23-5.31 (m, 4H), 4.40 - 4.37 (m, 4H), 3.09-3.06 (m, 4H), 2.29 (s, 6H ); 
13
C NMR 
(100 MHz, DMSO-d6): δ 169.0, 148.2, 145.8.0, 138.2, 132.4, 131.2, 129.7,128.5, 127.7, 
125.9, 110.8, 63.3, 53.5, 36.3, 21.2. FTIR (KBr pellet, cm
-1
): 3313, 2930, 2855, 1735, 1654, 
1534, 1499, 1459, 1175. HRMS (m/z): calcd for C26H28N3O6, 478.1978; found, 478.1974 
[M]
+
. 
Synthesis of polymer 4.5. Monomer 4.3 (1.0 g, 1.2 mmol, 1.0 equiv.) and sodium carbonate 
(0.25 g, 2.4 mmol, 2.0 equiv.) were dissolved in distilled water (30 mL). Sebacoyl chloride 
(4.4) (0.21 mL, 1.2 mmol, 1.0 equiv.) diluted in anhydrous CH2Cl2 (15 mL), was added 
dropwise over 30 min to the biphasic solution and was allowed to react for 17 h. Upon 
completion of the reaction, solvent was removed in vacuo. The resulting polymer was 
redissolved in DMF permitting filtration of the insoluble salts. The filtrate was then dialysis 
against DMF with MWCO 12-14 kg/mol for 24 h, with changing of the dialysate every 12 h. 
The solvent was removed in vacuo to provide polymer 4.5 (0.41 g, 52%). 
1
H NMR (400 
MHz, DMSO-d6): δ 8.26 (d, J = 7.6, 2H), 7.55 - 7.64 (m, 3H), 7.21 - 7.23 (m, 10H), 5.16 - 
5.24 (m, 4H), 4.45 - 4.51 (m, 4H), 2.86 - 2.99 (m, 4H ), 2.0-2.04 (m, 4H ), 1.07-1.45 (m, 8H 
). FTIR (KBr pellet, cm
-1
): 3292, 2928, 2853, 1751, 1654, 1538, 1455, 1174. SEC: Mn = 47 
kg/mol, Mw = 64 kg/mol, PDI = 1.3. 
Synthesis of polymer 4.7. Monomer 4.3 (0.50 g, 0.61 mmol, 0.80 equiv.) and sodium 
carbonate (0.13 g, 1.6 mmol, 2.0 equiv.) were dissolved in distilled water (15 mL). Monomer 
4.6 (0.065 g, 0.15 mmol, 0.20 equiv.) was dissolved in CH2Cl2 (5 mL) and added to the 
aqueous phase. After stirring for 30 min, sebacoyl chloride (4.4) (0.15 mL, 0.63 mmol, 1.0 
equiv.) diluted in anhydrous CH2Cl2 (10 mL), was added dropwise over 30 min to the 
biphasic solution and was allowed to react for 24 h. This polymer was purified as described 
above for polymer 4.5. (0.24 g, 62%). 
1
H NMR (400 MHz, DMSO-d6):  8.26-8.30 (d, J = 
8.1, 1.86H), 8.21-8.23 (d, J = 7.5, 0.56H), 7.55-7.64 (m, 3.0H), 7.15-7.25 (m, 9.99H), 5.16 - 
5.24 (m, 4.02H), 4.50 - 4.52 (m, 0.59H), 4.45-4.51 (m, 1.94), 4.03-4.07(m, 1.04 H), 2.98-
3.01 (m, 3.95H), 2.53 -2.7 (m, 1.18H), 2.0- 2.08 (m, 4.97 H), 1.36-1.59 (m, 12.31H), 1.07-
1.07 (m, 11.89H). FTIR (thin film, cm
-1
): 3292, 3061, 2928, 2853, 1751, 1653, 1533, 1363, 
1174. SEC: Mn = 39 kg/mol, Mw = 60 kg/mol, PDI = 1.5. 
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Synthesis of polymer 4.8. Polymer 4.7 (0.23 g, 0.36 mmol, 1.0 equiv) was dissolved in 
CH2Cl2 (1 mL). Trifluoroacetic acid (TFA) (1 mL) was added and the reaction mixture was 
stirred for 2 h.  Toluene (5 mL) was then added and the solvent was removed in vacuo to 
provide the unprotected polymer in quantitative yield. The crude polymer was then washed 
with cold ethyl acetate (3 mL) three times to provide polymer 4.8 (0.21 g, 98%). 
1
H NMR 
(400 MHz, DMSO-d6):  8.21-8.23 (d, J = 8.1, 1.69 H), 8.19 (J = 7.5, 0.49H), 7.50-7.59 (m, 
2.67H), 7.13 - 7.18 (m, 9.11H), 5.46 - 5.51 (m, 0.48H), 4.40 - 4.46 (m, 1.81), 3.98 (s, 0.95H), 
2.81 - 2.93 (m, 3.59H ), 2.51-2.64 (m, 1.14H), 1.96 - 2.15 (m, 6H), 1.49-1.30 (m, 8H),1.19-
1.03 (m, 8H). IR (thin film, cm
-1
): 3292, 2929, 2855, 1747, 1651, 1455, 1366, 1173. 
Synthesis of polymer 4.9. Polymer 4.8 (0.20 g, 0.065 mmol, 1.0 equiv) was dissolved in 
distilled CH2Cl2 (4 mL). Then, PTX (0.030 g, 0.027 mmol, 0.50 equiv. relative to pendant 
COOH), DCC (0.018 g, 0.087 mmol, 1.2) and DMAP (0.0073 g, 0.059 mmol, 0.80 equiv. 
relative to pendant COOH) were added into the above solution at 0 °C. After 12 h, the 
reaction was warmed to room temperature and stirred for another 8 h. The byproduct 
dicyclohexylurea was removed by filtration, and the resulting polymer was purified by 
dialysis against DMF using a 12-14 kg/mol MWCO membrane for 24 h, with changing of the 
dialysate every 12 hours to provide polymer 4.9 (0.19 g, 83%). 
1
H NMR (400 MHz, DMSO-
d6):  8.91 (d, J = 8.8, 0.55H), 8.27 (d, J = 7.6, 1.88H), 8.20 (d, J = 7.6, 0.49H), 7.98 (d, J = 
8.0, 0.50H), 7.89 (d, J = 7.9, 0.50H), 7.70-7.74 (m, 0.44H), 7.55 - 7.65 (m, 3.6H), 7.48-7.50 
(m, 0.49H), 7.40-7.43 (m, 0.77), 7.15 - 7.25 (m, 9.55H), 6.29 (br s, 0.53H), 6.18 (d, J = 7.6, 
6.17H), 5.88-5.91 (m, 0.32H), 5.39 - 5.43 (m, 0.79H), 5.17 - 5.23 (m, 4.04H), 4.90-4-92 (m, 
0.48H), 4.70 (br s, 0.48H), 4.54 - 4.59 (m, 0.92H), 4.46 - 4.50 (m, 1.98H), 4.09 - 4.13 (m, 
0.43H), 3.99 - 4.04 (m, 1.28H), 3.62 (d, J = 3.62, 0.53H), 2.97 - 3.04 (m, 2.19H), 2.83 - 2.89 
(m, 2.32H), 2.64-2.67 (m, 0.64H), 2.56 - 2.60 (m, 0.80H), 2.23 (s, 0.41H), 2.16 - 2.19 (m, 
0.8H), 2.09-2.11 (m, 0.39H), 2.01-2.10 (m, 4.49H), 1.88-1.92 (m, 0.40H), 1.74 - 1.79 (m, 
0.65H), 1.62 - 1.66 (m, 0.46), 1.58 (s, 0.86H), 1.45 - 1.51 (m, 1.9H), 1.34 - 1.39 (m, 4.12H), 
1.15 - 1.22 (m, 3.98H), 1.02 - 1.07 (m, 7.18H). IR (thin film, cm
-1
): 3270, 2928, 2854, 1747, 
1654, 1553, 1362, 1175.  
Synthesis of polymer 4.10. Polymer 4.9 (0.060 g, 0.017 mmol, 1.0 equiv) was dissolved in 
distilled CH2Cl2 (4 mL). PEO-NH2 (0.086 g, 0.017 mmol, 1.0 equiv. relative to pendant 
COOH), DCC (7.2 mg, 0.025 mmol, 1.5) and DMAP (2.1 mg, 0.017 mmol, 1.0 equiv. 
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relative to pendant COOH) were added into the above solution at 0 °C. The reaction was 
carried out under stirring at 0 °C for 12 h and then at room temperature for 8 h. The 
byproduct dicyclohexylurea was removed by filtration, and the resulting polymer was 
purified by dialysis against water using a 50 kg/mol MWCO membrane for 24 h, changing of 
the dialysate every 12 h, to provide polymer 4.10 (0.11g, 74%). 
1
H NMR (400 MHz, DMSO-
d6): 9.16-9.21 (s, 0.11H), 8.28 (d, J = 7.0 Hz, 2.1H), 7.79 (d, J = 6.6 Hz, 0.32H), 7.86-7.82 
(m, 0.25H), 7.78- 7.81(m, 0.22H), 7.70-7.74 (m, 0.14H), 7.57 - 7.63 (m, 3.26H), 7.41-7.49 
(m, 0.78H), 7.13-7.27 (m, 10.77H), 6.29 (br s, 0.14H), 5.81 (d, J = 6.6 Hz, 0.14H), 5.52-5.58 
(m, 0.12H), 5.39 - 5.43 (m, 0.35H), 5.16-5.24 (m, 4.02H), 4.88-4.93 (m, 0.25H), 4.62 (br s, 
0.28H), 4.45-4.50 (m, 2.22H), 4.01 - 4.10 (m, 0.9H), 3.65-3.70 (m,1.41H), 3.51(s, 154.79H), 
3.22-3.26 (m, 1.39H), 3.15-3.20 (m, 0.55H), 2.99 - 3.01 (m, 1.82H), 2.83 - 2.89 (m, 2.11H), 
2.64-2.69 (m, 0.30H), 2.32 - 2.36 (m, 0.17H), 2.25 (s, 0.21H), 2.19-2.22 (m, 0.11H), 2.06-
2.09 (m, 0.66H), 2.0-2.03 (m, 4.49H), 1.74-1.78 (m, 0.46H), 1.52-1.60 (m, 0.56H), 1.45 - 
1.51 (m, 1.69H), 1.29-1.40 (m, 3.99H), 1.12-1.25 (m, 4.50H), 0.99-1.07 - 1.07 (m, 8.15H). IR 
(thin film, cm
-1
): 3295, 3063, 3030, 2887, 1747, 1651, 1535, 1497, 1455, 1359, 1280, 1148. 
SEC: Mn = 25 kg/mol, Mw = 57 kg/mol, PDI = 2.3. 
General procedure for monitoring photodegradation by UV-vis spectroscopy. The 
polymer solution was prepared at the concentration of 4 μg/mL in spectroscopic grade 
dioxane. To a quartz cuvette 3 mL of solution was transferred and irradiated with UV light 
for the selected time interval. UV-vis spectra were obtained following each time interval. For 
micelles, the photodegradation was also studied by preparing micelles by the protocol 
described below and then diluting them in purified water to 4 μg/mL. They were also 
prepared and studied at a higher micelle concentration of 1.5 mg/mL. In this case, at each 
irradiation interval 100 μL of micelle solution was diluted to 3 mL with dioxane and the UV-
vis spectrum was obtained. 
General procedure for monitoring photodegradation by 
1
H NMR spectroscopy. The 
polymer solution was prepared at the concentration of 7 mg/mL in DMSO-d6. The solution 
was transferred to a quartz NMR tube and irradiated with UV light. 
1
H NMR spectra were 
obtained at selected time intervals. 
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Micelle formation. Polymer 4.10 (3.0 mg) was dissolved in THF (0.3 mL). The solution was 
stirred vigorously while distilled water was rapidly added to provide a final volume of 3 mL. 
THF was then removed by dialysis against distilled water using a 12–14 kg/mol MWCO 
membrane. The micelle solution was then filtered with a microfilter (pore size: 0.45 μm, 
Tuffryn® syringe filter, PALL) to eliminate dust and aggregates. 
TEM. The micelle suspension (prepared as described above, 20 μL of 0.1 mg/mL) was 
placed on a Formvar/Carbon grid and was left to stand for 5 min. The excess solution was 
then blotted off using a piece of filter paper. The resulting sample was dried under air 
overnight before imaging. Imaging was performed using a Phillips CM10 microscope 
operating at 80 kV with a 40 μm aperture. 
Procedure for monitoring PTX photodegradation by HPLC. Five samples containing 1 
mL of PTX in water at a concentration of 0.3 μg/mL were prepared. Each solution was 
transferred to a glass cuvette and irradiated with UV light. The concentration of PTX was 
measured as described above over 25 min in 5 min intervals.  
In vitro release of PTX from PTX-micelles. The in vitro release of PTX from the micelles 
of copolymer 4.10 was evaluated by a dialysis method. 3 mL of micelle suspension (PTX 
concentration: 0.60 μg/mL) were placed into a pre-swollen 3.5 kg/mol MWCO dialysis bag 
and immersed into 500 mL of 10 mM phosphate buffer at 37 °C. Dialysis was performed 
with gentle stirring and the amount of PTX released into media was measured every 24 h. At 
each time point an aliquot of release media (15 mL) was withdrawn, the complete volume of 
dialysate was removed and replaced with fresh media. For analysis of the PTX concentration, 
the 15 mL aliquot was dried via lyophilization and the solid was redissolved in 1 mL of 
60/40 water/acetonitrile. The solution was filtered with a 0.2 μm pore size (Tuffryn® syringe 
filter, PALL) filter into a vial for detection of the PTX concentration by HPLC as described 
above. The cumulative PTX release was calculated. The release experiments were conducted 
in triplicate, and the results presented are the mean  standard deviation. 
In vitro release of PTX from photoirradiated PTX-micelles. The same procedure 
described above for the non-irradiated micelles was used except that the micelle solution was 
exposed to UV light for 10 min prior to beginning the dialysis.  
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In vitro cytotoxicity assay. HeLa cells were cultured at 37 °C and 5% CO2 in DMEM 
(Invitrogen) supplemented with 10% (v/v) fetal bovine serum (Invitrogen) and antibiotics 
(penicillin and streptomycin, 100 units/mL each).  The cells were seeded into a Nunclon® 
96-well U bottom transparent polystrol plate at a density of 2500 cells per well in a final 
volume of 100 μL of DMEM. Cells were allowed to adhere for 24 hours at 37 °C in a 
humidified incubator with 5% CO2. Next, the growth medium was aspirated and was 
replaced with either the positive control SDS in the cell culture medium at concentrations of 
0.2, 0.15, 0.10, or 0.05 mg/mL, just the medium or testing materials. The cells were then 
incubated with resulting micelles of graft copolymer 4.10 with and without 10 min UV 
irradiation at PTX concentration of 25, 12.5, 6.2, 2.5, 1.2, 0.62, 0.31 ng/mL. A suspension 
solution of polymer without drug 4.8 was also prepared at concentration of 300, 30, 15, 7.5, 
3.6, 1.5 and 0.75 ng/mL. For comparison, PTX solubilized in CrEL/ethanol was prepared 
according to Lee et al.
51
 In short, 6 mg of PTX was dissolved in 0.5 mL dehydrated ethanol 
and to this solution 0.5 mL CrEL was added. Then this mixture was sonicated for 30 min. 
This sample also diluted to provide above concentration. A control formulation without PTX 
was prepared using 1/1 Cr EL/ethanol. This solution was diluted similar to PTX formulated 
with CrEL/ethanol. Eight replicates per concentration were performed. After 72 h, the media 
were aspirated and replaced with 110 μL of fresh medium containing 0.5 mg/mL MTT 
reagent. After 4 h of incubation (37 °C, 5% CO2), the MTT solution was carefully aspirated 
and the purple crystals were dissolved by addition of 50 μL of spectroscopic grade DMSO. 
After shaking (1 second, 2 mm amp, 654 rpm), the absorbance of the wells at 540 nm was 
read using an M1000-Pro plate reader (Tecan). The absorbance of wells not containing cells 
but treated by all of the above steps was subtracted as a background and the cell viability was 
calculated relative to wells containing cells that were exposed to just culture medium. No 
(0%) cell viability was detected for the cells exposed to the highest concentrations of the 
positive control sodium lauryl sulfate, confirming the sensitivity of the assay. 
4.2 Results and discussion 
4.2.1 Synthesis of a model photodegradable PEA 
Prior to preparing the target photodegradable PTX delivery system, a model photodegradable 
PEA was synthesized and studied to confirm its photodegradability. To accomplish this, o-
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nitrobenzyl moieties were selected as the photodegradable units as they have been widely 
studied for a variety of applications.
25
 An -amino acid-based PEA backbone was selected 
due to the possibility to readily incorporate amino acids with pendant functional groups for 
the grafting of PTX as well as hydrophilic chains for micelle formation. First, as shown in 
Scheme 4.1, L-phenylalanine (4.1) was condensed with 2-nitro-1,3-benzenedimethanol (4.2) 
in toluene, in the presence of p-toluenesulfonic acid (TsOH) to provide the diester 4.3. While 
in principle any amine acid could have been used, L-phenylalanine was ideal as the di-p-
toluenesulfonic acid salt of this monomer could be easily purified by recrystallization from 
water.  
 
Scheme 4.1. Synthesis of photodegradable monomer 4.3. 
As shown in Scheme 4.2, an interfacial polymerization was then performed by the 
addition of a solution of sebacoyl chloride (4.4) in CH2Cl2 to a solution of monomer 4.3 in an 
aqueous Na2CO3 solution to provide polymer 4.5. The structure of polymer 4.5 was 
confirmed through 
1
H NMR and IR spectroscopy. Based on SEC in DMF, the polymer had a 
Mw of 64 kg/mol and a PDI of 1.3. In this design, photodegradable moieties are inserted at 
each monomer unit throughout the polymer. This should ensure that upon UV-irradiation, it 
should be possible to completely degrade the polymer. 
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Scheme 4.2. Synthesis of the model photodegradable PEA 4.5.  
4.2.2 Photodegradation of the model polymer 4.5. 
The photodegradation of polymer 4.5 was studied by UV-vis spectroscopy and NMR 
spectroscopy. For the UV-vis study, a 4 μg/mL solution of polymer in dioxane was irradiated 
using a medium pressure mercury lamp for 120 min and the UV-vis spectra were recorded 
every 20 minutes. As shown in Figure 4.2, over the degradation period, a decrease in 
absorbance was observed for the band at 260 nm while an increase at 310 nm was observed. 
This is consistent with the expected result as the initial nitrobenzyl units absorb at 260 nm, 
while the nitrosobenzaldehyde product absorbs at 310 nm.
52,53
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Figure 4.2. UV-vis spectra of polymer 5 following different UV irradiation times. 
To study the photodegradation by 
1
H NMR spectroscopy, a 7.5 mg/mL solution of 
polymer 4.5 in deuterated DMSO was irradiated with a medium pressure mercury lamp in a 
quartz NMR tube for 240 min and spectra were collected every 60 min. As shown in Figure 
4.3, the multiplet at 5.15-5.24 ppm corresponding to the methylene groups of the o-
nitrobenzyl ester in the polymer backbone, decreases in intensity. Concomitantly, new peaks 
emerge and increase at 8.07-8.12 and 12.61 ppm, corresponding to the expected o-
nitrobenzaldehyde product. SEC traces of the degraded sample showed no polymer peak, 
demonstrating complete degradation of the material (see appendix). Overall, these data 
demonstrate that polymer 4.5 degrades in the expected manner. 
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Figure 4.3. 
1
H NMR spectra following different UV irradiation periods of a 7.5 mg/mL 
solution of polymer 4.5 in DMSO-d6.  
4.2.3 Synthesis of a photodegradable amphiphilic PEA-PTX 
conjugate.  
Having demonstrated the ability of o-nitrobenzyl esters to impart photodegradability to the 
PEA backbone, the next step was to incorporate sites for the conjugation of PTX and for the 
grafting of hydrophilic chains to induce micellization. As in our previous work with non-
photodegradable PEAs,
29
 this was accomplished through the incorporation of L-aspartic acid 
units throughout the backbone. As shown in Scheme 4.3, an 80:20 ratio of monomer 4.3 to 
the L-aspartic acid-based diester 4.6
50 
was polymerized interfacially with sebacoyl chloride 
to provide the random copolymer 4.7. The 80:20 ratio was selected to obtain a sufficient 
number of functional handles throughout the polymer backbone, while still maintaining the 
maximum number of photodegradable sites. The resulting polymer had an Mw of 60 kg/mol 
and a PDI of 1.5 as measured by SEC.  
024681012
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Scheme 4.3. Synthesis of a photodegradable amphiphilic PEA-PTX conjugate. 
The t-butyl protected carboxylic acids on polymer 4.7 were unmasked through treatment 
with 1:1 TFA:CH2Cl2 to provide polymer 4.8 (Scheme 4.3). The photodegradation of 
polymer 4.8 was studied by 
1
H NMR spectroscopy and the same changes observed for 
polymer 4.5 were also observed for this polymer, suggesting that the incorporation of 
monomer 4.6 does not interfere with the photodegradation process. The next step was the 
conjugation of PTX to polymer 4.8. This was accomplished by the reaction of 4.8 with 0.5 
equiv. of PTX per pendant carboxylic acid moiety in the presence of DCC and DMAP to 
provide the conjugate 4.9. This polymer contains a hydrolytically cleavable ester linkage 
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between the pendant carboxylic acid moieties of the polymer and the 2′-hydroxyl of PTX, 
which is generally more nucleophilic than the 7-hydroxyl because it experiences less steric 
hindrance.
36,45,54
 Based on 
1
H NMR spectroscopy, the conjugation yield was approximately 
80%, corresponding to the functionalization of approximately 40% of the pendant carboxylic 
acid moieties with PTX (see appendix). Using this method, it was found that the amount of 
PTX content was 16 % by weight.  
The final synthetic step was the grafting of hydrophilic chains to induce micellization. As 
in our previous work,
29
 PEO was selected because of its well known biocompatibility in 
various therapeutics, as well as its stealthy characteristics, allowing it to prolong the block 
circulation of drug delivery systems.
55-57
 PEO-NH2 with molecular weight of 5 kg/mol was 
reacted with polymer 4.9 under the same conditions used for the conjugation of PTX to 
provide polymer 4.10 (Scheme 4.3). Based on 
1
H NMR spectroscopy, approximately 35% of 
the carboxylic acid moieties were functionalized with PEO, resulting in a PEA graft 
copolymer with 67 wt % PEO and 6 wt% PTX. The resulting polymer had an Mw of 56 
kg/mol and a PDI of 2.3 as measured by SEC. 
It should be noted that the order of PTX and PEO couplings is very important. It was 
found that if PEO conjugation was carried out first, the subsequent PTX coupling failed. This 
can likely be attributed to the steric influence of PEO, which may block access to unreacted 
carboxylates.  
4.2.4 Preparation and characterization of micelles  
A nanoprecipitation method was used to prepare micelles from polymer 4.10. In short, the 
graft copolymer 4.10 was dissolved in THF, a good solvent for this polymer. Water was then 
added to induce the aggregation of the PEA to form the micelle core. Finally, the THF was 
removed by dialysis. The resulting micelle size was measured by DLS. The z-average 
micelle diameter and polydispersity index were 95  5 nm and 0.16 respectively, and a 
representative DLS trace is shown in Figure 4.4a. TEM was also performed to verify the 
micelle size and morphology measured by DLS. As shown in Figure 4.4b, spherical 
assemblies were indeed observed, characteristic of micelles. The diameter of these micelles 
was found to be 60 ± 11 nm. The smaller diameter measured by TEM relative to that 
obtained by DLS can likely be attributed to their dehydrated state.  
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Figure 4.4. a) Representative DLS trace for micelles formed from graft copolymer 4.10; b) 
TEM image of micelles formed from graft copolymer 4.10 prior to UV irradiation; c) TEM 
of micelles of graft copolymer 4.10 following 20 min of UV irradiation. 
4.2.5 Photoinduced dissociation of the micelles 
After preparation of micelles, their photodegradation behavior was studied. In this micellar 
system, photoirradiation should result in the disintegration of the micellar core due to main-
chain degradation of the hydrophobic PEA backbone. Fast photodegradation of the micelles 
is expected as multiple photo-cleavable moieties were inserted as a repeating unit into main 
chain of the polymer. Zhoa recently reported the preparation of amphiphilic block-copolymer 
micelles whose core-shell structure was disrupted under UV irradiation and fast degradation 
of the micellar core and hence micelle disruption was observed.
27
 The fast disintegration of 
micelles from copolymer 4.10 was demonstrated by TEM (Figure 4.4c). As described above, 
prior to irradiation, the micelles had a relatively uniform diameter of 60 ± 11 nm, while after 
20 min of UV irradiation the micelle structures appeared to disappear and instead just some 
loose aggregates were observed. These aggregates are likely fragments of the hydrophobic 
backbone without PEO, which arise from the backbone degradation and are insoluble in 
water. DLS experiments confirmed polymer aggregation with the size of 903 ± 10nm (see 
appendix). Photodegradation of the system was also studied by UV-vis spectroscopy. When 
performing this study purely in water, the results were complicated by the formation of these 
aggregates, which result in some turbidity. However, photodegradation in dioxane provides 
the expected changes in the UV-vis spectra (see appendix).  
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4.2.6 Photoinduced PTX release 
The in vitro release proﬁle of PTX from micelles formed from polymer 4.10 was evaluated in 
pH 7.4 phosphate buffer both with and without UV irradiation. As shown in Figure 4.5, 
consistent with our previous results for a non-photodegradable system,
29
 in the absence of 
UV irradiation, the release of PTX from the micelles is slow and sustained, with no burst 
release, and approximately 40% of the drug released over a period of 2 weeks. The slow 
release can be attributed to the requirement for ester bond hydrolysis to occur at the 
hydrophobic core of the micelle between PTX and the PEA backbone.  
Prior to performing the PTX release experiment with photoirradiation, it was important to 
confirm the stability of PTX to UV irradiation. Therefore, an aqueous solution of PTX was 
irradiated, and the purity of the drug was evaluated by HPLC. This experiment indicated that 
there were no changes in PTX purity following up to 10 minutes of exposure (see appendix). 
Therefore, a 10 min irradiation time was chosen for the PTX release study. It was confirmed 
by UV-vis spectroscopy that even at the increased concentrations of micelles used in the 
release study this 10 min irradiation period was sufficient to obtain significant changes in the 
UV-vis spectrum of the polymer, consistent with partial photodegradation of the polymer 
backbone (see appendix). As shown in Figure 4.5, after a 10 min UV irradiation of the 
micelles, there is an initial burst release of 20% of the PTX over the first 24 h. This can likely 
be attributed to the partial cleavage of the photolabile o-nitrobenzyl esters during the 10 min 
irradiation, which results in some degree of micelle breakdown and increased exposure of the 
ester linkages to water, resulting in accelerated hydrolysis. Following this initial 
photoinduced burst release, the release profile follows that of the non-irradiated sample, 
which likely corresponds to the release of PTX from some intact micelles or from aggregates 
of polymer fragments that contain PTX. These results show that this photodegradable micelle 
system is stable but exhibits light-induced PTX release.  
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Figure 4.5. In vitro release of PTX from with and without UV-irradiated micelles incubated 
at 37 °C in PBS buffer (pH 7.4). Data represent the mean and standard deviation of three 
independent experiments.  
4.2.7 In vitro toxicity studies 
The in vitro cytotoxic activities of the photodegradable PTX-micelles with and without UV 
irradiation were evaluated and compared with PTX in its CrEL/ethanol formulation in HeLa 
cells using an MTT assay. The micelles formed from polymer 4.8, without PTX as well as 
the CrEL/ethanol vehicle were also evaluated. As shown in Figure 4.6a, PTX was toxic (as 
defined by a cell viability of <70% that of the control
58
) at concentrations of 2.5 ng/mL and 
higher. The concentration of CrEL/ethanol vehicle required to formulate the higher 
concentrations of PTX was also toxic, suggesting that some toxicity at the higher PTX 
concentrations can likely be attributed to CrEL/ethanol. In contrast, the photodegradable 
PEA vehicle without drug did not exhibit significant toxicity at concentrations up to 300 ng. 
The PTX micelles both with and without UV irradiation were less toxic than the 
CrEL/ethanol formulation, with toxicity only observed at concentrations higher than 6.25 
ng/mL. This can likely be attributed to the gradual release of drug from these systems. 
Within the errors on the measurements, both the UV-irradiated and non-irradiated micelles 
exhibited similar toxicities. Although the irradiated micelles might be expected to exhibit 
higher toxicity, this assay was not sensitive enough to detect this, likely because the 
differences in free drug between the two systems may not be sufficient. It is also conceivable 
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that the release kinetics of PTX measured in phosphate buffer are not the same as those 
within the cellular environment, where the presence of enzymes and pH gradients may also 
play a role in mediating ester hydrolysis.  
 
Figure 4.6. In vitro cytotoxicity, as measured by MTT assays in HeLa cells following a 72 h 
incubation of a) PTX-CrEL/ethanol and the equivalent dose of CrEL without PTX; b) PTX 
micelles with and without UV irradiation and polymer 4.8.  
4.3 Conclusions 
In conclusion, a backbone photodegradable PEA was developed for the first time and was 
demonstrated to completely degrade upon UV irradiation. This chemistry was extended to 
the development of photodegradable PEA micelles with PTX conjugated via an ester linkage, 
based on the hypothesis that breakdown of the micelles induced by UV light would enable 
enhanced ester bond cleavage through increased exposure to water. This multifunctional graft 
copolymer was successfully synthesized and was used to prepare sub-100 nm micelles. A 
short, 10 min UV irradiation led to decomposition of the micelles, as demonstrated by TEM 
and UV-vis spectroscopy. It also resulted in a burst release of 20% of the PTX over the first 
24 h, in comparison with the non-irradiated control, which only exhibited 3 % release over 
the same time period. This demonstrated that it is indeed possible to modulate the release of 
PTX from this system by irradiation. In vitro toxicity studies demonstrated that the drug-free 
micelles were non-toxic up to 300 ng/mL, while the PTX-micelles were highly toxic, with 
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the irradiated and non-irradiated micelles having similar toxicity. Overall, this work provides 
a new photochemically degradable PEA backbone that can serve as a platform for various 
applications. It also demonstrates the promise of stimulus-mediated micelle breakdown as a 
means to alter the rate of the cleavage of linkages between drugs and polymers. 
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Chapter 5  
5 Polymer cross-linking: A nanogel approach to enhancing 
the relaxivity of MRI contrast agents1 
5.1 Introduction 
Noninvasive medical imaging plays a critical role in the detection and diagnosis of disease as 
well as in the monitoring of disease progression. MRI is a prominent noninvasive imaging 
modality due to its excellent spatial resolution, soft tissue contrast, and the absence of 
harmful ionizing radiation in its application. Despite its inherent high levels of soft tissue 
contrast, contrast agents based on small molecule chelates of Gd(III) are frequently employed 
in clinical MRI scans in order to aid in the differentiation between healthy and diseased 
tissues.
1-3
 These agents have enabled significant advancements in MRI over the last couple of 
decades. However, they do suffer from some limitations. For example, they typically possess 
longitudinal relaxivities (r1) in the range of 3-5 mM
-1
s
-1
, only a small fraction of the 
theoretically possible value. Thus, high doses are required, which can be problematic for 
patients with chronic renal disease.
4
 It can also limit their applicability in molecular imaging 
applications, where target receptors are present only at low concentrations.
5
 Furthermore, 
most these agents are non-targeted, are passively distributed throughout the body, and have 
very short circulation times in the blood.
1,2,6
 This can again limit their abilities to image 
specific disease targets. 
To address the limitations of small molecule MRI contrast agents, there is currently 
significant interest in the development of new nanoscale Gd(III) agents.
6,7
 Nanosized agents 
can exhibit higher relaxivities than small molecules due to their slower tumbling rates in 
solution and the resulting increase in rotational correlation time (R). They can also exhibit 
prolonged circulation times in the blood, a property that can be tuned based on their size and 
architecture. Moreover, nanomaterials typically possess multiple chemical functionalities, 
                                                 
1
 This chapter contains work that has been published: Soleimani, A.; Martinez, F.; Economopoulos, V.; Foster, 
P. J.; Scholl, T. J.; Gillies, E. R., Polymer cross-linking: a nanogel approach to enhancing the relaxivity of MRI 
contrast agents. Journal of Materials Chemistry B 2013, 1 (7), 1027-1034 
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which can enable the development of multimodal agents and derivatives targeted to specific 
disease sites in vivo. In recent years, many nanoscale scaffolds including linear polymers,
8-12
 
dendrimers,
13-15
 proteins,
16-19
 viral capsids,
20-22
 micelles,
23,24
 vesicles,
25-28
 fullerenes,
29
 and 
nanotubes
30
 have been investigated. Among the above approaches, the conjugation of Gd(III) 
complexes to proteins and viral capsids, which are assemblies of proteins, has proven to be 
particularly successful. Significant enhancements in relaxivity have been observed, on the 
order of 3 to 10-fold relative to the analogous small molecule chelates.
16-22
 In contrast, the 
conjugation of Gd(III) chelates to conventional linear polymers such as polylysine,
11
 PEO,
31
 
dextran
32
 or polynorbornene
8
 have led to more modest 1 to 3-fold improvements in 
relaxivity. It is hypothesized that the enhanced relaxivities of protein-based agents result 
from their high molecular weights, but also their well-defined, rigidified, 3-dimensional 
conformations. In contrast, many linear polymers are highly flexible, allowing the conjugated 
chelate to tumble like a small molecule in solution.  
For the current work, we proposed that the advantageous “rigidified” property of a 
protein could be obtained from a simple covalently cross-linked network based on a 
hydrophilic polymer. We describe here the simple, one-step preparation of a cross-linked 
polymer nanogel with a size on the order of 10 nm, ideal for in vivo circulation. A derivative 
of the clinically used chelate DTPA was conjugated and the properties of the agent were 
studied and compared with a control linear polymeric material prepared under the same 
conditions in the absence of a cross-linker. High relaxivity and in vivo contrast were 
demonstrated for the nanogel.  
5.2 Experimental section 
General procedures and materials. All reagents were purchased from commercial suppliers 
and used without further purification unless otherwise noted. Anhydrous DMF was obtained 
from a solvent purification system based on aluminum oxide columns. Pyridine and NEt3 
were distilled from CaH2. poly(ethylene glycol) methyl ether methacrylate (PEGMA), N-(2-
aminoethyl)methacrylamide hydrochloride (AEMA) and Ethylene glycol dimethacrylate 
(EGDMA) were purified by passing through a basic alumina column to remove the inhibitor. 
Dialyses were performed using Spectra/Por regenerated cellulose membranes with MWCO 
of either 1000 or 3.5 kg/mol. 
1
H (400 MHz) NMR spectra were obtained on a Varian Inova 
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400 spectrometer (Varian Canada Inc., Mississauga, ON). Chemical shifts are reported in 
ppm and are calibrated against residual solvent signal of D2O ( 4.79 ppm). FTIR spectra 
were obtained using a Bruker Tensor 27 (Bruker Corporation, Milton, ON) from KBr disks. 
SEC was performed in DMF with 10 mM LiBr and 1 % (v/v) NEt3 at 85 °C using a Waters 
2695 separations module equipped 6380 with a 2414 differential refractometer and two 
PLgel 5 μm mixed-D (300 mm 7.5 mm) columns from Polymer Laboratories (Agilent). The 
calibration was performed using polystyrene standards. DLS was performed in 0.1 M pH 7.4 
phosphate buffer on a Zetasizer Nano ZS instrument from Malvern Instruments. The sample 
was prepared at a concentration of 2 mg/mL by dissolution of the lyophilized solid in buffer 
followed by filtration through a 0.45 m Acrodisc syringe filter (PALL Life Sciences). 
AFM was performed using an XE-100 atomic force microscope from PSIA. Samples for 
AFM were prepared by spin coating a 100 µL solution of the polymer in methanol (1 
mg/mL) onto a  1 cm  1 cm silicon wafer at 4000 rpm for 30 s. Images were obtained by 
scanning surfaces in tapping mode using rectangular-shaped silicon cantilevers with a spring 
constant of 48 N/m. The data were then refined using the software Nanoscope. TEM was 
performed using a Phillips CM10 microscope operating at 80kV with a 40 μm aperture. 
Samples were prepared by dropping 20 μL of 0.1 mg/mL polymer sample in water onto a 
Formvar
®
/Carbon grid, letting it stand for 1 minute, then blotting off excess solution using a 
piece of filter paper.  
Synthesis of nanogel 5.4. PEOMA (5.1) (Mn = 475 g/mol) (600 mg, 1.3 mmol), AEMA, 
(5.2) (200 mg, 1.2 mmol), EGDMA (5.3) (200 mg, 1.0), and benzoyl peroxide (100 mg, 0.41 
mmol) were dissolved in 20 mL of methanol in a heavy walled Schlenk reaction tube. The 
reaction mixture was degassed and then stirred at 75 °C overnight. It was then concentrated 
to 5 mL and dialyzed against distilled water for 24 hours using a dialysis membrane with a 
MWCO of 1 kg/mol. The solution was then lyophilized to provide the product as a white 
solid (300 mg, 30%). 
1
H NMR (400 MHz, D2O): δ 4.15 (br s, 2.3 H), 3.63 (br s, 29 H), 3.31 
(br s, 3.9 H), 3.15 (br s, 2.0 H), 1.87 (br s, 4.1 H), 0.6-1.5 (br m, 7.0 H). FTIR max/cm
-1
: 
3500, 2930, 1730, 1650. SEC: Mn = 19 kg/mol, Mw = 46 kg/mol, PDI = 2.6. 
Synthesis of nanogel 5.5. The nanogel 5.4 (43 mg,  50 mol of amine) and the 
isothiocyanate derivative of DTPA (p-SCN-Bn-DTPA, Macrocyclics, Dallas, USA) (36.0 
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mg, 55 mol,  1.1 equiv. per nanogel amine) were dissolved in 1 mL of dry DMF and dry 
NEt3 (0.30 mL, 2.1 mmol) was added. The reaction mixture was stirred overnight at room 
temperature and then dialyzed against distilled water for 24 hours using a dialysis membrane 
with a MWCO of 3.5 kg/mol. The resulting solution was lyophilized to provide 72 mg of the 
product as a white solid. 
1
H NMR (400 MHz, D2O):   7.0-7.5 (br m, 4 H), 3.9-4.4 (br m, 3.4 
H), 3.5-3.8 (br m, 53 H), 3.2-3.5 (br m, 10 H),  2.7- 3.2 (br m, 12 H), 1.91 (br s, 4.4 H), 0.5-
1.5 (br m, 17H). FTIR max/cm
-1
: 3490, 2930, 1730, 1650, 1540. 
Synthesis of nanogel 5.6. The nanogel 5.5 (67 mg) was dissolved in 2 mL of distilled water. 
GdCl3·6H2O (54 mg, 0.14 mmol,  2 equiv. per amine) was dissolved in 1 mL of distilled 
water and was subsequently added to the nanogel solution. The solution was stirred 
overnight, and then dialyzed against distilled water for 24 hours using a dialysis membrane 
with a MWCO of 3.5 kg/mol. The resulting solution was lyophilized to provide 57 mg of the 
product as a white solid. The Gd content of the nanogel was determined by inductively 
coupled plasma mass spectrometry (ICP-MS), performed at the Environmental Analytical 
Laboratories of the Saskatchewan Research Council (Canada). Result = 59  1 g Gd/mg 
nanogel. FTIR max/cm
-1
: 3460, 2940, 1730, 1610. 
Synthesis of control polymer 5.7. PEOMA (5.1) (Mn = 475 g/mol) (840 mg, 1.7 mmol), 
AEMA (5.2) (370 mg, 1.7 mmol), and benzoyl peroxide (100 mg, 0.41 mmol) were dissolved 
in 20 mL of methanol in a heavy walled Schlenk reaction tube. The reaction mixture was 
degassed and then stirred at 75 °C overnight. It was then concentrated to 5 mL and then 
dialyzed against distilled water for 24 hours using a dialysis membrane with a MWCO of 1 
kg/mol. The solution was then lyophilized to provide the product as a white solid (264 mg, 
26%). 
1
H NMR (400 MHz, D2O):  4.12 (br s, 1.6 H), 3.45-3.94 (br m, 28 H), 3.21-3.45 (br 
m, 4.4 H), 3.05 (br s, 2.0 H), 1.86 (br s, 2.8 H), 0.6-1.37 (br m, 4.7 H). FTIR max/cm
-1
: 3400, 
2900, 1720, 1640. SEC: Mn = 9 kg/mol, Mw =18 kg/mol, PDI =1.9. 
Synthesis of control polymer 5.8. The linear polymer 5.7 (98 mg,  138  mol of amine) 
and the isothiocyanate derivative of DTPA (p-SCN-Bn-DTPA, Macrocyclics, Dallas, USA) 
(32 mg, 50 mol,  0.4 equiv. per nanogel amine) were dissolved in 1 mL of dry DMF and 
dry NEt3 (0.84 mL, 6.0 mmol) was added. The reaction mixture was stirred overnight at 
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room temperature and then dialyzed against distilled water for 24 hours using a dialysis 
membrane with a MWCO of 1 kg/mol. The resulting solution was lyophilized to provide 110 
mg of the product as a white solid. 
1
H NMR (400 MHz, D2O):  7.26 (br s, 4.0 H), 4.08 (br s, 
1.8 H), 3.41-3.86 (m, 31 H), 3.28 (s, 7.5 H), 2.60-3.11 (m, 10.9 H), 1.86 (br s, 3.1 H), 0.50-
1.43 (m, 10.4 H). FTIR max/cm
-1
: 3550, 2890, 1730, 1640. 
Synthesis of control polymer 5.9. The linear polymer 5.8 (60 mg) was dissolved in 2 mL of 
distilled water. GdCl3·6H2O (50 mg, 0.13 mmol,  2 equiv. per amine) was dissolved in 1 
mL of distilled water and was subsequently added to the linear polymer solution. The 
solution was stirred overnight, and then dialyzed against distilled water for 24 hours using a 
dialysis membrane with a MWCO of 1 kg/mol. The resulting solution was lyophilized to 
provide 52 mg of the product as a white solid. The Gd content of the nanogel was determined 
by inductively coupled plasma mass spectrometry (ICP-MS), performed at the 
Environmental Analytical Laboratories of the Saskatchewan Research Council (Canada). 
Result = 58  1 g Gd/mg nanogel. FTIR max/cm
-1
: 3454, 2933, 1731, 1614. 
Relaxivity measurements. The polymer was dissolved in a 100 mM pH 7.4 phosphate 
buffer at a concentration of approximately 20 g Gd/mL (exact concentration was 
determined by ICP-MS analysis of this solution. Nuclear magnetic resonance dispersion 
measurements were acquired using fast field-cycling relaxometry.
33,34
 Relaxation rates in the 
range from 0.01 – 42 MHz (2.35mT – 0.99T) were acquired using a Stelar Spinmaster 
FFC2000 1T C/DC relaxometer, (Stelar s.r.l., Italy) at 25°C and 37°C. Data at higher field 
strengths was gathered using an insertable field-cycling relaxometer system (MRIn, Stelar 
s.r.l., Italy). This system is capable of magnetic field shifts of ±0.25T around a clinical field 
strength and was modified to include control of the sample temperature by the addition of 
temperature-regulated airflow to the NMR probe. Relaxation rate measurements with the 
MRIn apparatus were acquired in the ranges of 55.9 to 71.9MHz (1.5T ± 0.2T) and 119.7 to 
135.7MHz (3T ± 0.2T). The relaxivity (r1) was calculated at each field point and temperature 
according to the following equation: 
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where           is the measured relaxation rate of buffered agent,         is the relaxation 
rate of the plain buffer solution in the absence of contrast agent and         is the 
concentration of gadolinium determined on a millimolar basis. Typical uncertainties for 
measurement of relaxation rates were less than 1%. The uncertainty in r1 was dominated by 
the 2% uncertainty in the Gd
III
 concentration. 
Animal protocol. All animal experiments were approved by the Animal Use Subcommittee 
of the University Council on Animal Care at The University of Western Ontario following 
the guidelines of the Canadian Council on Animal Care (protocol # 2010–210). Female CB-
17 SCID mice were anesthetized using isoflurane (1% in oxygen) and injected with 1×10
6
 
MDA-MB-231 cells into the right thoracic mammary fat pad. Briefly, the mice were 
anesthetized with isoflurane and an incision was made in the skin over the right thoracic 
mammary fat pad, allowing the fat pad to be exposed. Cells were injected into the fat pad in a 
volume of 50L and the incision was closed using surgical glue (VetBond™, 3M™). 
Imaging protocol. Tumor bearing animals were anesthetized using isoflurane (1% in 
oxygen) for all imaging experiments. Pre- and post-injection images were acquired on a 1.5 
Tesla clinical MR system (General Electric Medical Systems, Milwaukee, WI) equipped with 
a custom-built high performance gradient coil insert (inner diameter =17.5 cm, maximum 
gradient strength =500 mT/m, and peak slew rate =3000 T/m/sec) and a custom-built mouse 
body solenoid radiofrequency (RF) coil (4cm length, 3cm diameter).  Images were acquired 
using a 3D spoiled gradient echo (SPGR) pulse sequence. The imaging parameters were: 
repetition time of 10 ms, echo time of 2.4 ms, flip angle of 30
o
, bandwidth of ±31.25 kHz, 
field of view of 4 cm, slice thickness of 0.2 mm, isotropic resolution of 200 m, ¾ phase 
field of view, and 6 signal averages. The scan time was 19 minutes and 12 seconds. After a 
pre-injection image was acquired, the animal was injected with either Magnevist or nanogel 
5.6 (both at 0.1 mmol/kg of Gd(III), 100 l) via the tail vein, without removal from the RF 
coil or moving the animal position. Post contrast images were acquired immediately after 
injection.  Image data is displayed as a maximum intensity projection (MIP) through the 
entire image stack created using the freeware image analysis program ImageJ. 
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5.3 Results and discussion 
The monomers PEOMA (5.1), AEMA (5.2) and EGDMA (5.3) were selected for preparation 
of the nanogel. The pendant amine functionality on 5.2 should allow for the conjugation of 
the DTPA derivative to the resulting nanoparticles, while the 5.1 is hydrophilic and should 
enhance water access to the nanogel, a property that is critical in achieving high relaxivity in 
MRI contrast agents. Monomer 5.3 was selected as a cross-linking agent and benzoyl 
peroxide was used as an initiator. A number of reaction conditions were surveyed in order to 
obtain nanogels by a simple free radical polymerization method, without the need for 
preparing a stable colloidal suspension. It was found that at low loadings of monomer 5.3 or 
low overall concentrations no nanogel was detected, while at very high monomer 5.3 loading 
or high overall concentrations, macroscopic gels were formed. Similarly, the amount of the 
initiator was also important. At low initiator loadings macroscopic gels were formed, likely 
due to a high degree of polymerization, whereas nanogels were formed using 10 mol% of 
initiator. Conditions involving a 5.1:5.2:5.3 weight ratio of 60:20:20 (34:37:29 mole ratio) 
and 10 mol% of benzoyl peroxide (relative to the total monomer) reproducibly led to the 
formation of nanogel 5.4 as shown in Scheme 5.1.  
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Scheme 5.1. Synthesis of the nanogel and incorporation of Gd(III) chelates. 
The resulting material was characterized by several techniques. 
1
H NMR spectroscopy in 
D2O revealed broad peaks, as expected for a cross-linked polymeric material. The broadness 
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and overlap of peaks corresponding to the different monomers made exact quantification 
difficult, but peaks corresponding to all monomers were observed in the spectrum (see 
appendix). As shown in Figure 5.1, DLS suggested a volume average diameter of 
approximately 10 nm and a PDI of 0.61. Both TEM (Figure 5.2) and AFM (see appendix) 
revealed the presence of spherical materials, supporting the proposed cross-linked structure. 
Analysis by SEC in DMF containing 10 mM LiBr and 1 vol% NEt3 suggested that in 
comparison with the polystyrene calibration standards, the material had an Mn of 19 kg/mol 
and a PDI of 2.6. This Mn is likely an underestimate of the true Mn due to the branched, 
globular structure of the molecule. The relatively high PDI is expected for “non-living” free 
radical polymerization conditions, particularly those involving the formation of a branched 
network, though it would be ideal to later reduce this polydispersity and that of the 
nanoparticles to some extent for in vivo applications. Nevertheless, the distribution of 
nanoparticle sizes still lies within the range of sizes that allow for enhanced blood circulation 
times through reduced renal filtration, while avoiding uptake by the RES.
35 
 
Figure 5.1. Size distribution of the nanogel 5.4 and the linear polymer control 5.7 as 
measured by DLS. 
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Figure 5.2. TEM image of nanogel 5.4. 
To conjugate a Gd(III) chelate, nanogel 5.4 was reacted with a commercially available 
isothiocyanate derivative of DTPA to provide 5.5 (Scheme 5.1) and the excess unreacted 
chelate was removed by dialysis. This chelate was selected as the eight Gd(III) coordination 
sites present in DTPA are retained in this derivative, so the thermodynamic and kinetic 
stability of the Gd(III) complex should not be compromised.
1-3
 
1
H NMR spectroscopy of 
nanogel 5.5 after dialysis confirmed the presence of the conjugated chelate (see appendix). 
IR spectroscopy confirmed that any unconjugated chelate was successfully removed by 
dialysis as the characteristic C=S stretch from the isothiocyanate at 2130 cm
-1
 was absent 
(see appendix). Finally, Gd(III) was inserted into the chelates by the reaction of nanogel 5.5 
with GdCl3 in H2O at pH 7 to provide nanogel 5.6, and the product was purified by dialysis 
and lyophilized. At this stage, IR spectroscopic analysis revealed a shift in the C=O stretches 
of the ligand from 1650 cm
-1
 to 1610 cm
-1
, which is an indication of the successful 
coordination of Gd(III).
36
 ICP-MS was used to quantify the Gd content of the nanogel, which 
was measured to be 59  1 g/mg of nanogel. This suggests that approximately 54% of the 
theoretically available amines in the nanogel were reacted with the DTPA derivative. As 
amines at the core of the nanogel would likely be inaccessible to the bulky chelate, this 
number was within the expected range. In addition, the xylenol orange test
37
 was performed 
and only 1.2% of the total Gd(III) was detected, confirming that there was not a significant 
fraction of Gd(III) bound non-specifically and that dialysis had effectively removed the 
excess Gd(III) for further study of this agent. 
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In addition to the nanogel synthesis described above, a series of control experiments were 
also performed to further confirm the successful synthesis of the nanogel and to aid in the 
evaluation of its properties. To verify the importance of the cross-linker, the polymerization 
reaction was performed under the same conditions described above, but in the absence of 
monomer 5.3 (Scheme 5.2). The resulting polymer 5.7 was characterized by the same 
techniques described above. The 
1
H NMR spectrum of polymer 5.7 was significantly sharper 
than that of nanogel 5.4 as expected for a linear versus cross-linked polymer (see appendix). 
In addition, the peaks from monomers 5.1 and 5.2 moieties in the polymer were sufficiently 
well resolved to verify that the monomers were indeed both incorporated in a ratio similar to 
their feed ratio despite monomer 5.1 being a methacrylate and monomer 5.2 being a 
methacrylamide. As shown in Figure 5.1, DLS indicated a distribution of hydrodynamic 
diameters centered at approximately 4 nm, significantly smaller than that obtained for 
nanogel 5.4. In addition, an Mn of 9 kg/mol and a PDI of 1.9 were obtained from SEC 
measurements, again suggesting that the cross-linker played a role in increasing the size of 
the polymeric material, as would be expected. TEM showed only random aggregates of 
material rather than the spherical particles obtained for nanogel 5.4 and when a sample was 
prepared for AFM measurements under the same conditions as for 5.4, polymer 5.7 provided 
only a uniform coating of polymer (see appendix). These data are all suggestive of 5.4 
possessing a cross-linked spherical structure in comparison with 5.7, which behaved like a 
conventional linear polymer. Using the same protocols described above, polymer 5.7 was 
reacted with the isothiocyanate derivative of DTPA to provide polymer 5.8. As coupling of 
the DTPA isocyanate to the amines on the linear polymer was found to be much more 
efficient than to the nanogel, in order to obtain the same overall loading of Gd(III) chelates as 
in nanogel 5.6, only 0.4 equivalents of the chelate per amine were added. Following insertion 
of Gd(III) to provide 5.9, a Gd content of 58  1 g/mg of polymer was obtained, as 
measured by ICP-MS. 
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Scheme 5.2. Synthesis of a control linear polymer. 
The relaxivity of nanogel 5.6 was measured in 0.1 M pH 7.4 phosphate buffer at  
25 C and 37 C using a stand-alone field-cycling relaxometer from 0.01 – 42 MHz. A 
second insertable field-cycling relaxometer system was used to characterize this compound at 
higher fields. Relaxation rate data was acquired at the same temperatures for magnetic fields 
within ±0.25T of clinical field strengths at 1.5 and 3T. Relaxivity was calculated from 
separate relaxation rate measurements of the buffered agent and plain buffer solutions and 
knowledge of the Gd(III) concentration. On a per Gd(III) basis, at 20 MHz, nanogel 5.6 had 
r1 values of 20.8  0.2 mM
-1
s
-1
 and 19.5  0.1 mM-1s-1 at 25 C and 37 C respectively. At 60 
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MHz, corresponding to the clinical field strength of 1.5 T the r1 value was 17.5  0.4 mM
-1
s
-1
 
at 37 C, while at 128 MHz (3 T) it was 10.2  0.2 mM-1s-1. As shown in Figure 5.3, 5.6 
exhibits an r1 versus frequency curve shape that is characteristic of restricted tumbling 
motion of the Gd(III) complex.
3,38
 In comparison with the clinical agent Magnevist (Gd(III)-
DTPA), which has a reported relaxivity of 4.6 mM
-1
s
-1
 at 20 MHz, this nanogel agent 
provides a ~5-fold enhancement in relaxivity. This lies within the range of per ion 
enhancements observed upon the conjugation of DTPA derivatives to proteins and viral 
capsids.
16,17,20
 Although the long term stability of the nanogel in solution was not investigated 
in detail in the current work, it was found that the relaxivity remained constant when repeated 
measurements were performed over a period of a few weeks on the same solution, as did the 
size distribution measured by DLS. 
Perez-Baena et al. reported the preparation of poly(acrylic acid)-based nanoparticles 
based on single polymer chains with Gd(III) chelates incorporated within the cross-linking 
moieties.
39
 However, they obtained an r1 of only 6.8 mM
-1
s
-1
. Nam et al. have prepared 
chitosan particles bearing conjugated Gd(III) chelates and Cy5.5 dye molecules as dual 
modality optical-MRI agents, but their relaxivities were reduced relative to the small 
molecule chelates due to entrapment of the Gd(III) chelates within the hydrophobic cores of 
the particles, preventing access to water molecules.
40
 Using polymer nanoparticles based on 
cross-linked poly(methacrylic acid) approach, Okada et al. reported r1 values in the range of 
20 – 30 mM-1s-1; however, these relaxivities were pH sensitive and these values were only 
obtained at pH 4.
41
 At physiological pH, the relaxivities were ~2-fold lower due to 
morphological changes in the polymer structure. In addition, their particles were > 100 nm in 
diameter, which is not ideal for in vivo circulation. Hydrogels based on chitosan and 
hyaluronate with noncovalently ionized Gd(III)-DOTA were recently reported by Courant et 
al. to have very high per ion r1 values on the order of 70 s
-1
mM
-1
, but again these nanogels 
were very large (> 200 nm in diameter) and would therefore be rapidly cleared from the 
blood stream by the reticuloendothelial system.
42
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Figure 5.3. Longitudinal relaxivity (r1) of nanogel 5.6 and control linear polymer 5.9 in 
phosphate buffer (0.1 M, pH 7.4) as a function of field strength at 37 C.  
The relaxivity of the linear control polymer 5.9 was also measured in 0.1 M pH 7.4 
phosphate buffer at 25 C and 37 C in the same manner described above. At 20 MHz, it was 
found to have r1 values of 17.3  0.2 mM
-1
s
-1
 and 15.7  0.3 mM-1s-1 at 25 C and 37 C 
respectively. At 60 MHz, corresponding to the clinical field strength of 1.5 T the r1 value was 
15.7  0.3 mM-1s-1 at 37 C, while at 128 MHz (3 T) it was 11.5  0.2 mM-1s-1. These results 
are in the expected range for the conjugation of DTPA to a linear methacrylate/acrylate-
based polymer backbone.
43,44
  
Fitting of the nuclear magnetic resonance dispersion (NMRD) data to Solomon-
Bloembergen-Morgan theory suggested that the enhancement in relaxivity obtained for 
nanogel 5.6 versus the linear polymer 5.9 did indeed arise from its restricted motion, as the 
R values obtained were 2.7  0.1 ns and 1.6  0.1 ns for 5.6 and 5.9 respectively at 37 C. 
Both of these R values are much longer than the R of ~60 ps for Gd(III)-DTPA,
1
 indicating 
that even the linear polymer was not highly flexible prior to cross-linking; however, an 
enhancement was still obtained upon cross-linking. The R value for 5.6 is quite similar to 
that of MS-325, an albumin-binding derivative of Gd(III)-DTPA, which upon binding to the 
protein has been reported to have a R of ~5 ns, depending on the model.
45
 m was found to be 
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568.2  8.5 ns and 624  12 ns for 5.6 and 5.9 respectively at 37 C. This is somewhat longer 
than MS-325, which has been reported to exhibit a m of 70 – 296 ns.
45
 The longer m of the 
current agents can likely be attributed to the presence of the oligo(ethylene glycol) chains on 
the monomer, as the presence of PEO has been shown to slow water exchange with Gd(III) 
complexes.
46
 While the m for the nanogel 5.6 does not change significantly with temperature 
between 25 and 37 C, polymer 5.9 exhibits a decrease in m to 536  11 ns at 25 C. This 
was somewhat unexpected, but can perhaps be attributed to the well known 
thermoresponsive properties of linear polymers containing pendant oligo(ethylene glycol) 
moieties.
47
 Also noteworthy is that at higher field strengths, the nanogel and linear polymer 
become very similar to one another in terms of relaxivity, as the R for the nanogel may 
become longer than ideal at these field strengths and the relaxivity becomes limited by other 
parameters such as the water residence time m.
34
 
In order to assess the potential of the new contrast agent 5.6 for MRI applications, initial 
imaging studies were performed in C.B.-17 SCID mice bearing MDA-MB-231 tumors in 
their right mammary fat pad. The mice were injected with either the clinical agent Magnevist 
or nanogel 5.6 at a dose of 0.1 mmol/kg of Gd(III). They were imaged at 1.5 T using a T1 
weighted pulse sequence of approximately 20 minutes in length, both prior to injection and 
immediately following injection. As shown in Figure 5.4, enhancement was mainly found in 
the kidneys and very little enhancement was observed in the vasculature in animals injected 
with Magnevist. In contrast, in the case of nanogel 5.6, most of the agent remained in the 
vasculature at this time point and excellent contrast was observed, a result likely attributable 
to the enhanced r1 of this agent. In addition, as indicated in Figure 5.4d, nanogel 5.6 was 
readily visualized in the vasculature serving the tumor (arrow). This result holds promise for 
the development of a targeted version of the nanogel agent that can be designed for the 
selective visualization of tumors via the incorporation of targeting moieties. 
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Figure 5.4. Maximum intensity projections through the set of coronal images of C.B.-17 
SCID mice bearing MDA-MB-231 tumors in their right mammary fat pads. Head, tail, left 
and right sides are labeled in image (a) for reference. G = Gut, K = Kidney in contrast 
enhanced images. The tumor is circled. a) prior to injection of Magnevist; b) prior to 
injection of nanogel 5.6; c) 20 min following injection of Magnevist; d) 20 min following 
injection of nanogel 5.6. Imaging was performed at 1.5 T using a T1 weighted imaging 
sequence and the doses was 0.1 mmol/kg of Gd(III) in each case.  
5.4 Conclusions 
 A simple, free radical polymerization approach for the preparation of a new nanogel MRI 
contrast agent was developed. The resulting nanogel was characterized chemically by 
techniques including 
1
H NMR spectroscopy, SEC, TEM, and AFM, and was compared to a 
control polymer that was prepared under the same conditions but in the absence of the cross-
linker. The r1 values for the nanogel agent 5.6 and the control polymer 5.9 were measured 
and it was found that as expected, the molecular rigidification imparted by the cross-linking 
did lead to enhanced relaxivity. In addition, imaging experiments suggest that relative to the 
clinical agent Magnevist, the nanogel agent provides increased contrast and enhanced 
circulation in the vasculature. The modularity and chemical multivalency provided by this 
nanogel platform is currently being exploited for the development of new targeted and 
multimodal imaging agents through the conjugation of active targeting ligands and contrast 
agents for multiple imaging modalities. 
126 
 
5.5 References 
1. Caravan, P.; Ellison, J. J.; McMurry, T. J.; Lauffer, R. B., Gadolinium(III) chelates as 
MRI contrast agents: Structure, dynamics, and applications. Chemical Reviews 1999, 99 (9), 
2293-2352. 
2. Merbach, A. E.; Toth, E., The chemistry of contrast agents in medical magnetic 
resonance imaging. John Wiley and Sons: Chichester, 2001. 
3. Aime, S.; Botta, M.; Terreno, E., Gd (III)-based contrast agents for MRI. Advances in 
Inorganic Chemistry 2005, 57, 173-237. 
4. Prince, M. R.; Zhang, H. L.; Roditi, G. H.; Leiner, T.; Kucharczyk, W., Risk factors 
for NSF: a literature review. Journal of Magnetic Resonance Imaging 2009, 30 (6), 1298-
1308. 
5. Terreno, E.; Delli Castelli, D.; Viale, A.; Aime, S., Challenges for molecular 
magnetic resonance imaging. Chemical Reviews 2010, 110, 3019-3042. 
6. Botta, M.; Tei, L., Relaxivity enhancement in macromolecular and nanosized Gd(III) 
based MRI contrast agents. European Journal of Inorganic Chemistry 2012, 2012 (12), 
1945-1960. 
7. Villaraza, A. J. L.; Bumb, A.; Brechbiel, M. W., Macromolecules, dendrimers and 
nanomaterials in magnetic resonance imaging: The interplay between size, function, and 
pharmacokinetics. Chemical Reviews 2010, 110 (5), 2921-2959. 
8. Allen, M. J.; Raines, R. T.; Kiessling, L. L., Contrast agents for magnetic resonance 
imaging synthesized with ring-opening metathesis polymerization. Journal of the American 
Chemical Society 2006, 128 (20), 6534-6535. 
9. Grogna, M.; Cloots, R.; Luxen, A.; Jérôme, C.; Desreux, J.-F.; Detrembleur, C., 
Design and synthesis of novel DOTA (Gd
3+
) polymer conjugates as potential MRI contrast 
agents. Journal of Materials Chemistry 2011, 21 (34), 12917-12926. 
10. Atkins, K. M.; Martínez, F. M.; Nazemi, A.; Scholl, T. J.; Gillies, E. R., Poly (para-
phenylene ethynylene) s functionalized with Gd (III) chelates as potential MRI contrast 
agents. Canadian Journal of Chemistry 2010, 89 (1), 47-56. 
11. Sieving, P. F.; Watson, A. D.; Rocklage, S. M., Preparation and characterization of 
paramagnetic polychelates and their protein conjugates. Bioconjugate Chemistry 1990, 1, 65-
71. 
12. Keissling, F.; Heilmann, M.; Lammers, T.; Ulbrich, K.; Subr, V.; Peschke, P.; 
Waengler, B.; Mier, W.; Schrenk, H.-H.; Bock, M.; Schad, L.; Semmler, W., Synthesis and 
charecterization of HE-24.8: A polymeric contrast agent for magnetic resonance 
angiography. Bioconjugate Chemistry 2006, 17, 42-51. 
127 
 
13. Kobayashi, H.; Brechbiel, M. W., Nano-sized MRI contrast agents with dendrimer 
cores. Advanced Drug Delivery Reviews 2005, 57, 2271-2286. 
14. Kobayashi, H.; Brechbiel, M. W., Dendrimer-based macromolecular MRI contrast 
agents: Characteristics and application. Molecular Imaging 2003, 2, 1-10. 
15. Gang, Y.; Yamashita, M.; Tian, M.; Zhang, H.; Ozaki, N.; Yamashita, J.; Fujie, M.; 
Takehar, Y.; Sakahara, H., The Development of dendritic Gd-DTPA complexes for MRI 
contrast agents. Current Medical Imaging Reviews 2010, 6 (1), 42-45. 
16. Parmalee, D. J.; Walovitch, R. C.; Ouellet, H. S.; Lauffer, R. B., Preclinical 
evaluation of the pharmacokinetics, biodistribution, and elimination of MS-325, a blood pool 
agent for magnetic resonance imaging. Investigative Radiology 1997, 32, 741. 
17. Caravan, P.; Cloutier, N. J.; Greenfield, M. T.; McDermid, S. A.; Dunham, S. U.; 
Bulte, J. W.; Amedio, J. C.; Looby, R. J.; Supkowski, R. M.; Horrocks, W. D., The 
interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. 
Journal of the American Chemical Society 2002, 124 (12), 3152-3162. 
18. Caravan, P., Protein-targeted gadolinium-based magnetic resonance imaging (MRI) 
contrast agents: Design and mechanism of action. Accounts Chemical Research 2009, 42 (7), 
851-862. 
19. Zhang, Z.; Greenfield, M. T.; Spiller, M.; McMurry, T. J.; Lauffer, R. B.; Caravan, P., 
Multilocus binding increases the relaxivity of protein-bound MRI contrast agents. 
Angewandte Chemie International Edition 2005, 44 (41), 6766-6769. 
20. Anderson, E. A.; Isaacman, S.; Peabody, D. S.; Wang, E. Y.; Canary, J. W.; 
Kirshenbaum, K., Viral nanoparticles donning a parmagnetic coat: Conjugation of MRI 
contrast agents to the MS2 capsid. Nano Letter 2006, 6, 1160-1164. 
21. Hooker, J. M.; Datta, A.; Botta, M.; Raymond, K. N.; Francis, M. B., Magnetic 
resonance contrast agents from viral capsid shells: a comparison of exterior and interior 
cargo strategies. Nano Letter 2007, 7 (8), 2207-2210. 
22. Garimella, P. D.; Datta, A.; Romanini, D. W.; Raymond, K. N.; Francis, M. B., 
Multivalent, high-relaxivity MRI contrast agents using rigid cysteine-reactive gadolinium 
complexes. Journal of the American Chemical Society 2011, 133, 14704-14709. 
23. Accardo, A.; Tesauro, D.; Roscigno, P.; Gianolio, E.; Paduano, L.; D'Errico, G.; 
Pedone, C.; Morelli, G., Physicochemical properties of mixed micellar aggregates containing 
CCK peptides and Gd complexes designed as tumor specific contrast agents in MRI. Journal 
of the American Chemical Society 2004, 126 (10), 3097-3107. 
24. Zhang, G. D.; Zhang, R.; Wen, X. X.; Li, L.; Li, C., Micelles based on biodegradable 
poly(L-glutamic acid)-b-polylactide with paramagnetic gd ions chelated to the shell layer as a 
potential nanoscale IVIRI-visible delivery system. Biomacromolecules 2008, 9 (1), 36-42. 
128 
 
25. Mulder, W. J. M.; Strijkers, G. J.; Griffioen, A. W.; van Bloois, L.; Molema, G.; 
Storm, G.; Koning, G. A.; Nicolay, K., A liposomal system for contrast-enhanced magnetic 
resonance imaging of molecular targets. Bioconjugate Chemistry 2004, 15 (4), 799-806. 
26. Schühle, D. T.; van Rijn, P.; Laurent, S.; Vander Elst, L.; Muller, R. N.; Stuart, M. C. 
A.; Schatz, J.; Peters, J. A., Liposomes with conjugates of a calix[4]arene and a Gd-DOTA 
derivative on the outside surface; an efficient potential contrast agent for MRI. Chemical 
Communications 2010, 46 (24), 4399-4401. 
27. Cheng, Z.; Tsourkas, A., Paramagnetic porous polymersomes. Langmuir 2008, 24 
(15), 8169-8173. 
28. Grüll, H.; Langereis, S.; Messager, L.; Castelli, D. D.; Sanino, A.; Torres, E.; 
Terreno, E.; Aime, S., Block copolymer vesicles containing paramagnetic lanthanide 
complexes: a novel class of T(1)- and CEST MRI contrast agents. Soft Matter 2010, 6 (19), 
4847-4850. 
29. Mikawa, M.; Kato, H.; Okumura, M.; Narazaki, M.; Kanazawa, Y.; Miwa, N.; 
Shinohara, H., Paramagnetic water-soluble metallofullerenes having the highest relaxivity for 
MRI contrast agents. Bioconjugate Chemistry 2001, 12 (4), 510-514. 
30. Sitharaman, B.; Kissell, K. R.; Hartman, K. B.; Tran, L. A.; Baikalov, A.; Rusakova, 
I.; Sun, Y.; Khant, H.; Ludtke, S. J.; Chiu, W.; Laus, S.; Toth, E.; Helm, L.; Merbach, A. E.; 
Wilson, L. J., Superparamagnetic gadonanotubes are high-performance MRI contrast agents. 
Chemical Communications 2005, 31, 3915. 
31. Ladd, D. L.; Hollister, R.; Peng, X.; Wei, D.; Wu, G.; Delecki, D.; Snow, R. A.; 
Toner, J. L.; Kellar, K.; Eck, J.; Desai, V. C.; Raymond, G.; Kinter, L. B.; Desser, T. S.; 
Rubin, D. L., Polymeric gadolinium chelate magnetic resonance imaging contrast agents: 
Design, synthesis, and properties. Bioconjugate Chemistry 1999, 10, 361-370. 
32. Rebizak, R.; Schaefer, M.; Dellacherie, E., Macromolecular contrast agents for 
magnetic resonance imaging. European Journal of Pharmaceutical Sciences 1999, 7, 243-
248. 
33. Anoardo, E.; Galli, G.; Ferrante, G., Fast-field-cycling NMR: Applications and 
instrumentation. Applied Magnetic Resonance 2001, 20, 365-404. 
34. Kimmich, R.; Anoardo, E., Field-cycling NMR relaxometry. Progress in Nuclear 
Magnetic Resonance Spectroscopy 2004, 44, 257-320. 
35. Perrault, S. P.; Chan, W. C. W., In vivo assembly of nanoparticle components to 
improve targeted cancer imaging. Proceedings of the National Academy of Sciences of the 
United States of America 2010, 107 (25), 11194-11199. 
36. Konings, M. S.; Dow, W. C.; Love, D. B.; Raymond, K. N.; Quay, S. C.; Rocklage, 
S. M., Gadolinium complexation by a new DTPA amide ligand oxygen coordination. 
Inorgoganic Chemistry 1990, 29 (8), 1488-1491. 
129 
 
37. Barge, A.; Cravotto, G.; Gianolio, E.; Fedeli, F., How to determine free Gd and free 
ligand in solution of Gd chelates. A technical note. Contrast media & Molecular Imaging 
2006, 1 (5), 184-188. 
38. Caravan, P., Strategies for increasing the sensitivity of gadolinium based MRI 
contrast agents. Chemical Society Reviews 2006, 35 (6), 512-523. 
39. Perez-Baena, I.; Loinaz, I.; Padro, D.; Garcia, I.; Grande, H. J.; Odriozola, I., Single-
chain polyacrylic nanoparticles with multiple Gd(III) centres as potential MRI contrast 
agents. Journal of Material Chemistry 2010, 20, 6916-6922. 
40. Nam, T.; Park, S.; Lee, S.-Y.; Park, K.; Choi, K.; Song, I. C.; Han, M. H.; Leary, J. J.; 
Yuk, S. A.; Kwon, I. C.; Kim, K.; Jeong, S. Y., Tumor targeting chitosan nanoparticles for 
dual-modality optical/MR cancer imaging. Bioconjugate Chemistry 2010, 21, 578-582. 
41. Okada, S.; Mizukami, S.; Kikuchi, K., Switchable MRI contrast agents based on 
morphological changes of pH-responsive polymers. Bioorganic & medicinal chemistry 2012, 
20 (2), 769-774. 
42. Courant, T.; Roullin, V. G.; Cadiou, C.; Callewaert, M.; Andry, M. C.; Portefaix, C.; 
Hoeffel, C.; de Goltstein, M. C.; Port, M.; Laurent, S., Hydrogels Incorporating GdDOTA: 
Towards Highly Efficient Dual T1/T2 MRI Contrast Agents. Angewandte Chemie 
International Edition 2012, 51 (36), 9119-9122. 
43. Grogna, M.; Cloots, R.; Luxen, A.; Jérôme, C.; Passirani, C.; Lautram, N.; Desreux, 
J. F.; Detrembleur, C., Convenient grafting through approach for the preparation of stealth 
polymeric blood pool magnetic resonance imaging contrast agents. Journal of Polymer 
Science Part A: Polymer Chemistry 2011, 49 (17), 3700-3708. 
44. Li, Y.; Beija, M.; Laurent, S.; vander Elst, L.; Muller, R. N.; Duong, H. T. T.; Lowe, 
A. B.; Davis, T. P.; Boyer, C., Macromolecules DOI:10.1021/ma300521c. 
45. Caravan, P.; Parigi, G.; Chasse, J. M.; Cloutier, N. J.; Ellison, J. J.; Lauffer, R. B.; 
Luchinat, C.; McDermid, S. A.; Spiller, M.; McMurry, T. J., Albumin binding, relaxivity, 
and water exchange kinetics of the diastereomers of MS-325, a gadolinium(III)-based 
magnetic resonance angiography contrast agent. Inorganic Chemistry 2007, 46, 6632-6639. 
46. Doble, D. M.; Botta, M.; Wang, J.; Aime, S.; Barge, A.; Raymond, K. N., 
Optimization of the relaxivity of MRI contrast agents: Effect of poly(ethylene glycol) chains 
on the water-exchange rates of Gd(III) complexes. Journal of the American Chemical Society 
2001, 123, 10758-10759. 
47. Lutz, J.-F., Thermo-switchable materials prepared using the oligoethylene glycol 
methacrylate-platform. Advanced Materials 2011, 23 (19), 2237-2243. 
 
 
130 
 
Chapter 6 
6 Conclusions, limitations and future directions 
Overall, this thesis investigated the design, synthesis, and evaluation of new polymers for 
drug delivery and medical imaging applications. The work was aimed at understanding how 
the chemical structures of polymers can be designed to impart specific properties and 
functions. For example, it was demonstrated how the polymer backbone can be tuned to 
impart varying thermal, mechanical, and rheological properties, and how cross-linking can be 
used to control the motion of polymers in solution. In addition, it was shown that tunable 
drug release can be achieved through cleavage of chemical linkages in the polymer backbone 
as well as between the drug and polymer. 
 In Chapter 2, the thermal, mechanical and rheological properties of six different PEAs 
comprising of differing dicarboxylic acid, diol and amino acid components were thoroughly 
investigated. It was found that the thermal properties were significantly influenced by the 
particular monomeric combinations. PEAs containing a short diol or nonflexible moieties 
were completely amorphous. In contrast, the incorporation of a long chain diol and bulky 
amino acid moieties into the polymer backbone led to increased crystallinity. It was 
demonstrated that the chemical structure and molecular weights also have a significant effect 
on the rheological properties of a material. PEAs with a flexible backbone, and those having 
lower MWs and higher PDIs, have lower viscosities. The mechanical properties of the PEAs 
were diverse, ranging from highly brittle solids to elastomeric materials. As a limitation, a 
small library of monomers have been investigated for this study which can be used as a  
starting point for designing PEAs with predictable properties for different combinations of 
selected monomers. However, further investigation may be necessary to optimize the 
thermal, mechanical and rheological properties for specific applications.   
 In Chapter 3, a novel micellar delivery system based on a PEA-PEO graft copolymer 
covalently conjugated to PTX via a hydrolyzable ester linkage was described. As expected, a 
slow release of the drug was observed, with approximately 40% cumulative drug release over 
14 days in phosphate buffer (pH= 7.4). In contrast, an analogous construct in where the drug 
was simply physically encapsulated showed very rapid release with more than 70% of the 
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drug released after only 25 h. Both covalent PEA-PTX micelles and non-covalent PEA-PTX 
micelles exhibited comparable cytotoxicity to PTX itself against HeLa cancer cells. On the 
other hand, the drug-free micelles were less toxic than the CrEL vehicle, which is beneficial 
for in vivo applications. In vitro release of PTX from PEA-PEO-PTX micelles at lower pH 
value (4–5) would be ideal to investigate as the proton concentration within the endosomes 
and lysosomes of cells is usually higher than that outside of the cells. A study on the 
degradation rate of the nanoparticle itself would also be helpful to better understand the 
release mechanism. Future work will also focus on studying the bio-distribution of the 
micelles and in vivo antitumor efficacy as well as the development of micelles with an 
additional active targeting mechanism.   
 Chapter 4 involved an extension of the design strategy employed in Chapter 3, but 
using a PEA with a photodegradable backbone covalently conjugated to both PTX and PEO. 
The PTX release profile of the resulting micelles from this copolymer both before and after a 
10 min UV irradiation was studied. It was found that irradiation resulted in a burst release of 
20% of the PTX over the first 24 h, in comparison with the non-irradiated control, which 
only exhibited a 3% release over the same time period. In vitro toxicity studies demonstrated 
that the polymers were non-toxic at the concentrations investigated, while the PTX-micelles 
were highly toxic, with the irradiated and non-irradiated micelles had similar toxicity. 
Photochemically responsive groups in this study were sensitive to UV light, which suffers a 
number of drawbacks. Light in the UV and visible regions are strongly absorbed by skin and 
tissue and therefore cannot be used for deep-tissue triggering. Moreover, it will damage 
tissue at much lower powers than near-infrared. Therefore, the same strategy can be explored 
in the future to impart visible or near-infrared photoresponsive linkers into the polymer 
backbone. These materials can potentially open up new opportunities and solutions for 
biological or biomedical challenges. 
.Finally, Chapter 5 described the synthesis and characterization of a Gd(III)-nanogel as an 
MRI contrast agent. The nanogel was synthesized by a conventional free radical 
polymerization using AEMA as its amine functional handle, PEOMA for its biocompatible 
properties and EGDMA as a cross-linker, to construct a rigid amine-functionalized network 
polymer. SEC, DLS, TEM, AFM, and other comparisons with a control linear polymer were 
consistent with the proposed nanogel structure. p-SCN-DTPA was incorporated onto the 
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nanogel as a Gd(III) chelating agent and subsequently, Gd(III) was successfully introduced 
into each chelation site. The relaxivities of the Gd(III)-nanogel and the control polymer 
agents were measured as a function of field strength. It was found that the increase in 
molecular rigidity imparted by cross-linking did lead to enhanced relaxivity. In addition, 
imaging experiments suggested that relative to the clinical agent Magnevist®, the nanogel 
agent provided increased contrast and enhanced circulation in the vasculature. In the future, 
the chemical multivalency offered by this nanogel platform will be explored for the 
development of new targeted and multimodal imaging agents through the conjugation of 
active targeting ligands and contrast agents for multiple imaging techniques. In addition, it 
would be ideal to change the nondegradable methacrylate backbone for a biodegradable 
polymer backbone such as a PEA. It is anticipated that methodology could be developed to 
achieve this goal. 
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Appendix 2: Supporting information for chapter 2 
 
 
Figure A.2.1. 
1
H NMR spectrum of PCSe (400 MHz; CDCl3). 
 
Figure A.2.2. Overlay of SEC traces for PEAs (Int-U). 
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Figure A.2.3. Overlay SEC traces for POSe prepared and fractionated by different methods 
 
Figure A.2.4. Overlay of TGA traces for POSe prepared by different methods. 
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Figure A.2.5. Complex viscosity versus temperature for POSe, showing the effect of MW 
and MW distribution. 
 
Figure A.2.6. Complex viscosity versus temperature for PBSe, showing the effect of MW 
and MW distribution.  
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Figure A.2.7. Complex viscosity versus temperature for PBTe, showing the effect of MW 
and MW distribution. 
 
Figure A.2.8. Complex viscosity versus frequency for AOSe, showing the effect of MW and 
MW distribution. 
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Figure A.2.9. Complex viscosity versus frequency for PBSe showing the effect of MW and 
MW distribution. 
 
Figure A.2.10. Complex viscosity versus frequency for PBTe, showing the effect of MW 
and MW distribution 
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Figure A.2.11. Dog bone sample 
 
Figure A.2.12. Tensile stress versus tensile strain for AOSe 
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Figure A.2.13. Tensile stress versus tensile strain for POSe 
 
Figure A.2.14. Tensile stress versus tensile strain for PBSe 
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Figure A.2.15. POSe-Int-U under elongation test 
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Appendix 3: Supporting information for chapter 3 
 
 
Figure.A.3.1. 
1
H NMR spectrum of polymer 3.4 (400 MHz, DMSO-d6) 
 
Figure.A.3.2. 
1
H NMR  spectrum of polymer 3.5 (400 MHz, DMSO-d6) 
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Figure.A.3. 3. 
1
H NMR spectrum of polymer 3.6 (400 MHz, DMSO-d6) The amount of 
conjugated PTX was calculated from a comparison of the integration of the single peak 
corresponding to proton labeled (a) in PTX at 6.3 ppm and the α protons on the 
phenylalanine-butanediol monomer unit at 4.42-4.48 ppm. 
 
Figure.A.3.4. 
1
H NMR spectrum of polymer 3.7 (400 MHz, DMSO-d6) 
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Figure.A.3.5. 
1
H NMR spectrum of polymer 3.8 (400 MHz, DMSO-d6). The amount of 
conjugated PTO was calculated from a comparison of the integrations of the single peak 
corresponding to PEO proton  at 3.51 ppm and the α protons on the phenylalanine-butanediol 
monomer unit at 4.42-4.48 ppm. 
 
Figure.A.3.6. SEC traces for polymer 3.4, 3.8. 
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Table.A.3.1. Paclitaxel (PTX) loading into PEA-PEG micelles  
 
 
 
Figure.A.3.7. In vitro cytotoxicity of drug-free micelles prepared from PEA-PEO graft 
copolymer 3.7 as measured by the MTT assay following a 72 h incubation with HeLa cells  
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Appendix 4: Supporting information for chapter 4 
 
 
Figure.A.4.1. 
1
H NMR spectrum of monomer 4.3 (400 MHz, DMSO-d6) 
 
Figure.A.4.2. 
1
H NMR  spectrum of polymer 4.5 (400 MHz, DMSO-d6) 
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Figure.A.4.3. 
1
H NMR spectrum of polymer 4.7 (400 MHz, DMSO-d6) 
 
Figure.A.4.4. 
1
H NMR spectrum of polymer 4.8 (400 MHz, DMSO-d6) 
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Figure.A.4. 5. 
1
H NMR spectrum of polymer 4.9 (400 MHz, DMSO-d6). The amount of 
conjugated PTX was calculated from a comparison of the integrations of the single peak 
corresponding to the protons on labeled (a) in PTX at 6.30 ppm and the benzylic methylene 
protons on the photodegradable monomer unit at 5.25-5.17 ppm.  
 
Figure.A.4.6. 
1
H NMR spectrum of polymer 4.10 (400 MHz, DMSO-d6)NMR integration of 
the peaks corresponding to the PEO at 3.5 ppm and the benzylic methylene protons on the 
photodegradable monomer unit at 5.25-5.17 ppm.  
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Figure.A.4.7. SEC traces for polymer 4.5, 4.7, 4.10, and photodegradation of polymer 4.5. 
 
Figure.A.4.8. 
1
H NMR spectra evolution for the photolysis of a 7.5 mg/mL sample of 
functional polymer 4.8 
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Figure.A.4.9. UV-vis spectra of polymer 4.10 following photoirradiation in a) dioxane (4 
μg/mL) and b) water (4 μg/mL).  
 
Figure.A.4.10. Evolution of HPLC traces for PTX irradiated with UV light for various time 
intervals.  
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Figure.A.4.11. Photodegradation of micelles formed from polymer 4.10 at a concentration of 
1.5 mg/mL in water. At each time point, 100 L of the aqueous suspension was removed, 
diluted into dioxane and a UV-vis spectrum was obtained. 
 
 
Figure.A.4.12. DLS traces micelles formed from graft copolymer 4.10 after 20 min UV 
irradiation. 
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Figure.A.4.13. In vitro cytotoxicity of polymer copolymer 4.8 as measured by the MTT 
assay following a 72 h incubation with HeLa cells  
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Appendix 5: Supporting information for chapter 5 
 
 
Figure.A5.1. 
1
H NMR  spectrum of polymer 5.4 (400 MHz, D2O ) 
 
 
Figure.A5.2. Size exclusion chromatogram of nanogel 5.4 (DMF with 10 mM LiBr and 1% 
(v/v) NEt3, detection based on differential refractive index). 
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Figure.A5.3. AFM image of nanogel 5.4. 
 
Figure.A5.4. Size distribution by intensity of the nanogel 5.4. Z-average size is 20 nm. As 
shown by the larger peak at ~150 nm, a small degree of aggregation is present but this is not 
present in the volume distribution (Figure 5.1 in manuscript) as large objects scatter much 
more strongly than small ones and thus account for a very small volume fraction of the 
sample. 
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Figure.A5.5. 
1
H NMR spectrum of functionalized nanogel 5.5 (400 MHz, D2O). 
 
Figure.A5.6. Infrared spectra of a) the isothiocyanate derivative of DTPA (p-SCN-Bn-
DTPA), b) nanogel 5.5, and c) nanogel 5.6 illustrating the successful conjugation of the 
chelate and coordination of Gd(III). 
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Figure.A5.7. 
1
H NMR  spectrum of polymer 5.7 (400 MHz, D2O ) illustrating shaper peaks 
than the corresponding NMR spectrum of nanogel 5.4. 
 
 
Figure.A5.8. Transmission electron micrograph of linear polymer 5.7, illustrating the 
formation of random aggregates rather than spherical particles. 
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Figure.A5.9. Atomic force microscopy image of linear polymer 5.7 showing the absence of 
spherical aggregates. 
 
 
 
 
Figure.A5.10. Longitudinal relaxivity (r1) of nanogel 5.6 and control linear polymer 5.9 in 
phosphate buffer (0.1 M, pH 7.4) as a function of field strength at 25 C. 
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NMRD Modeling 
Longitudinal relaxation was modeled using a modification of the Solomon-Bloembergen-
Morgan theory formulated by R. Lauffer.  Contributions from the inner hydration sphere 
were included as: 
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 is the spin-lattice relaxation rate due to inner-sphere interactions, 
[M] is the molar concentration of the paramagnetic species, 
[H2O] is the molar concentration of water 
qIS is the inner-sphere hydration number  
T1M is the relaxation time for bound inner-sphere water molecules and 
τm is the water residency time. 
The inner sphere spin-lattice relaxation rate including dipolar and contact interactions was 
calculated from the following formula: 
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Constants in this equation include: 
  , the magnetic permeability of vacuum,  
  , the gyromagnetic ratio for protons, 
  , the electronic g-factor, 
   the total electronic spin for the metal ion, 
  , the Bohr Magneton,  
    , the metal ion-proton separation and 
 
 
, the electron-nuclear hyperfine coupling constant. 
         are respectively, the proton and electron Larmor precessional frequencies (rad/s) 
in the applied magnetic field. 
The dipole-dipole correlation time,   , depends on the longitudinal electronic spin relaxation 
time,    ,  the water residency time,    and the rotational correlation time,    as: 
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The longitudinal electronic spin relaxation rate has the following dependency:  
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Finally, the scalar relaxation time,   , is equal to: 
 
 
  
 
 
   
 
 
  
. 
The quantities,               
 
 
 were held at fixed values of 7/2, 0.31 nm, 1 and   
          respectively. Remaining parameters,    (water residency time),    (rotational 
correlation time),    (correlation time for modulation of the transient zero-field splitting) and 
    (electronic relaxation time at zero field) where determined from a non-linear least-
squares fit of this relaxation model to relaxivity  data from NMRD measurements using even 
weighting of the data.  The fitted parameters and their uncertainties (one standard deviation) 
are given in Table A.5.1. A graph of the typical fitting results is illustrated in Figure A.5.11.   
 
Table A.5.1. NMRD Fitting Results. 
  Nanogel 5.6 Polymer 5.9 
Parameter Units 25°C 37°C 25°C 37°C 
   ps 39.4 ± 2.6 34.9 ± 1.9 40.2 ± 2.5 38.8 ± 2.5 
   ns 2.72 ± 0.11 2.72 ± 0.10 1.68 ± 0.08 1.56 ± 0.08 
   ns 576.4 ± 9.5 568.2 ± 8.5 536 ± 11 624 ± 12 
    ps 313 ± 12 261 ± 8.1 247.3 7.8 225.1 ± 7.8 
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Figure.A5.11.  Relaxivity of Nanogel 5.6.  The Lauffer model for inner-sphere dipole-dipole 
relaxation (red circles) has been fit to relaxivities (black squares) derived from NMRD data 
at 37°C.  The error bars represent a measurement uncertainty of one standard deviation. 
 
 
 
Figure.A5.12. Additional MRI images of a tumor-baring animal injected with nanogel 5.6. 
(a) Pre-contrast image, (b) post-contrast image. The location of the tumor is highlighted by 
the red ovals in both images. The arrows highlight the difference in the contrast in the 
vasculature between the pre- and post-contrast images. 
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